Multi-capped and multi-capped mRNA and uses thereof
By adding multiple poly-A tails or 5' caps to the 3' or 5' end of the mRNA and using dendrimer protection, the instability and short-acting problems in mRNA treatment were solved, significantly improving its in cells The stability and translation efficiency in the system enhance the clinical application potential.
Patent Information
- Application Number
- CN202380027377.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-18
- Filing Date
- 2023-01-18
- Publication Date
- 2024-12-06
AI Technical Summary
mRNA treatment faces problems of instability, toxicity, short-term efficacy and potential immune response, resulting in limited feasibility in clinical applications.
By connecting multiple poly-A tails to the 3' end or multiple 5' caps to the 5' end, click chemical reactions enhance the stability of the mRNA and bind dendrimers to protect the mRNA from nucleic acids by connecting multiple poly-A tails to the 3' end or multiple 5' caps to the 5' end. Degradation of enzymes, prolonging its half-life and improving translation efficiency.
It significantly increases the stability and translation efficiency of mRNA in cells, extends its lifespan, thereby increasing the amount of protein production and enhancing the clinical application potential of mRNA therapy.
Smart Images

Figure CN119095964A_ABST
Abstract
Description
[0001] References to Electronic Sequence Listings
[0002] The contents of the electronic Sequence Listing (B119570144WO00-SEQ-JQM.xml; size: 61,200 bytes; and creation date: January 18, 2023) are incorporated herein by reference in their entirety. Background Art
[0003] Messenger RNA (mRNA) technology is an emerging alternative to conventional small molecule, DNA and protein therapeutics, as well as conventional vaccine approaches, because it is efficient, programmable, and can rapidly produce mRNA with a desired sequence. mRNA therapy is a rapidly developing field and has been used for the expression of therapeutic proteins ranging from angiogenesis factors (e.g., vascular endothelial growth factor A (VEGF-A), GATA binding protein 4 (GATA4), myocyte enhancer factor 2C (MEF2C), T-box transcription factor 5 (TBX5), myocardin (MYOCD)) to vaccines against COVID-19, influenza, and Zika virus. Despite recent clinical successes, mRNA therapy still faces challenges of instability, toxicity, short-term efficacy, and potential immune responses. Increasing the stability of mRNA to enhance its in vivo efficacy remains an important issue that must be addressed to increase the feasibility of mRNA therapy in clinical applications. Summary of the invention
[0004] Provided herein are modified mRNAs with modified poly-A tails and / or modified 5' caps to improve the stability of mRNA in cells and in vitro translation systems, thereby enhancing the production of proteins, and methods for preparing and using such modified mRNAs. Conventional mRNAs include poly-A tails, which include about 100-250 adenosine nucleotides at the 3' end. The poly-A tail can be degraded or removed by a cell exonuclease that removes 3' nucleotides. Once the exonuclease removes the poly-A tail and begins to remove nucleotides of the 3' untranslated region (UTR) and / or open reading frame (ORF), the mRNA cannot be translated into the encoded protein. The mRNAs that are more resistant to 3' exonuclease activity degrade more slowly, and are therefore more stable, with increased half-life in cells, and therefore more proteins can be produced from a given mRNA molecule. The poly-A tail is also required for binding to poly-A binding protein (PABP), which enhances the translation of mRNA molecules by binding to eukaryotic initiation factor 4 complex (eIF4G). Conventional mRNA also includes a 5' cap similar to a poly-A tail, which protects mRNA from the influence of 5' exonucleases and serves as a site for the recruitment of the translation mechanism. Modified nucleotides containing one or more structural modifications to the nucleobases, sugars or phosphate bonds of mRNA can interfere with 3' and 5' exonucleases, thereby making mRNA more stable. However, the same structural modifications that inhibit exonucleases also hinder the ability of enzymes to incorporate these modified nucleotides into mRNA, thereby making modified mRNA difficult to produce.
[0005] However, alternative strategies have been demonstrated to enhance the stability of mRNA molecules without significantly impairing the synthesis and / or translation of mRNA. Disclosed herein are strategies for enhancing the stability of mRNA by attaching multiple poly-A tails to the 3' end of the mRNA and / or attaching multiple 5' caps to the 5' end. One strategy involves attaching an oligonucleotide comprising one or more nucleotides modified with a click chemistry handle to the 3' and / or 5' end of an existing mRNA molecule. Additional oligonucleotides comprising a 3' poly-A tail or a 5' cap are in turn attached to one or more modified nucleotides via a click chemistry reaction (see Figure 1C and 1G Alternatively, the same result can be achieved by attaching oligonucleotides linked to dendrimers to the 3' and / or 5' ends of existing mRNA molecules via click chemistry. Dendrimers modified with click chemistry handles can then be attached to additional oligonucleotides including a 3' poly-A tail or a 5' cap via click chemistry (see Figure 1E and 1I). In addition to extending the life of mRNA by protecting existing mRNA molecules from exonuclease activity, thereby reducing degradation of ORFs, these strategies can also directly enhance the translation of mRNA, because each additional poly-A tail or 5' cap attached to the mRNA can interact with the modified mRNA and recruit its translation machinery. These strategies can be used in conjunction with each other and with other known techniques for enhancing mRNA stability, including, for example, introducing modified nucleotides at the 3' and / or 5' ends of the mRNA, introducing modified nucleotides into the 3' and / or 5' untranslated regions (UTRs) of the mRNA, introducing exonuclease resistance sequences into the mRNA, and / or cyclizing by ligating the ends of a linear mRNA to produce a circular mRNA.
[0006] Thus, in some aspects, the present disclosure provides a modified mRNA comprising:
[0007] (i) an open reading frame (ORF), which encodes a protein;
[0008] (ii) a poly-A region; and
[0009] (iii) 5' cap region;
[0010] wherein the poly-A region is located 3' of the ORF and comprises 10 or more nucleotides, and the 5' cap region is located 5' of the ORF, and wherein the poly-A region comprises two or more poly-A tails, and / or the 5' cap region comprises two or more 5' caps.
[0011] In some embodiments, the modified mRNA includes a poly-A region and a 5' cap region, the poly-A region includes two or more poly-A tails, and the 5' cap region includes a 5' cap. In some embodiments, the modified mRNA includes a poly-A region and a 5' cap region, the poly-A region includes a poly-A tail, and the 5' cap region includes two or more 5' caps. In some embodiments, the modified mRNA includes a poly-A region and a 5' cap region, the poly-A region includes two or more poly-A tails, and the 5' cap region includes two or more 5' caps.
[0012] In some embodiments, the modified mRNA comprises a 5' untranslated region (5'UTR) and a 3' untranslated region (3'UTR), wherein the ORF is located between the 5'UTR and the 3'UTR, wherein the 3'UTR is located between the ORF and the poly-A region, and wherein the 5'UTR is located between the 5' cap region and the ORF.
[0013] In some embodiments, the modified mRNA is a linear mRNA, wherein the 5' cap region is located at the 5' end of the modified mRNA and the poly-A region is located at the 3' end of the modified mRNA.
[0014] In some embodiments, the modified mRNA is a circular mRNA, wherein the poly-A region is located between the 3'UTR and the 5' cap region.
[0015] In some embodiments, the poly-A region comprises two or more poly-A tails, and at least two instances of the poly-A tail are covalently linked by a first linker.
[0016] In some embodiments, the poly-A region comprises -(first poly-A tail)-[(first linker)-(second poly-A tail) n1 ] n2 wherein each instance of n1 is independently an integer between 1 and 20 (inclusive), n2 is an integer between 2 and 10 (inclusive), the first poly-A tail is covalently linked to the 3'UTR, and the first linker is covalently linked to the first poly-A tail and the second poly-A tail.
[0017] In some embodiments, each instance of n1 is 1.
[0018] In some embodiments, at least one instance of the first linker is covalently linked to an internal nucleotide of the first poly-A tail.
[0019] In some embodiments, at least one instance of the first linker is covalently attached to the second poly-A tail at the 3' nucleotide of the second poly-A tail.
[0020] In some embodiments, at least one instance of the first linker comprises at least one moiety formed by reacting two orthogonal click chemistry handles.
[0021] In some embodiments, at least one moiety formed by reacting two orthogonal click chemistry handles has the formula:
[0022]
[0023] In some embodiments, each instance of the first linker is independently substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene, substituted or unsubstituted C 1-200 wherein said substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with a substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
[0024] In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently replace.
[0025] In some embodiments, at least one instance of the first linker has the formula: L 1 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 heteroalkylene; and L 2 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 Heteroalkylene.
[0026] In some embodiments, at least one instance of the first linker has the formula:
[0027]
[0028] In some embodiments, each instance of n1 is independently an integer between 2 and 20, inclusive.
[0029] In some embodiments, at least one instance of the first linker comprises a dendrimer. In certain embodiments, at least one instance of the dendrimer is a first generation dendrimer. In certain embodiments, at least one instance of the dendrimer is a second generation dendrimer. In certain embodiments, at least one instance of the dendrimer is a third generation dendrimer. In certain embodiments, at least one instance of the dendrimer is a fourth generation dendrimer. In certain embodiments, at least one instance of the dendrimer comprises 2, 3, 4, 5, 6, 7, or 8 dendrons.
[0030] In certain embodiments, at least one example of the dendrimer is a polypropyleneimine dendrimer, a polypropyleneamine dendrimer, a poly(glutamic acid) dendrimer, a polymelamine dendrimer, a polyester dendrimer, or a pegylated dendrimer. In some embodiments, at least one example of the dendrimer is a polyamidoamine (PAMAM) dendrimer.
[0031] In some embodiments, at least one instance of the PAMAM dendrimer has the formula:
[0032]
[0033] wherein each instance of n3 is independently an integer between 1 and 10 (inclusive); each instance of n4 is independently an integer between 0 and 10 (inclusive); R 2 Each instance of is independently hydrogen or The condition is R 2 At least three instances of R 1 Each instance of is substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene or substituted or unsubstituted C 1-10 heteroalkynylene; optionally substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and each instance of n5 is independently an integer between 0 and 10, inclusive.
[0034] In some embodiments, at least one example of the PAMAM dendrimer comprises:
[0035]
[0036] In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently replace.
[0037] In some embodiments, at least one instance of the first linker has the formula:
[0038]
[0039] In some embodiments, at least one instance of the first linker is covalently linked to the 3' nucleotide of the first poly-A tail.
[0040] In some embodiments, at least one instance of the first linker is covalently linked to the 3' nucleotide of the second poly-A tail.
[0041] In some embodiments, the poly-A region of the modified mRNA comprises one or more modified nucleotides.
[0042] In some embodiments, 3 or more nucleotides of the last 10 nucleotides of at least one of the two or more poly-A tails are modified nucleotides and / or non-adenosine nucleotides.
[0043] In some embodiments, the one or more modified nucleotides of the poly-A region are modified adenosine nucleotides.
[0044] In some embodiments, the one or more modified nucleotides of the poly-A region are modified non-adenosine nucleotides.
[0045] In some embodiments, the one or more modified nucleotides of the poly-A region comprise a modified nucleobase.
[0046] In some embodiments, the modified nucleobase comprised by the one or more modified nucleotides of the poly-A region is selected from the group consisting of xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, digoxigenated adenine, digoxigenated cytosine, digoxigenated guanine, digoxigenated uracil, 6-chloropurine nucleoside, N6-methyladenine, methylpseudouracil, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyluracil, 5,6-dihydrouracil, 5-[(3-indolyl)propionamide-N-allyl]uracil, 5-aminoallylcytosine, 5-aminoallyluracil, 5 -bromouracil, 5-bromocytosine, 5-carboxycytosine, 5-carboxymethyl ester uracil, 5-carboxyuracil, 5-fluorouracil, 5-formylcytosine, 5-formyluracil, 5-hydroxycytosine, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5-hydroxyuracil, 5-iodocytosine, 5-iodouracil, 5-methoxycytosine, 5-methoxyuracil, 5-methylcytosine, 5-methyluracil, 5-propargylaminocytosine, 5-propargylaminouracil, 5-propynylcytosine, 5-propynyluracil, 6-azacytosine, 6-azauracil, 6-chloropurine, 6-thioguanine, 7-deazaadenine, 7-deazaguanine, 7-guanine-7-propargylaminocytosine Adenine, 7-deaza-7-propargylaminoguanine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, arabinoadenine, arabinocytosine, arabinoguanine, arabinouracil, biotin-16-7-deaza-7-propargylaminoguanine, biotin-16-aminoallylcytosine, biotin-16-aminoallyluracil, cyanine-3-5-propargylaminocytosine, cyanine-3-6-propargylaminouracil, cyanine-3-aminoallylcytosine, cyanine-3-aminoallyluracil, cyanine-5-6-propargylaminocytosine, cyanine-5-6-propargylaminouracil, cyanine-5-aminoallylcytosine, cyanine-5 -aminoallyluracil, cyanine 7-aminoallyluracil, dabcyl-5-3-aminoallyluracil, desthiobiotin-16-aminoallyl-uracil, desthiobiotin-6-aminoallylcytosine, isoguanine, N1-ethylpseudouracil, N1-methoxymethylpseudouracil, N1-methyladenine, N1-methylpseudouracil, N1-propylpseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthosine, 3-deazaadenine, 2,6-diaminoadenine, 2,6-diaminoguanine, 5-formamide-uracil, 5-ethyluracil, N6-isopentenyladenine (i6A), 2-methyl-thio-N6-isopentenyladenine (ms2i6A), 2-methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine (g6A), N 6-Threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxynorvalylcarbamoyladenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A).
[0047] In some embodiments, one or more modified nucleotides of the poly-A region comprise a modified sugar.
[0048] In some embodiments, the modified sugar comprised by the one or more modified nucleotides of the poly-A region is selected from the group consisting of: 2'-thioribose, 2',3'-dideoxyribose, 2'-amino-2'-deoxyribose, 2'deoxyribose, 2'-azido-2'-deoxyribose, 2'-fluoro-2'-deoxyribose, 2'-O-methylribose, 2'-O-methyldeoxyribose, 3'-amino-2',3'-dideoxyribose , 3'-azido-2',3'-dideoxyribose, 3'-deoxyribose, 3'-O-(2-nitrobenzyl)-2'-deoxyribose, 3'-O-methylribose, 5'-aminoribose, 5'-thioribose, 5-nitro-1-indolyl-2'-deoxyribose, 5'-biotin-ribose, 2'-O,4'-C-methylene-linked ribose, 2'-O,4'-C-amino-linked ribose, and 2'-O,4'-C-thio-linked ribose.
[0049] In some embodiments, the one or more modified nucleotides of the poly-A region comprise a modified phosphate.
[0050] In some embodiments, the modified phosphate comprised by the one or more modified nucleotides of the poly-A region is selected from the group consisting of phosphorothioate (PS), thiophosphate, 5'-O-methylphosphonate, 3'-O-methylphosphonate, 5'-hydroxyphosphonate, hydroxyphosphonate, phosphoroselenoate, selenophosphate, phosphoramidate, carbonylphosphonate, methylphosphonate, phenylphosphonate, ethylphosphonate, H-phosphonate, guanidine ring, triazole ring, borophosphate (BP), methylphosphonate and guanidinopropylphosphoramidate.
[0051] In some embodiments, the poly-A region includes 1 to 3, 3 to 5, 5 to 10, 10 to 15, 15 to 30, 30 to 50, 50 to 100, or 100 to 200 phosphorothioates.
[0052] In some embodiments, the poly-A region comprises 5 to 30 phosphorothioates.
[0053] In some embodiments, the poly-A region includes 3 to 5, 5 to 10, 10 to 15, 15 to 30, 30 to 50, 50 to 100, or 100 to 200 deoxyribose sugars.
[0054] In some embodiments, the poly-A region comprises 5 to 30 deoxyribose sugars.
[0055] In some embodiments, the mRNA comprises a 3' terminal nucleotide, wherein the 3' terminal nucleotide is dideoxyadenosine, dideoxycytidine, dideoxyguanosine, dideoxythymidine, dideoxyuridine, or inverted deoxythymidine.
[0056] In some embodiments, the poly-A region comprises 25 to 500 nucleotides.
[0057] In some embodiments, the poly-A region comprises 50 to 100, 100 to 150, 150 to 200, 200 to 300, 300 to 400, or 400 to 500 nucleotides.
[0058] In some embodiments, the poly-A region comprises 10 or more adenosine nucleotides.
[0059] In some embodiments, 25-100%, 30-100%, 40-100%, 50-100%, 60-100%, 70-100%, 80-100%, 90-100%, 95-100%, 96-100%, 97-100%, 98-100%, or 99-100% of the nucleotides of the poly-A region are adenosine nucleotides.
[0060] In some embodiments, the first poly-A tail comprises 10 to 50 adenosine ribonucleotides, 1 to 10 modified uridine deoxyribonucleotides including a connection point, and a 3' terminal dideoxyribonucleotide or an inverted deoxyribonucleotide; and the second poly-A tail comprises 10 to 50 adenosine ribonucleotides.
[0061] In some embodiments, the first poly-A tail comprises a nucleotide sequence as shown below: 5'-rArArArArArArAdU(a1)rArArArArArArArArArArArAdU(a1)rArArArArArArArArArArAd U(a1)ddC-3'(SEQ ID NO:1); wherein at least one instance of the second poly-A tail comprises a nucleotide sequence as shown below: 5'-rArArArArArArArArArArArArArArArArArArArArArA*rA*rA*rA*rA*rA*(b1)-3'(SEQ ID NO:2); and each instance of the first linker is independently Wherein "rA" represents an adenosine ribonucleotide; "dU(a1)" represents a modified uridine deoxyribonucleotide; "ddC" represents a cytosine dideoxyribonucleotide; "*" represents a phosphorothioate bond; a1 of each instance of dU(a1) represents a point of attachment on the uridine of said dU(a1); b1 of rA*(b1) represents a point of attachment on the * of said rA*(b1); each instance of a1 is connected to an instance of a2; and each instance of b1 is connected to an instance of b2. In some embodiments, the modified uridine deoxyribonucleotide is 5-octadiynyl deoxyuridine.
[0062] In some embodiments, the first poly-A tail and the second poly-A tail comprise 10 to 50 adenosine ribonucleotides and a 3' terminal azide moiety.
[0063] In some embodiments, the first poly-A tail and the second poly-A tail comprise 10 to 50 adenosine ribonucleotides and a 5' terminal azide moiety.
[0064] In some embodiments, the first poly-A tail and the second poly-A tail comprise a nucleotide sequence as shown below: 5'-rArArArArArArArArArArArArArArArArArArArArArArA*rA*rA*rA*rA*rA*rA* / Azide N / -3' (SEQ ID NO:3); wherein "Azide N" represents a 3' azide moiety and "*" represents a phosphorothioate bond.
[0065] In some embodiments, the first poly-A tail and the second poly-A tail comprise a nucleotide sequence as shown below: 5'-5 / Azide N / rArArArArArArArArArArArArArArArArArArArArArArAr A*rA*rA*rA*rA*rA-3' (SEQ ID NO:27); wherein "Azide N" represents the 3' azide moiety and "*" represents a phosphorothioate bond.
[0066] In some embodiments, the 5' cap region comprises two or more 5' caps, and at least two instances of the 5' cap are covalently linked via a second linker.
[0067] In some embodiments, the 5' cap region comprises -(first 5' cap)-[(second linker)-(second 5' cap) m1 ] m2 ; wherein each instance of m1 is independently an integer between 1 and 20 (inclusive); m2 is an integer between 2 and 10 (inclusive); the first 5' cap is covalently linked to the 5'UTR; and the second linker is covalently linked to the first 5' cap and the second 5' cap.
[0068] In some embodiments, each instance of m1 is 1.
[0069] In some embodiments, at least one instance of the second linker is covalently linked to an internal nucleotide of the first 5' cap.
[0070] In some embodiments, at least one instance of the second linker is covalently attached to the second 5'-cap at the 3' nucleotide of the second 5'-cap.
[0071] In some embodiments, at least one instance of the second linker comprises at least one moiety formed by reacting two orthogonal click chemistry handles.
[0072] In some embodiments, at least one moiety formed by reacting two orthogonal click chemistry handles has the formula:
[0073]
[0074] In some embodiments, each instance of the second linker is independently substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene, substituted or unsubstituted C 1-200 wherein said substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with a substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
[0075] In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently replace.
[0076] In some embodiments, at least one instance of the second linker has the formula: L 3 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 heteroalkylene; and L 4 Each instance of is independently substituted or unsubstituted C 1-199Alkylene or substituted or unsubstituted C 1-199 Heteroalkylene.
[0077] In some embodiments, at least one instance of the second linker has the formula:
[0078]
[0079] In some embodiments, each instance of m1 is independently an integer between 2 and 20, inclusive.
[0080] In some embodiments, at least one instance of the second linker comprises a dendrimer. In certain embodiments, at least one instance of the dendrimer is a first generation dendrimer. In certain embodiments, at least one instance of the dendrimer is a second generation dendrimer. In certain embodiments, at least one instance of the dendrimer is a third generation dendrimer. In certain embodiments, at least one instance of the dendrimer is a fourth generation dendrimer. In certain embodiments, at least one instance of the dendrimer comprises 2, 3, 4, 5, 6, 7, or 8 dendrons.
[0081] In certain embodiments, at least one example of the dendrimer is a polypropyleneimine dendrimer, a polypropyleneamine dendrimer, a poly(glutamic acid) dendrimer, a polymelamine dendrimer, a polyester dendrimer, or a pegylated dendrimer. In some embodiments, at least one example of the dendrimer is a polyamidoamine (PAMAM) dendrimer.
[0082] In some embodiments, at least one instance of the PAMAM dendrimer has the formula:
[0083]
[0084] wherein each instance of m3 is independently an integer between 1 and 10 (inclusive); each instance of m4 is independently an integer between 0 and 10 (inclusive); R 12 Each instance of is independently hydrogen or The condition is R 12 At least three instances of R 11 Each instance of is substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10heteroalkenylene or substituted or unsubstituted C 1-10 heteroalkynylene; optionally substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced by substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and each instance of m5 is independently an integer between 0 and 10, inclusive.
[0085] In some embodiments, at least one example of the PAMAM dendrimer comprises:
[0086]
[0087] In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently replace.
[0088] In some embodiments, at least one instance of the first linker has the formula:
[0089]
[0090] In some embodiments, at least one instance of said second linker is covalently linked to the 3' nucleotide of said first 5' cap.
[0091] In some embodiments, at least one instance of the second linker is covalently linked to the 3' nucleotide of at least one instance of the second 5' cap.
[0092] In some embodiments, the 5' cap region of the modified mRNA comprises one or more modified nucleotides.
[0093] In some embodiments, the one or more modified nucleotides of the 5' cap region comprise a modified nucleobase.
[0094] In some embodiments, the modified nucleobase is selected from the group consisting of: xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, digoxigenated adenine, digoxigenated cytosine, digoxigenated guanine, digoxigenated uracil, 6-chloropurine nucleoside, N6-methyladenine, methylpseudouracil, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyluracil, 5,6-dihydrouracil, 5-[(3-indolyl)propionamide-N-allyl]uracil, 5-aminoallylcytosine, 5-aminoallyluracil, 5-bromouracil, 5-bromocytosine, 5-carboxycytosine , 5-carboxymethyl ester uracil, 5-carboxyl uracil, 5-fluorouracil, 5-formyl cytosine, 5-formyl uracil, 5-hydroxy cytosine, 5-hydroxymethyl cytosine, 5-hydroxymethyl uracil, 5-hydroxy uracil, 5-iodo cytosine, 5-iodo uracil, 5-methoxy cytosine, 5-methoxy uracil, 5-methyl cytosine, 5-methyl uracil, 5-propargyl amino cytosine, 5-propargyl amino uracil, 5-propynyl cytosine, 5-propynyl uracil, 6-azacytosine, 6-azauracil, 6-chloropurine, 6-thioguanine, 7-deazaadenine, 7-deazaguanine, 7-guanine-7-propargyl amino adenine, 7-deaza-7- Propargylaminoguanine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, arabinoadenine, arabinocytosine, arabinoguanine, arabinouracil, biotin-16-7-deaza-7-propargylaminoguanine, biotin-16-aminoallylcytosine, biotin-16-aminoallyluracil, cyanine 3-5-propargylaminocytosine, cyanine 3-6-propargylaminouracil, cyanine 3-aminoallylcytosine, cyanine 3-aminoallyluracil, cyanine 5-6-propargylaminocytosine, cyanine 5-6-propargylaminouracil, cyanine 5-aminoallylcytosine, cyanine 5-aminoallyluracil Pyrimidine, cyanine 7-aminoallyl uracil, dabcyl-5-3-aminoallyl uracil, desthiobiotin-16-aminoallyl-uracil, desthiobiotin-6-aminoallyl cytosine, isoguanine, N1-ethyl pseudouracil, N1-methoxymethyl pseudouracil, N1-methyladenine, N1-methyl pseudouracil, N1-propyl pseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthosine, 3-deazaadenine, 2,6-diaminoadenine, 2,6-diaminoguanine, 5-formamide-uracil, 5-ethyluracil, N6-isopentenyladenine (i6A), 2-methyl-thio-N6-isopentenyladenine (ms2i6A), 2-methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine (g6A), N 6-Threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxynorvalylcarbamoyladenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A).
[0095] In some embodiments, the one or more modified nucleotides of the 5' cap region comprise a modified sugar.
[0096] In some embodiments, the modified sugar comprised by the one or more modified nucleotides of the 5' cap region is selected from the group consisting of 2'-thioribose, 2',3'-dideoxyribose, 2'-amino-2'-deoxyribose, 2'deoxyribose, 2'-azido-2'-deoxyribose, 2'-fluoro-2'-deoxyribose, 2'-O-methylribose, 2'-O-methyldeoxyribose, 3'-amino-2',3'-dideoxyribose, 3'- '-Azido-2',3'-dideoxyribose, 3'-deoxyribose, 3'-O-(2-nitrobenzyl)-2'-deoxyribose, 3'-O-methylribose, 5'-aminoribose, 5'-thioribose, 5-nitro-1-indolyl-2'-deoxyribose, 5'-biotin-ribose, 2'-O,4'-C-methylene-linked ribose, 2'-O,4'-C-amino-linked ribose, and 2'-O,4'-C-thio-linked ribose.
[0097] In some embodiments, the one or more modified nucleotides of the 5' cap region comprise a modified phosphate.
[0098] In some embodiments, the modified phosphate comprised by the one or more modified nucleotides of the 5' cap region is selected from the group consisting of phosphorothioate (PS), thiophosphate, 5'-O-methylphosphonate, 3'-O-methylphosphonate, 5'-hydroxyphosphonate, hydroxyphosphonate, phosphoroselenoate, selenophosphate, phosphoramidate, carbonylphosphonate, methylphosphonate, phenylphosphonate, ethylphosphonate, H-phosphonate, guanidine ring, triazole ring, borophosphate (BP), methylphosphonate and guanidinopropylphosphoramidate.
[0099] In some embodiments, the 5' cap region comprises 1 to 3, 3 to 5, 5 to 10, 10 to 15, 15 to 30, 30 to 50, 50 to 100, or 100 to 200 phosphorothioates.
[0100] In some embodiments, the 5' cap region comprises 5 to 30 phosphorothioates.
[0101] In some embodiments, the 5' cap region comprises 3 to 5, 5 to 10, 10 to 15, 15 to 30, 30 to 50, 50 to 100, or 100 to 200 deoxyribose sugars.
[0102] In some embodiments, the 5' cap region comprises 5 to 30 deoxyribose sugars.
[0103] In some embodiments, the mRNA comprises a 3' terminal nucleotide, wherein the 3' terminal nucleotide is dideoxyadenosine, dideoxycytidine, dideoxyguanosine, dideoxythymidine, dideoxyuridine, or inverted deoxythymidine.
[0104] In some embodiments, the 5' cap region comprises 25-500 nucleotides.
[0105] In some embodiments, the 5' cap region comprises 50 to 100, 100 to 150, 150 to 200, 200 to 300, 300 to 400, or 400 to 500 nucleotides.
[0106] In some embodiments, the 5' cap region includes 1 to 3, 3 to 5, 5 to 7, or 7 to 10 5' caps.
[0107] In some embodiments, the 5' cap region comprises one or more 7-methylguanylate caps comprising a 5'-5' triphosphate bond.
[0108] In some embodiments, the 5' cap region comprises one or more 2,2,7-trimethylguanosine caps comprising a 5'-5' triphosphate bond.
[0109] In some embodiments, the 5' cap region comprises one or more modified 5' caps.
[0110] In some embodiments, the one or more modified 5' caps are locked nucleic acid (LNA) modified caps, 5' caps comprising a 5'-5' triphosphate bond modified by a 5'-phosphorothioate, or 5' caps comprising a 5'-5' tetraphosphate bond.
[0111] In some embodiments, the 5' cap region comprises one or more 5' caps comprising one or more modified nucleotides.
[0112] In some embodiments, the one or more modified nucleotides comprised by the 5' cap are 2'-O-methylated nucleotides.
[0113] In some embodiments, the first 5' cap comprises 10 to 50 ribonucleotides, 1 to 10 modified uridine deoxyribonucleotides including the attachment point, and a 5' cap; and the second 5' cap comprises 10 to 50 ribonucleotides and a 5' cap.
[0114] In some embodiments, the first 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArArAdU(c1)rArArGrArGrArArArGrArArGrArGdU(c1)rArArGrArArGrArArAdU(c1)rA-3'(SEQ ID NO:4); the second 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArGrArCrTrGrCrCrArCrCrCrA*rA*rA*rA*rA*rA*(d1)-3'(SEQ ID NO:5); and each instance of the second linker is independently
[0115] "rA" represents an adenosine ribonucleotide; "rT" represents a thymidine ribonucleotide; "rC" represents a cytidine ribonucleotide; "rG" represents a guanosine ribonucleotide; "dU(c1)" represents a modified uridine deoxyribonucleotide; "dU(c1)" represents a modified uridine deoxyribonucleotide; wherein "*" represents a phosphorothioate bond; "Cap" represents a 5' cap; c1 of each instance of dU(c1) represents a point of attachment on the uridine of said dU(c1); d1 of rA*(d1) represents a point of attachment on the * of said rA*(d1); each instance of c1 is connected to an instance of c2; and each instance of d1 is connected to an instance of d2. In some embodiments, the modified uridine deoxynucleotide is 5-octadiynyl deoxyuridine.
[0116] In some embodiments, the first 5'-cap comprises 5 to 10 ribonucleotides and a 5'-azide moiety; and the second 5'-cap comprises 10 to 50 ribonucleotides, a 3'-azide moiety, and a 5'-cap.
[0117] In some embodiments, the first 5' cap comprises a nucleotide sequence as shown below: 5'- / 5 Azide N / rArArA rArA-3'; and the second 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArGrArCrTrGrCrCrArCrCrA*rA*rA*rA*rA*rA* / 3 Azide N / -3' (SEQ ID NO:6); wherein "rA" represents an adenosine ribonucleotide; "rT" represents a thymidine ribonucleotide; "rC" represents a cytidine ribonucleotide; "rG" represents a guanosine ribonucleotide; "dU(c1)" represents a modified uridine deoxyribonucleotide; "5 Azide N" represents a 5' azide portion; "3 Azide N" represents a 3' azide portion, "*" represents a phosphorothioate bond, and "Cap" represents a 5' cap.
[0118] In some aspects, the present disclosure provides a method for producing any one of the modified mRNAs described herein, the method comprising ligating a first RNA comprising an open reading frame (ORF) encoding a protein to a tailing nucleic acid comprising two or more poly-A tails and / or a capping nucleic acid comprising two or more 5' caps, in the presence of an RNA ligase, whereby the RNA ligase forms a covalent bond between the 3' nucleotide of the first RNA and the 5' nucleotide of the tailing nucleic acid, and / or forms a covalent bond between the 5' nucleotide of the first RNA and the 3' nucleotide of the capping nucleic acid, to produce the modified mRNA.
[0119] In some embodiments, the modified mRNA comprises a 5' untranslated region (5'UTR) and a 3' untranslated region (3'UTR), wherein the ORF is located between the 5'UTR and the 3'UTR, wherein the 3'UTR is located between the ORF and the linked tailing nucleic acid, and wherein the 5'UTR is located between the ORF and the linked capping nucleic acid.
[0120] In some embodiments, the tailed nucleic acid comprises a first poly-A tail and one or more second poly-A tails, wherein the first poly-A tail is covalently linked to the 3'UTR.
[0121] In some aspects, the present disclosure provides a modified mRNA produced by the method of producing a modified mRNA provided herein.
[0122] In some aspects, the present disclosure provides a delivery agent comprising any of the modified mRNAs provided herein, wherein the delivery agent comprises a lipid, a peptide, a protein, an antibody, a carbohydrate, a nanoparticle, or a microparticle.
[0123] In some embodiments, the nanoparticles or microparticles provided herein are lipid nanoparticles or lipid microparticles, polymer nanoparticles or polymer microparticles, protein nanoparticles or protein microparticles, or solid nanoparticles or solid microparticles.
[0124] In some aspects, the disclosure provides cells comprising any of the modified mRNAs provided herein.
[0125] In some embodiments, the cell is a mammalian cell.
[0126] In some aspects, the present disclosure provides a composition comprising any of a modified mRNA provided herein, a delivery agent provided herein, or a cell provided herein.
[0127] In some embodiments, the composition further comprises an additional agent. In some embodiments, the additional agent is an agent that has a therapeutic effect when administered to a subject. In some embodiments, the additional agent is a nucleotide, a nucleic acid, an amino acid, a peptide, a protein, a small molecule, an aptamer, a lipid or a carbohydrate. In some embodiments, the additional agent is a shRNA, a siRNA or an ASO. In some embodiments, the additional agent is an antigen or an adjuvant.
[0128] In some embodiments, the composition is a pharmaceutical composition, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
[0129] In some aspects, the disclosure provides a method comprising introducing any of the modified mRNA provided herein, the delivery agent provided herein, or the composition provided herein into a cell.
[0130] In some aspects, the present disclosure provides a method comprising introducing any of the modified mRNA provided herein, the delivery agent provided herein, the cell provided herein, or the composition provided herein into a subject.
[0131] In some aspects, the present disclosure provides a method of preventing a disease in a subject in need thereof, the method comprising introducing an effective amount of any of the modified mRNA provided herein, the delivery agent provided herein, the cell provided herein, or the composition provided herein into the subject, wherein the open reading frame of the modified mRNA encodes a protein.
[0132] In some aspects, the present disclosure provides a method of treating a disease in a subject in need thereof, the method comprising introducing an effective amount of any of the modified mRNA provided herein, the delivery agent provided herein, the cell provided herein, or the composition provided herein into the subject, wherein the open reading frame of the modified mRNA encodes a protein.
[0133] In some embodiments, the protein is a protein antigen or a fragment thereof from a cell or virus that causes the disease.
[0134] In some embodiments, the protein is a protein that is expressed in the subject at a level lower than a reference value.
[0135] In some aspects, the present disclosure provides a method of replacing an enzyme in a subject, the method comprising introducing any of the modified mRNA provided herein, the delivery agent provided herein, the cell provided herein, or the composition provided herein into the subject, wherein the open reading frame of the modified mRNA encodes an enzyme.
[0136] In some embodiments, the subject is a human.
[0137] In some aspects, the disclosure provides any of the modified mRNA provided herein, the delivery agent provided herein, the cell provided herein, or the composition provided herein for use in treating a disease in a subject in need thereof.
[0138] In some aspects, the disclosure provides a kit comprising the first RNA and the tailing nucleic acid and / or the capping nucleic acid in the method of producing any of the modified mRNAs provided herein.
[0139] In some embodiments, the kit further comprises an RNA ligase.
[0140] In some aspects, the present disclosure provides a kit comprising a pharmaceutical composition provided herein, a device for administering the pharmaceutical composition to a subject, and instructions for administering the pharmaceutical composition to a subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0141] Figure 1A -J shows a schematic diagram depicting alternate design pathways and approaches for synthesizing poly-tailed and poly-capped mRNAs. Figure 1A The typical pathway for eukaryotic translation initiation is shown. Figure 1B A pseudo-closed-circle model of actively translating mRNA is shown, in which the poly(A) tail is degraded by exonuclease activity. Figure 1CA first orthogonal design pathway for synthesizing multi-tailed mRNA is shown, in which cross-linking chemistry (e.g., click chemistry) is used to generate multi-tailed mRNA. The poly-A branches are attached to the mRNA using site-specific "cross-linking" groups that are incorporated into the 3' end of the mRNA transcript as modified nucleotides (e.g., added by polymerase or site-specific modification by enzymatic treatment or by ligation of molecules / oligonucleotides containing cross-linking groups). Figure 1D A schematic diagram depicting the pathway for synthesizing a multi-tailed mRNA construct starting with a poly-A oligonucleotide modified with several internal 5-octadiynyl dU sites, to which more poly-A oligonucleotides are attached by click chemistry (at the triangles) to produce a brushed poly-A tail. The brushed poly-A tail is then attached to the 3' end of the RNA including the coding sequence (CDS). Figure 1E A second orthogonal design pathway for the synthesis of multi-tailed mRNA is shown, in which a poly-A tail functionalized dendrimer is attached to the 3' end of a linear mRNA using chemical or enzymatic ligation. Figure 1F A schematic diagram depicting the pathway for the synthesis of a multi-tailed mRNA construct starting from a PAMAM dendrimer functionalized with alkyne groups to which a poly-A oligonucleotide is attached by a click chemistry reaction (at the triangle). One of the poly-A oligonucleotides of the dendrimer is then attached to the 3' end of an RNA comprising a coding sequence (CDS). Figure 1G A first orthogonal design pathway for synthesizing multi-capped mRNA is shown, in which cross-linking chemistry (e.g., click chemistry) is used to generate multi-capped mRNA. The multi-cap branches are attached to the mRNA using site-specific "cross-linking" groups that are incorporated into the 5' end of the mRNA transcript as modified nucleotides (e.g., by ligation of molecules / oligonucleotides containing cross-linking groups). Figure 1H A schematic diagram depicting the pathway for synthesizing a multi-capped mRNA construct starting with a 5' capping oligonucleotide modified with several internal 5-octadiynyl dU sites, to which more 5' capping oligonucleotides are ligated by click chemistry (at triangles) to generate a brush 5' capping sequence. The brush 5' capping sequence is then ligated to the 5' end of the RNA including the coding sequence (CDS). Fig. 1I A second orthogonal design pathway for the synthesis of multi-capped mRNA is shown, in which a multi-capped functionalized dendrimer is attached to the 5' end of a linear mRNA using chemical or enzymatic ligation. Figure 1JA schematic diagram depicting the pathway for the synthesis of a multi-capped mRNA construct starting from a PAMAM dendrimer functionalized with alkyne groups to which a 5' capping oligonucleotide is attached by a click chemistry reaction (at the triangle). One of the dendrimer's 5' capping oligonucleotides is then attached to the 5' end of an RNA comprising a coding sequence (CDS).
[0142] Figure 1K and 1L Protein expression from different multi-tailed mRNA constructs is shown. Figure 1K GFP production over time from different multi-tailed mRNA constructs is shown. Untreated GFP mRNA: GFP mRNA obtained by in vitro transcription. Mock ligation: product of ligation reaction between GFP mRNA and no oligonucleotide. Brush oligonucleotide ligation only: product of ligation reaction between GFP mRNA and brush oligonucleotide precursors shown in Table 1. Brush 3' Azide Click and Ligation: product of ligation reaction between GFP mRNA and brush oligonucleotide, which is synthesized by click reaction between brush oligonucleotide precursor and 3' Azide poly(A) oligonucleotide in Table 1. Brush 5' Azide Click and Ligation: product of ligation reaction between GFP mRNA and brush oligonucleotide, which is synthesized by click reaction between brush oligonucleotide precursor and 5' Azide poly(A) oligonucleotide in Table 1. mCherry mRNA was always unligated and therefore used as an internal control and was co-transfected with GFP mRNA. GFP / mCherry ratio was calculated based on the intensity of GFP and mCherry signals, respectively. Figure 1LFirefly luciferase production over time from different multi-tailed mRNA constructs is shown. Untreated luciferase mRNA: Firefly luciferase mRNA obtained by in vitro transcription. Mock ligation: The product of the ligation reaction between firefly luciferase mRNA and no oligonucleotide. Brush oligonucleotide ligation only: The product of the ligation reaction between firefly luciferase mRNA and the brush oligonucleotide precursor shown in Table 1. Brush 3' Azide Click and Ligation: The product of the ligation reaction between firefly luciferase mRNA and a brush oligonucleotide, which is synthesized by a click reaction between a brush oligonucleotide precursor and a 3' azide poly(A) oligonucleotide in Table 1. Brush 5' Azide Click and Ligation: The product of the ligation reaction between firefly luciferase mRNA and a brush oligonucleotide, which is synthesized by a click reaction between a brush oligonucleotide precursor and a 5' azide poly(A) oligonucleotide in Table 1. Renilla luciferase mRNA was always unligated and therefore used as an internal control and co-transfected with firefly luciferase mRNA.The firefly / renilla ratio was calculated from the intensity of the bioluminescent signal induced by firefly luciferase and renilla luciferase, respectively.
[0143] Figures 2A-2D Conceptualization of chimeric mRNAs carrying multiple poly(A) tails is shown. Figure 2A A pseudo-closed-loop model for actively translating mRNA is shown. Figure 2B A summary of the oligonucleotide chemical conjugation methods is shown. Screening was performed using micromolar concentrations of the 15-ntdA model substrate. Modification handles were incorporated by solid phase synthesis, followed by amine-NHS labeling and HPLC purification as required. Figure 2C Shown is gel electrophoresis of crude thiol-ene / yne oligonucleotide conjugation of a 15-nt model substrate containing only one conjugation handle. Figure 2D Shown is the gel electrophoresis of crude CuAAC and IEDDA 30-nt oligonucleotides carrying three EU / TCO handles reacted with 30-nt N3 / Tz modified oligonucleotides. Figure 2E Preliminary dual luciferase assays using branched mRNA prepared from unpurified CuAAC mixtures are shown, the mixture being enriched with branched oligonucleotides of different equivalents. Branched oligonucleotides contain native (5' to 3') or reverse (3' to 5') directionality and are modified on the last six bases. As outlined in Figure 1, time course assays were performed. n = 3 independent transfections were performed under each biological condition. Mean ± sem. P values (α = 0.05) were calculated by ordinary two-factor ANOVA (Dunnett's multiple comparison test, mean values across time points compared), and multiple comparisons were performed with linear constructs.**** P<0.0001, not significant. P>0.1234.
[0144] Figure 3A -F shows the conceptualization of a chimeric mRNA molecule carrying multiple poly-A tails. Figure 3A The synthesis and screening pipeline of branched mRNA is shown. EU and azide containing oligonucleotides are chemically conjugated, HPLC purified and enzymatically connected to the 3' end of mRNA to produce translatable branched mRNA encoding firefly luciferase reporter gene. Constructs were screened in a dual luciferase assay over a 72-hour time course with Renilla luciferase as a transfection control. M, marker. Figure 3B-3D HPLC purification chromatogram and gel electrophoresis characterization of an oligonucleotide containing 1 / 2 / 3 branched poly(A) are shown. Fractions containing the desired product (boxed) were pooled and separated. Figure 3E Representative RNase H characterization of chimeric mRNA branched poly(A) conjugates is shown. The RNase H probe was designed 200 nt upstream of the 3' end of the mRNA, and the conjugated product (boxed) was characterized by the corresponding band shift after RNase H digestion on gel electrophoresis. Figure 3F A bar graph of a time course dual luciferase assay screening for chemical modifications on the polymerized poly(A) tail is shown. Protein expression was measured at 24, 48, and 72 hours post-transfection by firefly luciferase luminescence normalized to Renilla luciferase luminescence and linear mRNA control. Mean ± sem. P values (α = 0.05) were calculated by ordinary two-way ANOVA (Dunnett's multiple comparison test, comparison of means across time points), and multiple comparisons were performed with the linear construct. * P<0.0332, ** P<0.0021, *** P < 0.0002, **** P<0.0001, not significant. P>0.1234.
[0145] Figures 4A-4K Mechanistic characterization of mRNA stabilization by polymerizing the poly-A tail is shown. Figure 4A-4B Kinetic characterization of firefly degrader reporter mRNA is shown. Firefly RLU / Renilla RLU * Mean values (Renilla RLU) normalizes the firefly RLU of each construct at the corresponding time point to the Renilla luciferase control, and normalizes the firefly RLU of each construct at 8 hours. The decay half-life is calculated by fitting exponential curve. P value (α=0.05) is calculated by common two-factor ANOVA (Dunnett's multiple comparison test, mean value comparison across time points), and multiple comparisons are carried out with linear constructs.**** P<0.0001. Figure 4C Shows Figure 2C Decay kinetics of the internal control Renilla luciferase RLU outlined in . P values (α=0.05) were calculated by ordinary two-way ANOVA (Dunnett's multiple comparison test, comparison of means across time points) and multiple comparisons with the linear construct. Not significant. P>0.1234. Figure 4D A schematic diagram of the coordinated in situ sequencing characterization of targeted mRNA transcripts using STARmap+RIBOmap is shown. Six hours after co-transfection of firefly and Renilla luciferase mRNA, cells were re-seeded into two wells at each time point under each condition. RIBOmap and STARmap characterization of engineered firefly luciferase transcripts in each replicate measured ribosome-bound mRNA or total mRNA, respectively. In all replicates, unmodified Renilla luciferase mRNA was sequenced by STARmap to calculate transfection efficiency. Representative STARmap / RIBOmap images were collected under the same confocal imaging settings. For each case, at least three independent transfections were performed, with four FOVs imaged for each transfection. DAPI (blue), cell nucleus; firefly luciferase amplicon (magenta); Renilla luciferase amplicon (yellow). The firefly / Renilla amplicon (white dots) co-localized in STARmap is a lipid transfection vesicle and is excluded from downstream quantification. Figure 4E Representative STARmap / RIBOmap images collected under the same confocal imaging settings are shown. Modified firefly luciferase mRNA has been STARmap / RIBOmap characterized, and internal control Renilla luciferase mRNA has been STARmap characterized, as summarized in Figure 2. DAPI (blue), nucleus; Firefly luciferase amplicon (magenta); Renilla luciferase amplicon (yellow). The firefly / Renilla amplicon (white dots) co-localized in STARmap is a lipid transfection vesicle and is excluded from downstream quantification. Figure 4F-4G Violin plots of single cell quantification of firefly luciferase STARmap / RIBOmap amplicons are shown. P values were calculated by ordinary two-way ANOVA (α=0.05). **** P<0.0001. Figure 4HComparison of translation efficiency (TE) of branched and linear mRNA across different time points is shown. For each single cell, total firefly mRNA abundance was measured by log10 (firefly STARmap / Sea Renilla STARmap); ribosome-bound firefly mRNA abundance was measured by log10 (firefly RIBOmap / Sea Renilla STARmap). TE was calculated by the ratio of ribosome-bound fireflies / total fireflies, and the median of each FOV was normalized for linear firefly mRNA. Mean ± sem. P values were calculated by unpaired t-test and Welch's correction. ** P<0.004; not significant. P>0.1234. Fig. 4I Shown is a gel shift assay of three branched poly-A oligonucleotides with different concentrations of PABPC1-GST, where the stem oligonucleotide was labeled at the 5' end with Alexa Fluor 546. Both the stem and branched poly-A are 30 nt and modified with PS-2MOE at the last six bases and with ddC at the 3' end (top). Fig. 4I Also shown is a gel shift assay of the same modified poly-A oligonucleotide without branching (middle). Fig. 4I Shown is a competitive binding assay of Alexa 546-labeled branched poly(A) oligonucleotides versus unlabeled linear poly(A) oligonucleotides to PABCP1-GST (bottom). Figures 4J-4K The apparent K values of branched / linear poly(A) oligonucleotides are shown. d The percentage of poly(A) oligonucleotides that bound to x-mers of PABP was calculated as the total percentage of oligonucleotides that bound to >x-mers of PABP, and the apparent K d It was calculated by plotting the percentage of poly(A) oligonucleotide bound by PABP versus PABP concentration (specific binding with Hill slope) using GraphPad Prism.
[0146] Figures 5A-5C Comparison of branched versus circular mRNAs is shown. Figure 5A Shown is a gel electrophoresis of circRNAs generated by IVT, back-splicing and enriched by RNase R treatment. Figure 5BComparison of linear / branched / circular mRNA with optimized UTRs at different doses of circRNA using secreted nanoluciferase 24 hours after transfection in HeLa cells is shown. Both branched and linear mRNAs are co-transcriptionally capped and tailed and contain human α-globin UTRs. Branched mRNAs are connected to optimized branched constructs with 6*PS-2MOE modifications. CircRNAs are designed to encode HRV IRES (with proximal loop Apt-eIF4G insertion) and 3'-PABP binding motifs. Figure 5C A time course comparison of linear, branched, and circular mRNAs encoding secreted NanoLuc is shown. Both branched and linear mRNAs are co-transcriptionally capped and tailed and contain human alpha globin UTRs. Branched mRNAs are linked to optimized branched constructs with 6*PS-2MOE modifications. CircRNAs are designed to encode HRV IRES (with proximal loop Apt-eIF4G insertion) and 3'-PABP binding motifs. Cells were transfected with equimolar (0.2 pmol) amounts of each construct (three independent liposome transfections were performed in each case). Cells were cultured in DMEM medium without phenol red. On each day, the medium was completely renewed and luciferase assays were performed using 50uL of old medium. Mean ± sem. n = 3 independent transfections were performed under each biological condition.
[0147] Figures 6A-6J Shown is GFP ablation using branched Cas9 mRNA. Fig. 6A A schematic diagram of a GFP ablation experiment is shown. Branched / linear Cas9 mRNA was co-transfected with sgRNA targeting GFP CDS. Figure 6B Representative images acquired under the same confocal imaging settings are shown. Hoechst (blue), cell nuclei; GFP (green). Figure 6C Violin plots showing % GFP intensity of HEK293-uGFP cells treated with 100 ng branched / linear Cas9 mRNA after 72 hours normalized to control. Fig.6D A bar graph of single cell GFP intensity 72 hours after transfection is shown. The average GFP intensity in individual cells was measured and normalized to the average GFP density of untreated cells. Mean ± sem. P values were calculated by ordinary one-way ANOVA (α = 0.05), (Tukey's multiple comparison test), with multiple comparisons between each group. **** P<0.0001. Not significant. P>0.1234. Fig. 6ERepresentative images acquired 72 hours after transfection under the same confocal imaging settings are shown. For each condition, the same amount of sgRNA was transfected while varying the dose of Cas9 mRNA. Hoechst (blue), cell nucleus; GFP (green). Fig. 6F Schematic diagram of in vivo expression of branched / linear NanoLuc mRNA is shown. mRNA was formulated in LNPs and equimolar branched / linear mRNA-LNP complexes were administered by retro-orbital injection. Mice were imaged at the indicated time points and serum was collected 15 days after injection. Figure 6G Shown are in vivo luminescence images of mice treated with polyC / linear / branched mRNA-LNPs at 24 / 72 / 144 / 240 hours after LNP administration. Figures 6H-6I In vivo luminescence signals of linear / branched NanoLuc mRNA are shown. Luminescence was measured by integrating the total flux per mouse, normalized by subtracting the background (poly-C treated mice). Mean ± sem. n = 3 male mice per condition. Figure 6J Serum levels of immunogenicity and hepatotoxicity biomarkers are shown. Serum concentrations of TNF-α, AST, and ALT were quantified by ELISA. Mean ± sem. n = 3 mice, each biological condition was measured in duplicate. P values (α = 0.05) were calculated by common one-way ANOVA (Tukey's multiple comparison test). Multiple comparisons were performed between each group. ** P < 0.004; **** P<0.0001; not significant. P>0.1234.
[0148] Figures 7A-7E Conceptualization of chimeric mRNAs carrying multiple 5' caps is shown. Fig. 7A Depicted is the chemical structure of the eukaryotic mRNA 5' cap. Figure 7B A pseudo-closed-loop model for cap-dependent mRNA translation initiation is shown. The 5' cap is recognized by eIF4E, leading to the formation of the translation initiation complex and ribosome recruitment. Figure 7C A mocRNA carrying a chemically conjugated handle is shown attached to a capping oligonucleotide via click chemistry. Multiple m7G caps lead to increased binding to eIF4E and higher ribosome loading on the mRNA transcript. Fig.7D Shown that Type 1 poly-capped mocRNA is characterized by branching in the 5'UTR by chemical conjugation to capping oligonucleotides. Fig. 7E It is shown that Type 2 poly-capped mocRNA is characterized by attachment to a multivalent small molecule handle that is conjugated to a poly-capping oligonucleotide.
[0149] Figures 8A-8D The general synthesis workflow of type 1 poly-capped mRNA is shown. Fig. 8A Shown are chemically synthesized mRNA transcripts and oligonucleotides carrying click chemistry handles chemically capped with m7G-imidazolide, HPLC purified, and finally cross-linked by the corresponding click reactions. Figure 8B Chemically synthesized mRNA transcripts and oligonucleotides carrying click chemistry handles are shown to be cross-linked by click reaction and HPLC purified. The conjugated product is then capped using m7G-imidazole to incorporate multiple caps. Figure 8C Chemically synthesized oligonucleotides carrying click chemistry handles are shown to undergo cross-linking and HPLC purification to generate branched oligonucleotides, which are then capped with m7G-imidazole to incorporate multiple caps. The multi-capped oligonucleotides are ligated to 5'-monophosphorylated mRNA transcripts generated by IVT and RppH hydrolysis. Fig.8D Shows Figure 8C An alternative workflow is described in which oligonucleotides are first chemically capped and then cross-linked.
[0150] Figures 9A-9D A proof-of-concept experiment using type 1 poly-capped mRNA encoding a HiBit tag is shown. Fig.9A Shown is a synthetic HiBit mRNA with a EU handle in the 5'UTR that was chemically capped and ligated to a 5' capped 3'-azide oligonucleotide. The dually capped HiBit mRNA was then transfected into HeLa cells and evaluated by a luciferase assay. Fig. 9B The synthesis of m7G-imidazole chemical capping reagent is shown. Fig. 9C Representative HPLC traces for purification of uncapped and click chemistry handle capped oligonucleotides are shown. Fig.9D Shown is agarose gel electrophoresis of individually capped / single-capped and branched / double-capped HiBit mRNA. Fig.9E Hibit bioluminescence 12 h after mRNA transfection is shown. Mean ± sem. P values were calculated by unpaired t-test with Welch's correction. **** P < 0.0001; ** P<0.004; not significant. P>0.1234. DETAILED DESCRIPTION
[0151] Provided herein are modified mRNAs that include additional poly-A tails and / or additional 5' caps to improve the stability of modified mRNA in cells and thereby enhance the production of encoded gene products (such as proteins). Also provided are methods for preparing modified mRNAs described herein by adding a poly-A region including multiple poly-A tails to the 3' end of the mRNA and / or adding a 5' cap region including multiple 5' caps to the 5' end of the mRNA. Various methods for producing multi-tailed and multi-capped mRNAs are contemplated herein. In one method, an oligonucleotide including a poly-A tail or an oligonucleotide including a 5' cap oligonucleotide is connected to the 3' or 5' end of an mRNA molecule, respectively. The connected oligonucleotide is then connected to an additional poly-A tailed or 5' capped oligonucleotide (e.g., by a click chemistry reaction with a modified oligonucleotide), depending on whether it is present at the 3' end or the 5' end of the modified mRNA ( Figure 1B and 1D In an alternative approach, a dendrimer linked to multiple oligonucleotides including a poly-A tail or a 5' cap (eg, by click chemistry with modified oligonucleotides) is attached to the 3' or 5' end of the mRNA molecule, respectively ( Figure 1C and 1E ). Additionally, the present disclosure provides compositions comprising one or more of the modified mRNAs provided herein, including pharmaceutical compositions. Kits containing reagents for producing modified mRNAs are also described herein. Methods for administering one or more of the modified mRNAs described herein to cells or subjects, and kits for administering any of the pharmaceutical compositions provided herein to subjects are further provided herein.
[0152] Conventional mRNA includes a poly-A tail, wherein there are multiple adenosine nucleotides at the 3' end, and a 5' cap at the 5' end. Although each of these components protects mRNA and helps to recruit factors involved in protein translation, mRNA is degraded by exonucleases. Once the exonucleases remove the poly-A tail and / or the 5' cap and begin to remove the nucleotides of the open reading frame, the mRNA cannot be translated into the encoded protein. One of the main determinants of mRNA stability in cells is the time required to degrade the ends of the mRNA. The degradation rate of mRNA that is more resistant to 3' and 5' exonucleases is slower. The modified mRNA of the present invention generally has a longer half-life in cells, and is therefore more stable. Due to its increased stability (i.e., resistance to exonucleases), the modified mRNA of the present invention has a higher translation efficiency (i.e., the number of gene products (such as proteins) translated from mRNA per second) than its unmodified counterpart. Modified mRNA can further contain one or more structural changes to the core base of mRNA, sugar and / or phosphate bond, and these changes also can disturb exonuclease activity.In addition, other poly-A tail and / or 5 ' cap added to mRNA described herein can also improve translation efficiency by introducing more sites for binding by the factors involved in eukaryotic protein translation on mRNA.By modifying mRNA molecule to include other poly-A tail and other 5 ' cap, these effects can be combined.There is higher stability in cell and therefore can produce more modified mRNA of encoded protein from given RNA molecule and can be used for various applications, comprise and be used for treating and preventing diseases, for example, for vaccine and other therapy based on RNA, as the mRNA of coding essential enzyme, coagulation factor, transcription factor, growth factor, cytokine, chemokine, antibody, protein hormone, signal transduction protein, structural protein or cell surface receptor is delivered to experimenter's cell.
[0153] definition
[0154] As used herein, "messenger RNA" ("mRNA") refers to a nucleic acid that includes an open reading frame encoding a gene product (such as a protein) and a poly-A region located 3' of the open reading frame. The mRNA may also include a 5' untranslated region (5'UTR) located 5' (upstream) of the open reading frame and a 3' untranslated region located 3' (downstream) of the open reading frame. The mRNA may also include a 5' cap located at the 5' end of the mRNA.
[0155] As used herein, "open reading frame encoding a protein" refers to a nucleic acid sequence including a coding sequence, which, when the open reading frame is translated, results in the production of a protein. The nucleic acid sequence may be an RNA sequence, in which case the translation of the RNA sequence produces a polypeptide having the amino acid sequence of the protein. The nucleic acid sequence may be a DNA sequence, in which case the protein is produced when RNA polymerase uses the DNA sequence to transcribe an RNA molecule including an RNA sequence complementary to the DNA sequence and the translation of the RNA sequence produces a polypeptide having the amino acid sequence of the protein. The open reading frame typically begins with a start codon, such as AUG in an RNA sequence (ATG in a DNA sequence), and ends with a stop codon, such as UAG, UAA or UGA in an RNA sequence (TAG, TAA or TGA in a DNA sequence), wherein the number of bases between the G of the start codon and the T or U of the stop codon is a multiple of 3 (e.g., 3, 6, 9).
[0156] RNA molecules that can be translated are called messenger RNA or mRNA. DNA or RNA sequences encode genes through codons. Codons refer to a group of three nucleotides in a nucleic acid (such as DNA or RNA) sequence. Anticodons refer to a group of three nucleotides in a nucleic acid (such as transfer RNA (tRNA)), which are complementary to codons so that the codon of a first nucleic acid associates with the anticodon of a second nucleic acid through hydrogen bonds between the bases of the codon and the anticodon. For example, the codon 5'-AUG-3' on mRNA has a corresponding anticodon 3'-UAC-5' on tRNA. During translation, tRNA with an anticodon complementary to the codon to be translated associates with the codon on the mRNA, which is generally used to deliver the amino acid corresponding to the codon to be translated, or to promote the termination of translation and the release of the translated polypeptide from the ribosome.
[0157] Translation is a process in which an RNA coding sequence is used to guide the production of a polypeptide. The first step in translation is initiation, in which a ribosome associates with an mRNA, and a first transfer RNA (tRNA) carrying a first amino acid associates with a first codon or a start codon. The next stage of translation, extension, involves three steps. First, a second tRNA associates with an mRNA, the tRNA having an anticodon complementary to a codon after the start codon or the second codon and carrying a second amino acid. Second, a carbon atom of the terminal non-side chain carboxylic acid portion of the first amino acid reacts with a nitrogen of the terminal non-side chain amino portion of the carried second amino acid, thereby forming a peptide bond between the two amino acids, wherein the second amino acid is bound to the second tRNA, and the first amino acid is bound to the second amino acid, but not to the first tRNA. Third, the first tRNA dissociates from the mRNA, and the ribosome advances along the mRNA, so that the position where the first tRNA associates with the ribosome is now occupied by the second tRNA, and the position previously occupied by the second tRNA can now be used for another tRNA carrying another amino acid to associate with the mRNA. These three steps: 1) association of a tRNA carrying an amino acid; 2) formation of a peptide bond, adding an additional amino acid to the growing polypeptide; and 3) advancement of the ribosome along the mRNA, continue until the ribosome reaches a stop codon, which terminates translation. Typically, the tRNA associated with the stop codon does not carry an amino acid, so the association of a tRNA that does not carry an amino acid during the elongation step results in cleavage of the bond between the polypeptide and the tRNA carrying the final amino acid in the polypeptide, allowing the polypeptide to be released from the ribosome. Alternatively, if no tRNA is associated with the stop codon, the ribosome may dissociate from the mRNA and release the polypeptide.
[0158] As used herein, "nucleic acid" or "polynucleotide" refers to an organic molecule comprising two or more covalently bonded nucleotides. As used herein, "nucleotide" refers to an organic molecule comprising the following: 1) a nucleoside comprising a sugar covalently bonded to a nitrogenous base (nucleobase); and 2) a phosphate group covalently bonded to the sugar of the nucleoside. The nucleotides in a polynucleotide are usually joined by a phosphodiester bond, wherein the 3' carbon of the sugar of the first nucleotide is connected to the 5' carbon of the sugar of the second nucleic acid by a bridging phosphate group. Typically, the bridging phosphate includes two non-bridging oxygen atoms and two bridging oxygen atoms, the non-bridging oxygen atoms are only combined with the phosphorus atom of the phosphate, and each of the bridging oxygen atoms connects the phosphorus atom to the 3' carbon of the first nucleotide or the 5' carbon of the second nucleotide. In a nucleic acid sequence describing the order of nucleotides in a nucleic acid, if the 3' carbon of the first nucleotide is connected to the 5' carbon of the second nucleotide, the first nucleotide is referred to as being located at the 5' place (upstream) of the second nucleotide. Similarly, if the 5' carbon of the second nucleotide is linked to the 3' carbon of the first nucleotide, the second nucleotide is said to be located 3' (downstream) of the first nucleotide. Nucleic acid sequences are usually read in 5'->3' order, starting with the 5' nucleotide and ending with the 3' nucleotide.
[0159] As used herein, a "modified nucleotide" refers to a nucleotide whose structure is not the canonical structure of an adenosine nucleotide, a cytidine nucleotide, a guanine nucleotide, or a uracil nucleotide. The canonical structure of a molecule refers to the structure of the structure referred to by the name of the molecule as generally known in the art. The canonical structure of an adenosine nucleotide, including an adenine base, a ribose sugar, and one or more phosphate groups, is shown below in the form of adenosine monophosphate:
[0160]
[0161] The canonical structure of AMP also refers to a structure in which one or more hydroxyl groups of a phosphate and / or one or more hydroxyl groups of a sugar are deprotonated, and a structure in which an oxygen atom of a phosphate and / or a 3' oxygen atom of a sugar is bound to an adjacent nucleotide in a nucleic acid sequence.
[0162] The canonical structure of a cytosine nucleotide comprising a cytosine base, a ribose sugar, and one or more phosphate groups is shown below in the form of cytidine monophosphate:
[0163] The canonical structure of CMP also refers to a structure in which one or more hydroxyl groups of phosphate and / or one or more hydroxyl groups of sugar are deprotonated, and a structure in which an oxygen atom of phosphate and / or a 3' oxygen atom of sugar is bound to an adjacent nucleotide in a nucleic acid sequence.
[0164] The canonical structure of a guanine nucleotide comprising a guanine base, a ribose sugar, and one or more phosphate groups is shown below in the form of guanosine monophosphate:
[0165] The canonical structure of GMP also refers to a structure in which one or more hydroxyl groups of phosphate and / or one or more hydroxyl groups of sugar are deprotonated, and a structure in which an oxygen atom of phosphate and / or a 3' oxygen atom of sugar is bound to an adjacent nucleotide in a nucleic acid sequence.
[0166] The canonical structure of a uracil nucleotide comprising a uracil base, a ribose sugar, and one or more phosphate groups is shown below in the form of uridine monophosphate:
[0167] The canonical structure of UMP also refers to a structure in which one or more hydroxyl groups of phosphate and / or one or more hydroxyl groups of sugar are deprotonated, and a structure in which an oxygen atom of phosphate and / or a 3' oxygen atom of sugar is bound to an adjacent nucleotide in a nucleic acid sequence.
[0168] The structure of a modified nucleotide may differ from the structure of a canonical nucleotide due to one or more modifications in the sugar, nitrogenous base, or phosphate of the nucleotide. In some embodiments, a modified nucleotide includes a modified nucleoside that is not a canonical structure of adenosine, cytosine, guanosine, or uridine. As used herein,
[0169] An example of the canonical structure of adenosine, the adenine nucleoside, is reproduced below:
[0170] The canonical structure of adenosine also refers to a structure in which one or more hydroxyl groups of the phosphate and / or one or more hydroxyl groups of the sugar are deprotonated, a structure in which the 5' carbon is bound to the 5' phosphate in the nucleic acid sequence, and a structure in which the 3' oxygen atom is bound to the 5' phosphate group of an adjacent nucleotide in the nucleic acid sequence.
[0171] An example of the canonical structure of cytidine, i.e., cytosine nucleoside, is reproduced below:
[0172] The canonical structure of cytidine also refers to a structure in which one or more hydroxyl groups of a phosphate and / or one or more hydroxyl groups of a sugar are deprotonated, a structure in which the 5' carbon is bound to a 5' phosphate in a nucleic acid sequence, and a structure in which the 3' oxygen atom is bound to a 5' phosphate group of an adjacent nucleotide in a nucleic acid sequence.
[0173] An example of the canonical structure of guanosine, the guanosine nucleoside, is reproduced below:
[0174] The canonical structure of guanosine also refers to a structure in which one or more hydroxyl groups of the phosphate and / or one or more hydroxyl groups of the sugar are deprotonated, a structure in which the 5' carbon is bound to a 5' phosphate in a nucleic acid sequence, and a structure in which the 3' oxygen atom is bound to a 5' phosphate group of an adjacent nucleotide in a nucleic acid sequence.
[0175] An example of the canonical structure of uridine, i.e., the uridine nucleoside, is reproduced below:
[0176] The canonical structure of uridine also refers to a structure in which one or more hydroxyl groups of a phosphate and / or one or more hydroxyl groups of a sugar are deprotonated, a structure in which the 5' carbon is bound to a 5' phosphate in a nucleic acid sequence, and a structure in which a 3' oxygen atom is bound to a 5' phosphate group of an adjacent nucleotide in a nucleic acid sequence.
[0177] As used herein, "ligase" refers to an enzyme capable of forming a covalent bond between two nucleotides, and the process of "ligation" refers to the formation of a covalent bond between two nucleotides.
[0178] As used herein, "tailed nucleic acid" refers to a nucleic acid that is linked to the 3' end of another nucleic acid. The tailed nucleic acid may include a poly-A tail.
[0179] As used herein, "capped nucleic acid" refers to a nucleic acid that is linked to the 5' end of another nucleic acid. A capped nucleic acid may include a 5' cap.
[0180] As used herein, "poly-A tail" refers to a nucleic acid sequence comprising adenosine nucleotides, which are connected to the 3' end of a nucleic acid (such as RNA). As used herein, "poly-A region" refers to a nucleic acid comprising one or more poly-A tails. The poly-A tail or poly-A region can be composed of nucleotides that are 25-100%, 30-100%, 40-100%, 50-100%, 60-100%, 70-100%, 80-100%, 90-100%, 95-100%, 96-100%, 97-100%, 98-100% or 99-100% adenosine nucleotides. The adenosine nucleotides included in the poly-A tail or poly-A region can be canonical adenosine nucleotides or modified (non-canonical) adenosine nucleotides.
[0181] As used herein, "5' cap" refers to one or more nucleotides covalently linked to the 5' end of a nucleic acid (such as RNA). As used herein, "5' cap region" refers to a nucleic acid comprising one or more 5' caps. The 5' cap may include a 5' capping nucleotide connected to the 5' end of the mRNA by a 5' to 5' triphosphate internucleotide bond. In some embodiments, the nucleotides connected to the mRNA by a 5' to 5' triphosphate internucleotide bond are referred to as "natural" 5' capping nucleotides. In some embodiments, the natural 5' capping nucleotide is a 7-methylguanosine (m7G) nucleotide. In some embodiments, the 5' cap is a modified 5' cap, which includes one or more modified nucleotides, such as a 5' capping nucleotide, or one or more modified internucleotide modifications, such as modifications to a 5' to 5' triphosphate internucleotide bond. In some embodiments, the 5' cap includes one or more nucleotides with a sugar modification (such as 2'-O-methylation).
[0182] An example of a canonical structure of 7-methylguanosine linked to a ribonucleic acid sequence (such as mRNA) via a 5' to 5' triphosphate internucleotide bond is reproduced below:
[0183]
[0184] As used herein, a "brush oligonucleotide" refers to a nucleic acid sequence that includes an internal covalent linkage to the 3' end or the 5' end of one or more second nucleic acid sequences.
[0185] As used herein, "dendrimer" refers to an organic polymer compound that includes a core structure (called a "dendron") to which multiple end groups are covalently attached. The dendrons of the dendrimer can be modified to attach to oligonucleotides (e.g., by click chemistry).
[0186] Modified mRNA
[0187] In some aspects, the present disclosure provides a modified mRNA comprising: i) two or more poly-A tails; and / or ii) two or more 5' caps, wherein each poly-A tail is included at the 3' end of the mRNA by a poly-A region, and each 5' cap is included at the 5' end of the mRNA by a 5' cap region. In some embodiments, the modified mRNA provided herein comprises a poly-A tail and two or more 5' caps. In some embodiments, the modified mRNA provided herein comprises two or more poly-A tails and a 5' cap. In some embodiments, the modified mRNA provided herein comprises two or more poly-A tails and two or more 5' caps.
[0188] As defined herein, the "poly-A region" of an mRNA, also referred to as a "poly(A) region", refers to a region of an mRNA located 3' (downstream) of an open reading frame (ORF) and a 3' untranslated region (UTR) that includes a plurality of consecutive adenosine nucleotides (i.e., any adenosine nucleotide covalently linked to at least one other adenosine nucleotide). The poly-A region typically includes 50 to 300 consecutive adenosine nucleotides, and may encompass a plurality of non-adenosine nucleotides located upstream, downstream, or interspersed between the consecutive adenosine nucleotides. The "5' cap region" of an mRNA refers to a region of an mRNA located 5' (upstream) of an ORF and a 5' UTR. In a cell, after transcription of a DNA sequence that produces a precursor messenger RNA (pre-mRNA), a poly-A tail is added by a polyadenylation enzyme such as a poly-A polymerase (PAP) to produce a long sequence of multiple consecutive adenosine nucleotides at the 3' end of the RNA, and a 5' cap is added by a 5' capping enzyme such as an mRNA guanylyltransferase. The poly-A region and the 5' cap each play a variety of important roles in the production of proteins encoded by mRNA. First, the poly-A region provides a connection site for poly-A binding protein (PABP), which associates with mRNA in the nucleus and promotes export to the cytoplasm (see, for example, Tudek et al. Philosophical Transactions of the Royal Society B-Biological Sciences (Philos Trans R Soc Lond B Biol Sci) .2018.373(1762):20180169). Secondly, the presence of poly-A tail and 5' cap in mRNA helps the initiation of translation (see, for example, Gallie. Genes & Dev. 1991.5:2108–2116, and Munroe et al. Molecular Cell Biology (Mol Cell Biol) .1990.10(7):3441-3455). Finally, the poly-A tail and 5' cap stabilize the mRNA by protecting the ORF from the activity of exonucleases, such as polynucleotide phosphorylase (PNPase), which can remove 3' and 5' nucleotides from the mRNA. As the exonuclease removes nucleotides, the mRNA will gradually become shorter, and once all nucleotides downstream of the open reading frame are removed, the nucleotides removed by the exonuclease will be those of the ORF. Removing nucleotides from the ORF will prevent the translation of the encoded protein. In addition, the association of exonucleases with mRNA near the ORF can inhibit translation by spatially hindering the association of ribosomes and tRNAs with the mRNA.Removal of the poly-A tail is generally considered to be the rate-limiting step in mRNA degradation, where the lifespan of an mRNA in a cell depends on the time required to remove its poly-A tail (see, e.g., Dreyfus et al., Cell. 2002. 111(5): 611-613). The composition of the poly-A tail of an mRNA varies, but contains about 75 adenosine nucleotides in yeast cells and 250 adenosine nucleotides in mammalian cells. The composition of the 5' cap in an mRNA varies less, typically including a 5'7-methylguanosine linked to the mRNA via a 5' to 5' triphosphate internucleotide bond, however, it is known that certain natural modifications occur naturally in the nucleotides to which the 5' cap is linked, such as 2'-O-methylation in the first nucleotide of an mRNA (cap 1) and 2'-O-methylation in the first and second nucleotides of an mRNA (cap 2). The 5' cap in which 2'-O-methylation does not occur is referred to as a "cap 0" cap.
[0189] In some embodiments of the modified mRNA provided herein, the modified mRNA includes a poly-A region and / or a 5' cap region that does not include modified nucleotides (i.e., each nucleotide in the poly-A region and / or the 5' cap region is a canonical nucleotide). In some embodiments, 50% to 60%, 60% to 70%, 70% to 80%, 80% to 90%, 90% to 95%, 95% to 99%, or 100% of the nucleotides in the poly-A region or the 5' cap region are canonical nucleotides. In some embodiments, 50% to 60%, 60% to 70%, 70% to 80%, 80% to 90%, 90% to 95%, 95% to 99%, or 100% of the adenosine nucleotides in the poly-A region are canonical adenosine nucleotides.
[0190] In some embodiments of the modified mRNA provided herein, the modified mRNA includes one or more modified nucleotides in the poly-A region and / or the 5' cap region of the mRNA. In some embodiments, the poly-A region and / or the 5' cap region contain one or more nucleotides that are not standard adenosine nucleotides, cytidine nucleotides, guanosine nucleotides or uridine nucleotides. In some embodiments, the poly-A region includes one or more nucleotides located at 3' (downstream) of a nucleic acid sequence including a plurality of continuous adenosine nucleotides. In some embodiments, the poly-A region includes 10-25 continuous adenosine nucleotides, which may be standard adenosine nucleotides or modified adenosine nucleotides. In some embodiments, the poly-A region includes 10-15 continuous adenosine nucleotides, 15-20 continuous adenosine nucleotides or 20-25 continuous adenosine nucleotides, which may be standard adenosine nucleotides or modified adenosine nucleotides. In some embodiments, the poly-A region includes at least 25 continuous adenosine nucleotides, which may be standard adenosine nucleotides or modified adenosine nucleotides. In some embodiments, the poly-A region includes 25-500 consecutive adenosine nucleotides, which may be canonical adenosine nucleotides or modified adenosine nucleotides. In some embodiments, the poly-A region includes 25-300 consecutive adenosine nucleotides. In some embodiments, the poly-A region includes at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 consecutive adenosine nucleotides. In some embodiments, the 5' cap region includes 1 to 3, 3 to 5, 5 to 7 or 7 to 10 5' caps. In some embodiments, the poly-A region and / or the 5' cap region includes 10-500 nucleotides. In some embodiments, the poly-A region and / or the 5' cap region comprises 10 to 15, 15 to 20, 20 to 25, 25 to 50, 50 to 100, 100 to 150, 150 to 200, 200 to 300, 300 to 400, or 400 to 500 nucleotides.
[0191] In some embodiments, each nucleotide of the modified mRNA includes a canonical phosphate group. In some embodiments, the modified mRNA includes one or more nucleotides, and the one or more nucleotides include a modified phosphate group. The modified phosphate group to which the two nucleotides of the modified mRNA are connected is referred to as a "modified internucleotide bond" or a "modified internucleoside bond". The modified phosphate group is a phosphate group that is different from the canonical structure of a phosphate (phosphodiester). Examples of canonical structures of phosphates (phosphodiesters) are shown below:
[0192] Where R5 and R3 are atoms or molecules bonded to a canonical phosphate. For example, for a phosphate in a nucleic acid sequence, R5 may refer to an upstream nucleotide of the nucleic acid, and R3 may refer to a downstream nucleotide of the nucleic acid. The canonical structure of a phosphate also refers to a structure in which one or more hydroxyl groups of the phosphate are deprotonated, or a structure in which an oxygen atom of the phosphate is bonded to an adjacent nucleotide in a nucleic acid sequence. Non-limiting examples of modified phosphate groups that can replace canonical phosphates in nucleic acids include phosphorothioate (PS; R and / or S stereoisomers), thiophosphate, 5'-O-methylphosphonate, 3'-O-methylphosphonate, 5'-hydroxyphosphonate, hydroxyphosphonate, phosphoroselenoate, selenophosphate, phosphoramidate, carbonylphosphonate, methylphosphonate, phenylphosphonate, ethylphosphonate, H-phosphonate, guanidine ring, triazole ring, borophosphate (BP), methylphosphonate, guanidinopropylphosphoramidate, peptide bond (e.g., in peptide nucleic acids), thiophosphoramidate.
[0193] In some embodiments of the modified mRNA comprising modified nucleotides provided herein, at least one modified nucleotide comprises a modified nucleobase. In some embodiments, at least one modified nucleotide comprises a modified sugar. In some embodiments, at least one modified nucleotide comprises a modified phosphate. In some embodiments, at least one modified nucleotide comprises a modified nucleobase selected from the group consisting of: xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, digoxigenated adenine, digoxigenated cytosine, digoxigenated guanine, digoxigenated uracil, 6-chloropurine nucleoside, N6-methyladenine, methyl pseudouracil, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyluracil, 5,6-dihydrouracil, 5-[(3-indolyl)propionamido-N-allyl]uracil, 5-aminoallylcytosine, 5-aminoallyluracil, 5-bromouracil, 5-bromocytosine, 5-carboxycytosine, 5-carboxymethyl ester uracil, 5-carboxyuracil, 5-fluorouracil, 5-formylcytosine, 5-formyluracil, 5-hydroxycytosine, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5-hydroxyuracil, 5-iodocytosine, 5-iodouracil, 5-methoxycytosine, 5-methoxyuracil, 5-methylcytosine, 5-methyl Uracil, 5-propargylaminocytosine, 5-propargylaminouracil, 5-propynylcytosine, 5-propynyluracil, 6-azacytosine, 6-azauracil, 6-chloropurine, 6-thioguanine, 7-deazaadenine, 7-deazaguanine, 7-guanine-7-propargylaminoadenine, 7-deaza-7-propargylaminoguanine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, arabinoadenine, arabinocytosine, arabinoguanine, arabinouracil, biotin-16-7 -deaza-7-propargylaminoguanine, biotin-16-aminoallylcytosine, biotin-16-aminoallyluracil, cyanine 3-5-propargylaminocytosine, cyanine 3-6-propargylaminouracil, cyanine 3-aminoallylcytosine, cyanine 3-aminoallyluracil, cyanine 5-6-propargylaminocytosine, cyanine 5-6-propargylaminouracil, cyanine 5-aminoallylcytosine, cyanine 5-aminoallyluracil, cyanine 7-aminoallyluracil, dabcyl-5-3-aminoallyluracil, desulfurized bio 16-aminoallyl-uracil, desthiobiotin-6-aminoallyl-cytosine, isoguanine, N1-ethylpseudouracil, N1-methoxymethylpseudouracil, N1-methyladenine, N1-methylpseudouracil, N1-propylpseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthosine, 3-deazaadenine, 2,6-diaminoadenine, 2,6-diaminoguanine, 5-formamide-uracil, 5-ethyluracil, N6-isopentenyladenine (i6A), 2-methyl-thio-N6-isopentenyladenine (ms2i6A), 2-methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine (g6A), N 6-Threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxynorvalylcarbamoyladenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A). In some embodiments, at least one modified nucleotide comprises a modified sugar selected from the group consisting of 2'-thioribose, 2',3'-dideoxyribose, 2'-amino-2'-deoxyribose, 2'deoxyribose, 2'-azido-2'-deoxyribose, 2'-fluoro-2'-deoxyribose, 2'-O-methylribose, 2'-O-methyldeoxyribose, 3'-amino-2',3'-dideoxyribose, 3'-azido-2'-deoxyribose, -2',3'-dideoxyribose, 3'-deoxyribose, 3'-O-(2-nitrobenzyl)-2'-deoxyribose, 3'-O-methyl ribose, 5'-amino ribose, 5'-thio ribose, 5-nitro-1-indolyl-2'-deoxyribose, 5'-biotin-ribose, 2'-O,4'-C-methylene linked ribose, 2'-O,4'-C-amino linked ribose and 2'-O,4'-C-thio linked ribose. In some embodiments, at least one modified nucleotide includes a 2' modification, such as a locked nucleic acid (LNA) modification (i.e., a nucleotide including an additional carbon atom bound to the 2' oxygen and 4' carbon of the ribose) or 2'-O-methylation. In some embodiments, at least one modified nucleotide comprises a modified phosphate selected from the group consisting of phosphorothioate (PS), thiophosphate, 5'-O-methylphosphonate, 3'-O-methylphosphonate, 5'-hydroxyphosphonate, hydroxyphosphonate, phosphoroselenoate, selenophosphate, phosphoramidate, carbon phosphonate, methylphosphonate, phenylphosphonate, ethylphosphonate, H-phosphonate, guanidine ring, triazole ring, borophosphate (BP), methylphosphonate and guanidinopropylphosphoramidate. ,
[0194] In some embodiments, the modified mRNA includes more than one type of modified nucleotides. In some embodiments, the modified mRNA includes at least a first modified nucleotide and a second modified nucleotide having a structure different from the first modified nucleotide. The structure of the nucleotides may be different due to differences in nucleobases, sugars, and / or phosphate groups. In some embodiments, the modified mRNA includes at least a first modified phosphate and a second modified phosphate having a structure different from the first modified phosphate. In some embodiments, the modified mRNA includes a first modified nucleoside and a second modified nucleoside.
[0195] Aspects of the present disclosure relate to modified mRNAs comprising poly-A regions having 10 or more adenosine nucleotides. Adenosine nucleotides are nucleotides comprising adenine nucleosides and phosphate groups. Adenosine nucleosides include sugars and adenine bases. In some embodiments, the poly-A region includes 10 or more canonical adenosine nucleotides, for example, 10-15 canonical adenosine nucleotides, 15-20 canonical adenosine nucleotides, or 20-25 canonical adenosine nucleotides. In some embodiments, the poly-A region includes 25 or more canonical adenosine nucleotides, for example, 25-500 canonical adenosine nucleotides. Canonical adenosine nucleotides include adenine bases, ribose, and phosphate groups, as arranged in the structure of adenosine monophosphate (AMP). In some embodiments, one or more hydroxyls of the hydroxyl group of the phosphate and / or the 3' hydroxyl group of the ribose are deprotonated, including oxygen ions instead of -OH groups, as shown in the following structure:
[0196] When present in the nucleic acid sequence of mRNA, a canonical adenosine comprises the following structure and is linked to adjacent nucleotides in the following manner:
[0197] Wherein R5 is the adjacent nucleotide located at 5' (upstream) of the adenosine nucleotide in the mRNA, and R3 is the adjacent nucleotide at 3' (downstream) of the adenosine nucleotide in the mRNA. In some embodiments, the canonical adenosine nucleotide is the 3' terminal nucleotide (the last nucleotide) of the linear mRNA, R3 is hydrogen, and the 3' terminal nucleotide includes a 3' terminal hydroxyl group (-OH). In some embodiments, the canonical adenosine nucleotide is the 3' terminal nucleotide (the last nucleotide) of the linear mRNA, and R3 is an electron.
[0198] Aspects of the present disclosure also relate to modified mRNAs including 5' cap regions with 2 or more 5' caps. The 5' cap may include a 5' capping nucleotide, i.e., the 5' terminal nucleotide (first nucleotide) of a linear mRNA, which is connected to the mRNA via a 5' to 5' triphosphate bond. In some embodiments, the cap includes one or more modified nucleotides, for example, one or more modified nucleotides including 2' modifications (such as locked nucleic acid (LNA) modifications (i.e., nucleotides including additional carbon atoms bound to the 2' oxygen and 4' carbon of ribose) or 2'-O-methylation). In some embodiments, the 5' cap includes a 5' capping nucleotide connected to the mRNA via a non-canonical bond, such as a 5'-5' triphosphate bond or a 5'-5' tetraphosphate modified by a 5'-thiophosphate. In some embodiments, the 5' capping nucleotide is a canonical 5' capping nucleotide, such as a 7-methylguanosine (m7G) nucleotide:
[0199]
[0200] In some embodiments of the modified mRNA provided herein, the mRNA includes a 5' untranslated region (5'UTR) and a 3' untranslated region (3'UTR). 5' and 3'UTR are sequences within the mRNA that do not encode the amino acids of the protein encoded by the mRNA and are therefore not part of the open reading frame. The 5'UTR is located at the 5' (upstream) of the open reading frame. The 3'UTR is located at the 3' (downstream) of the open reading frame. In certain embodiments, the 3'UTR includes one or more nucleotides located at the 3' of the open reading frame of the mRNA and the 5' (upstream) of the poly-A region.
[0201] In some embodiments of the mRNA provided herein, the mRNA includes, in a 5' to 3' order: 1) a 5' cap region; 2) a 5'UTR; 3) an open reading frame (ORF); 4) a 3'UTR; and 5) a poly-A region. In some embodiments, the first nucleotide of the 5'UTR is located 3' (downstream) of the last nucleotide of the 5' cap region, and the last nucleotide of the 5'UTR is located 5' (upstream) of the first nucleotide of the open reading frame. In some embodiments, the first nucleotide of the open reading frame is located 3' (downstream) of the last nucleotide of the 5'UTR, and the last nucleotide of the open reading frame is located 5' (upstream) of the first base of the 3'UTR. In some embodiments, the open reading frame is located between the last nucleotide of the 5'UTR and the first nucleotide of the 3'UTR. In some embodiments, the first nucleotide of the 3'UTR is located 3' (downstream) of the last nucleotide of the open reading frame, and the last nucleotide of the 3'UTR is located 5' (upstream) of the first nucleotide of the poly-A region. In some embodiments, the 5'UTR is located between the last nucleotide of the 5' cap region and the first nucleotide of the open reading frame. In some embodiments, the 3'UTR is located between the last nucleotide of the open reading frame and the first nucleotide of the poly-A region. In some embodiments, the last nucleotide of the 5' cap region is located 5' (upstream) of the first nucleotide of the 5'UTR. In some embodiments, the first nucleotide of the poly-A region is located 3' (downstream) of the last nucleotide of the 3'UTR.
[0202] In some embodiments, mRNA is a linear mRNA. Linear mRNA refers to an mRNA having a 5' terminal nucleotide and a 3' terminal nucleotide. The 5' terminal nucleotide of a linear mRNA is covalently bonded to only one adjacent nucleotide of the mRNA, wherein the adjacent nucleotide appears at 3' of the 5' terminal nucleotide in the nucleic acid sequence of the mRNA. The 3' terminal nucleotide of a linear mRNA is covalently bonded to only one adjacent nucleotide of the mRNA, wherein the adjacent nucleotide appears at 5' of the 3' terminal nucleotide in the nucleic acid sequence of the mRNA. In a nucleic acid sequence that includes each nucleotide of a linear mRNA in the order of 5' to 3', the 5' terminal nucleotide is the first nucleotide in the sequence, and the 3' terminal nucleotide is the last nucleotide in the sequence.
[0203] In some embodiments of the linear mRNA provided herein, the mRNA includes a 5' cap. Most mRNAs produced in eukaryotic cells contain a 5' cap added during the processing of the precursor mRNA into mature mRNA. The 5' cap plays a variety of roles in the process of mRNA production, export and translation. First, the assembly of the spliceosome that mediates the removal of introns from the precursor mRNA requires the nuclear cap binding complex (CBC) to bind to the 5' cap. In addition, the interaction between the CBC and the nuclear pore mediates the export of mRNA from the 5' end to the cytoplasm. Finally, the CBC bound to the 5' cap mediates the recruitment of multiple factors, such as CBP80, CTIF, eIF3g, eIF4III, Met-tRNAi and ribosomal subunits, which are necessary for the initiation of translation (see, for example, Ramanathan et al. "Nucleic Acids Res". 2016.44 (16): 7511-7526). In some embodiments, the 5' cap includes 7-methylguanosine. In some embodiments, 7-methylguanosine includes the following structure:
[0204]
[0205] Cap analogs, also referred to herein as synthetic cap analogs, chemical caps, chemical cap analogs, or structural or functional cap analogs, have a chemical structure that differs from the chemical structure of a natural (i.e., endogenous, wild-type, or physiological) 5'-cap while retaining cap function. Cap analogs can be chemically synthesized (i.e., non-enzymatically synthesized) or enzymatically synthesized and / or attached to a nucleic acid molecule. For example, an anti-reverse cap analog (ARCA) cap contains two guanines linked by a 5'-5'-triphosphate group, one of which contains an N7 methyl group as well as a 3'-O-methyl group (i.e., N7,3'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine (m 7G-3'mppp-G; which can be equivalently designated as 3'O-Me-m7G(5')ppp(5')G). The 3'-O atom of another unmodified guanine is attached to the 5'-terminal nucleotide of the capped nucleic acid molecule (e.g., such as mRNA or mmRNA). The N7- and 3'-O-methylated guanines provide the terminal portion of the capped nucleic acid molecule (e.g., mRNA or mmRNA). Another exemplary cap is mCAP, which is similar to ARCA, but has a 2'-O-methyl group on guanosine (i.e., N7,2'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine, m7Gm-ppp-G). Non-limiting examples of 5' cap structures include 7-benzylguanosine (Bn7G), 7-(4-chlorophenoxyethyl)-guanosine and its analogs (see, e.g., Kore et al. (2013) Bioorganic & Medicinal Chemistry 21(15):4570-4574), 7-ethylguanosine (e7G), 7-propylguanosine (p7G), 7-isopropylguanosine (ip7G), 7-butylguanosine (b7G), 7-isobutylguanosine (ib7G), 7-cyclopentylguanosine (cp7G), 7-(carboxymethyl)guanosine (cm7G), 7-benzylguanosine (bn7G), 7-(2-phenylethyl)guanosine [7-(2-PhEt)G], 7-(1-phenylethyl)guanosine [7-(1-PhEt)G], m 7 Gppp BH3 G (D1 and D2 stereoisomers), m 7 Gpp BH3 G (D1 and D2 stereoisomers), m 7 Gp BH3 G (D1 and D2 stereoisomers), m 7 Gpp BH3 pm 7 G、m2 7,2 ' -O Gppp BH3 G (D1 and D2 stereoisomers), m27 , 2 ' -O Gpp BH3 pG (D1 and D2 diastereomers), m2 7,2 ' -O Gpp SpG (D1 and D2 diastereomers), N-arylmethyl analogs (see, e.g., Wojcik et al. (2021) Pharmaceutics 13(11) 1941), glyceryl, inverted deoxy abasic residues (partial), 4',5'-methylene nucleotides, 1-(β-D-erythrofuranosyl) nucleotides, 4'-thionucleotides, carbocyclic nucleotides, 1,5-anhydrohexitol nucleotides, L-nucleotides, α-nucleotides, modified base nucleotides, thre- Pentofuranosyl nucleotide, non-cyclic 3',4'-tetranucleotide, non-cyclic 3,4-dihydroxybutyl nucleotide, non-cyclic 3,5-dihydroxyphenyl nucleotide, 3'-3'-inverted nucleotide portion, 3'-3'-inverted abasic portion, 3'-2'-inverted nucleotide portion, 3'-2'-inverted abasic portion, 1,4-butanediol phosphate, 3'-amidite, hexyl phosphate, aminoethyl phosphate, 3'-phosphate, 3'-thiophosphate, phosphorothioate or bridged or non-bridged methylphosphonate portion. Additional modified 5'-cap structures that can be used in the context of the present invention are cap 1 (additional methylation of the ribose of the adjacent nucleotide of m7GpppN), cap 2 (additional methylation of the ribose of the second nucleotide downstream of m7GpppN), cap 3 (additional methylation of the ribose of the third nucleotide downstream of m7GpppN), cap 4 (additional methylation of the ribose of the fourth nucleotide downstream of m7GpppN), ARCA (anti-reverse cap analog), modified ARCA (e.g., phosphorothioate-modified ARCA), inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine and 2-azido-guanosine.
[0206] In some embodiments, the 5' cap includes one or more phosphates that connect 7-methylguanosine to adjacent nucleotides of the modified mRNA. In some embodiments, the one or more phosphates of the 5' cap are modified phosphates selected from the group consisting of: thiophosphates, triazole rings, dihalomethylene diphosphonates, iminodiphosphonates, and methylene bis(phosphonates). In some embodiments, 7-methylguanosine is connected to adjacent nucleotides of the mRNA via a 5' to 5' triphosphate bridge. In some embodiments, the 5' cap includes the following structure:
[0207]
[0208] wherein R is the 5' carbon of the first transcribed nucleotide of the mRNA. In some embodiments, the 5' cap comprises 3'-O-Me-m7G(5')ppp(5')G.
[0209] In certain embodiments, the sugar backbone of mRNA includes ribose. In certain embodiments, the sugar backbone includes modification. The non-limiting examples of sugar modification include 2' modification in sugar residues, such as 2'-amino 2'-O-methyl, 2'-O-alkyl, 2'-O-alkyl-O-alkyl, morpholino nucleic acid or 2'-fluoro modified nucleotides. In certain embodiments, mRNA includes locked nucleic acid (LNA). Locked nucleic acid is a nucleotide with a modified ribose moiety, wherein the ribose moiety includes an extra bridge connecting 2' and 4' carbon. This structure effectively "locks" ribose in a 3'-endostructural conformation. In other embodiments, the mRNA backbone includes deoxyribose. In certain embodiments, mRNA includes 2'-fluoro-deoxyribose.
[0210] In some embodiments, the mRNA is a circular mRNA. A circular mRNA refers to an mRNA without a 5' terminal nucleotide or a 3' terminal nucleotide. Each nucleotide in the circular mRNA is covalently bonded to the following two: 1) a 5' adjacent nucleotide; and 2) a 3' adjacent nucleotide. In a circular mRNA having a nucleic acid sequence that includes each nucleotide of the circular mRNA in the order of 5' to 3', the last nucleotide of the nucleic acid sequence is covalently bonded to the first nucleotide of the nucleic acid sequence. In some embodiments of a circular mRNA having a 5' cap region, a 5' UTR, a 3' UTR, and a poly-A region, the poly-A region is located at 3' (downstream) of the 3' UTR and 5' (upstream) of the 5' cap region.
[0211] In some embodiments of the modified mRNA provided herein, 1% to 90% of the nucleotides in the poly-A region or the 5' cap region are modified nucleotides. In some embodiments, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% of the nucleotides in the poly-A region or the 5' cap region are modified nucleotides.
[0212] In some embodiments of the modified mRNA provided herein, 3 or more nucleotides in the last 10 nucleotides of the poly-A region are modified nucleotides. In some embodiments of the modified mRNA provided herein, 3 or more nucleotides in the last 15 nucleotides of the poly-A region are modified nucleotides. In some embodiments of the modified mRNA provided herein, 3 or more nucleotides in the last 20 nucleotides of the poly-A region are modified nucleotides. In some embodiments of the modified mRNA provided herein, 3 or more nucleotides in the last 25 nucleotides of the poly-A region are modified nucleotides. In some embodiments, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20 or 25 nucleotides in the last 10-25 nucleotides of the poly-A region are modified nucleotides.
[0213] In some embodiments of the modified mRNA provided herein, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the nucleotides in the poly-A region are adenosine nucleotides. One or more adenosine nucleotides in the poly-A region can be a canonical adenosine nucleotide or a modified adenosine nucleotide comprising a structure different from the canonical adenosine nucleotide. Non-limiting examples of modified adenosine nucleotides include N6-isopentenyl adenosine (i6A), 2-methyl-thio-N6-isopentenyl adenosine (ms2i6A), 2-methylthio-N6-methyl adenosine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenosine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms2io6A), N6-glycylcarbamoyladenosine (g6A), N6-threonylcarbamoyladenosine (t6A), 2-methylthio-N6-threonylcarbamoyladenosine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenosine (m6t6A), N6-hydroxynorval ...m6t6A), N6-hydroxyvalylcarbamoyladenosine (m6t6A), N6-hydroxyvalylcarbamoyladenosine (m6t6A), N6-hydroxyvalylcarbamoyladenosine (m6t6A), N6-hydroxyvalylcarbamoyladenosine (m6t6A), N6-hydroxyvalylcarbamoyladenosine (m6t6A), N6-hydroxyvalylcarbamoyladenosine (m6t6A), N6-hydroxyvalylcarbamoyladenosine (m6t6A), N6-hydroxyvalylcarbamoyladenosine (m6t adenosine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyladenosine (ms2hn6A), 2'-O-ribosyladenosine (phosphate) (Ar(p)), N6,N6-dimethyladenosine (m62A), N6,2'-O-dimethyladenosine (m6Am), N6,N6,O-2'-trimethyladenosine (m62Am), 1,2'-O-dimethyladenosine (m1Am), N6-acetyladenosine (ac6A), 2'-thioadenosine (2'SA), 5'-thioadenosine (5'SA), 2'-O-(2-azidoethyl)-adenosine, 2'-azido-adenosine, deoxyadenosine (dA), dideoxyadenosine (ddA), and amino-deoxyadenosine (amino-dA).
[0214] In some embodiments of the modified mRNA provided herein, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the nucleotides of the poly-A region are canonical adenosine nucleotides.
[0215] In some embodiments of the modified mRNA provided herein, the poly-A region and / or the 5' cap region include 10-25 nucleotides. In some embodiments of the modified mRNA provided herein, the poly-A region and / or the 5' cap region include 10-15 nucleotides, 15-20 nucleotides or 20-25 nucleotides. In some embodiments of the modified mRNA provided herein, the poly-A region and / or the 5' cap region include 25-500 nucleotides. In certain embodiments, the poly-A region and / or the 5' cap region include at least 25, at least 30, at least 50, at least 100, at least 150 or at least 200 nucleotides. In some embodiments, the poly-A region and / or the 5' cap region comprises at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, or at least 300 nucleotides. In some embodiments, the poly-A region and / or the 5' cap region comprises about 200 to about 300 nucleotides. In some embodiments, the poly-A region and / or the 5' cap region comprises about 250 nucleotides.
[0216] In some embodiments, the poly-A region and / or the 5' cap region include at least 3, at least 4, at least 5 phosphorothioates or at least 6 phosphorothioates. In some embodiments, the poly-A region of the mRNA includes at least 3 phosphorothioates and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 guanine nucleotides and at least 3 phosphorothioates and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 deoxyriboses and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region and / or the 5' cap region include at least 20 deoxyriboses. In some embodiments, the poly-A region of the mRNA includes at least 20 deoxyriboses and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 copies of the G-quadruplex sequence and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 6 phosphorothioates and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 6 consecutive phosphorothioates and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 6 phosphorothioates and 3 guanosine nucleosides and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 copies of the G-quadruplex sequence and at least 6 phosphorothioates and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 copies of the telomeric repeat sequence and at least 6 phosphorothioates and does not include the 3' terminal hydroxyl group. In some embodiments, the 3' terminal nucleotide that does not include the 3' terminal hydroxyl group is a dideoxycytidine or an inverted deoxythymidine.
[0217] In some embodiments, the poly-A region includes two or more poly-A tails, and at least two instances of the poly-A tail are covalently linked to the first linker. In some embodiments, the poly-A region includes the following structure: -(first poly-A tail)-[(first linker)-(second poly-A tail) n1]n2; wherein each instance of n1 is independently an integer between 1 and 20 (including the end value); n2 is an integer between 2 and 10 (including the end value); and the first poly-A tail is covalently linked to the 3'UTR of the mRNA.
[0218] In some embodiments, the poly-A region comprises a brush oligonucleotide comprising two or more poly-A tails.
[0219] In some embodiments, each instance of n1 is 1. In some embodiments, at least one instance of the first linker is covalently linked to the internal nucleotide of the first poly-A tail. In some embodiments, at least one instance of the first linker is covalently linked to the second poly-A tail at the 3' nucleotide of the second poly-A tail. In some embodiments, at least one instance of the first linker includes at least one portion formed by reacting two orthogonal click chemistry handles. Any click chemistry reaction known in the art can be used. Click chemistry is a chemical method introduced by Sharpless in 2001, and describes a chemical method for quickly and reliably producing substances by joining small units together. See, for example, Kolb, Finn and Sharpless "Angewandte Chemie International Edition" (2001) 40: 2004-2021; Evans, "Australian Journal of Chemistry" (2007) 60: 384-395). Exemplary click chemistry reactions include: formation of esters, thioesters, amides from activated acids or acyl halides (e.g., peptide coupling); nucleophilic displacement reactions (e.g., nucleophilic displacement of halides or opening of strained ring systems); azide-alkyne Huisgen cycloaddition; thiol-alkyne addition; imine formation; Michael addition (e.g., maleimide addition); and Diels–Alder reaction (e.g., tetrazine [4+2] cycloaddition).Examples of click chemistry reactions can be found, for example, in the following literature: Kolb, HC; Finn, MG and Sharpless, KB "Angew. Chem. Int. Ed. 2001, 40, 2004-2021; Kolb, HC and Shrapless, KB "Drug Disc. Today", 2003, 8, 112-1137; Rostovtsev, VV; Green LG; Fokin, VV and Shrapless, KB "Angewandte Chemie International Edition" 2002, 41, 2596-2599; Tomoe, CW; Christensen, C. and Meldal, MJ "Org. Chem." 2002, 67, 3057-3064; Wang, Q. et al. "Journal of the American Chemical Society (J. Am. Chem. Soc.)" 2003, 125, 3192-3193; Lee , LV et al. Journal of the American Chemical Society 2003125, 9588-9589; Lewis, WG et al. Angewandte Chemie International Edition 2002, 41, 1053-41057; Manetsch, R. et al. Journal of the American Chemical Society 2004, 126, 12809-12818; Mocharla, VP et al. Angewandte Chemie International Edition 2005, 44, 116-120; each of the documents is incorporated herein by reference in its entirety. In certain embodiments, each instance of the click chemistry handle is a monovalent moiety. In certain embodiments, two orthogonal click chemistry handles (a first click chemistry handle and a second click chemistry handle) react to form a divalent moiety by a click chemistry reaction. In certain embodiments, at least one instance of the first click chemistry handle includes C≡C or C=C. In certain embodiments, at least one instance of the first click chemistry handle includes C≡CH, C=CH, CH=CH, C=CH2, or CH=CH2. In certain embodiments, at least one instance of the first click chemistry handle is -C≡CH, substituted or unsubstituted cyclooctynyl optionally independently fused to one or more instances of substituted or unsubstituted phenyl, substituted or unsubstituted cyclopropenyl, substituted or unsubstituted cyclobutenyl, substituted or unsubstituted trans-cyclooctenyl optionally independently fused to one or more instances of substituted or unsubstituted phenyl, or substituted or unsubstituted. In certain embodiments, at least one instance of the first click chemistry handle comprises -C≡CH. In certain embodiments, at least one instance of the first click chemistry handle comprises In certain embodiments, at least one instance of the first click chemistry handle comprises a trans-cyclooctenyl group, e.g., In certain embodiments, at least one instance of the second click chemistry handle comprises -N3. In certain embodiments, at least one instance of the second click chemistry handle comprises Where R 19 is H, halogen, unsubstituted C 1-6 Alkyl or -O-(unsubstituted C 1-6 In certain embodiments, R 19 In some embodiments, at least one moiety formed by reacting two orthogonal click chemistry handles has the formula:
[0220] In some embodiments, at least one moiety formed by reacting two orthogonal click chemistry handles has the formula: In some embodiments, at least one moiety formed by reacting two orthogonal click chemistry handles has the formula: In some embodiments, each instance of the first linker is independently substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene or substituted or unsubstituted C 1-200 In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with a substituted or unsubstituted carbocyclylene, a substituted or unsubstituted heterocyclylene, a substituted or unsubstituted arylene, or a substituted or unsubstituted heteroarylene. 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, at least one instance of the first linker has the formula: Where L 1 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 heteroalkylene; and L 2 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 In some embodiments, at least one instance of the first linker has the formula:
[0221] In some embodiments, the first poly-A tail comprises a nucleotide sequence as shown below: 5'-rArArArArArAdU(a1)rArArArArArArArArArArArAdU(a1)rArArArArArArArArArArAd U(a1)ddC-3'(SEQ ID NO:1); and at least one instance of the second poly-A tail comprises a nucleotide sequence as shown below: 5'-rArArArArArArArArArArArArArArArArArArArArA*rA*rA*rA*rA*rA*(b1)-3'(SEQ ID NO:2); wherein each instance of the first linker is independently Wherein "rA" represents an adenosine ribonucleotide; "dU(a1)" represents a modified uridine deoxyribonucleotide; "ddC" represents a cytosine dideoxyribonucleotide; "*" represents a phosphorothioate bond; a1 of each instance of dU(a1) represents a point of attachment on the uridine of said dU(a1); b1 of rA*(b1) represents a point of attachment on the * of said rA*(b1); each instance of a1 is connected to an instance of a2; and each instance of b1 is connected to an instance of b2. In some embodiments, the modified uridine deoxyribonucleotide is 5-octadiynyl deoxyuridine, which is shown in the following structure:
[0222]
[0223] In some embodiments, the poly-A region comprises a dendrimer comprising two or more poly-A tails.
[0224] In some embodiments, each instance of n1 is independently an integer between 2 and 20 (inclusive). In some embodiments, at least one instance of the first linker comprises a dendrimer. In some embodiments, at least one instance of the dendrimer is a polyamidoamine (PAMAM) dendrimer. In some embodiments, at least one instance of the PAMAM dendrimer has the formula:
[0225]
[0226] wherein each instance of n3 is independently an integer between 1 and 10 (inclusive); each instance of n4 is independently an integer between 0 and 10 (inclusive); R 2 Each instance of is independently hydrogen or The condition is R 2 At least three instances of And R 1 Each instance of is substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene or substituted or unsubstituted C 1-10 In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced by substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and each instance of n5 is independently an integer between 0 and 10 (inclusive). In some embodiments, at least one instance of the PAMAM dendrimer has the following formula:
[0227]
[0228] In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, at least one instance of the first linker has the following formula:
[0229]
[0230] In some embodiments, the first poly-A tail and the second poly-A tail comprise a nucleotide sequence as shown below:
[0231] 5'-rArArArArArArArArArArArArArArArArArArArArA*rA*rA*rA*rA*rA* / Azide N / -3' (SEQ ID NO: 3); wherein "Azide N" represents the 3' azide moiety and "*" represents a phosphorothioate linkage.
[0232] In some embodiments, at least one instance of the first linker is covalently linked to the 3' nucleotide of the first poly-A tail. In some embodiments, at least one instance of the first linker is covalently linked to the 3' nucleotide of at least one instance of the second poly-A tail.
[0233] In some embodiments, the 5' cap region includes two or more 5' caps, and at least two instances of the 5' cap are covalently linked via a second linker. In some embodiments, the 5' cap region includes the following structure: -(first 5' cap)-[(second linker)-(second 5' cap) m1]m2; wherein each instance of m1 is independently an integer between 1 and 20 (including end values); m2 is an integer between 2 and 10 (including end values); the first 5' cap is covalently linked to the 5'UTR; and the second linker is covalently linked to the first 5' cap and the second 5' cap.
[0234] In some embodiments, the 5' cap region comprises a brush oligonucleotide comprising two or more 5' caps.
[0235] In some embodiments, each instance of m1 is 1. In some embodiments, at least one instance of the second linker is covalently linked to an internal nucleotide of the first 5' cap. In some embodiments, at least one instance of the second linker is covalently linked to the second 5' cap at the 3' nucleotide of the second 5' cap. In some embodiments, at least one instance of the second linker comprises at least one portion formed by reacting two orthogonal click chemistry handles. In certain embodiments, the click chemistry handle is as described herein. In some embodiments, each instance of the second linker is independently substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene or substituted or unsubstituted C 1-200 In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with a substituted or unsubstituted carbocyclylene, a substituted or unsubstituted heterocyclylene, a substituted or unsubstituted arylene, or a substituted or unsubstituted heteroarylene. 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, at least one instance of the second linker has the formula: Where L 3 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 heteroalkylene; and L 4 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 In some embodiments, at least one instance of the second linker has the formula:
[0236] In some embodiments, the first 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArArAdU(c1)rArArGrArGrArArArGrArArGrArGdU(c1)rArArGrArArGrArArAdU(c1)rA-3'(SEQ ID NO:4); and the second 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArGrArCrTrGrCrCrArCrCrCrA*rA*rA*rA*rA*rA*(d1)-3'(SEQ ID NO:5); wherein each instance of the second linker is independently Wherein "*" represents a phosphorothioate bond; "Cap" represents a 5' cap; c1 of each instance of dU(c1) represents the connection point on U of said dU(c1); d1 of rA*(d1) represents the connection point on * of said rA*(d1); each instance of c1 is connected to an instance of c2; and each instance of d1 is connected to an instance of d2.
[0237] In some embodiments, the 5' cap region comprises a dendrimer comprising two or more 5' caps.
[0238] In some embodiments, each instance of m1 is independently an integer between 2 and 20 (inclusive). In some embodiments, at least one instance of the second linker comprises a dendrimer. In some embodiments, at least one instance of the dendrimer is a polyamidoamine (PAMAM) dendrimer. In some embodiments, at least one instance of the PAMAM dendrimer has the formula:
[0239]
[0240] wherein each instance of m3 is independently an integer between 1 and 10 (inclusive); each instance of m4 is independently an integer between 0 and 10 (inclusive); R 12 Each instance of is independently hydrogen or The condition is R 12 At least three instances of And R 11 Each instance of is substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10heteroalkenylene or substituted or unsubstituted C 1-10 In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced by substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and each instance of m5 is independently an integer between 0 and 10 (inclusive). In some embodiments, at least one instance of the PAMAM dendrimer comprises the following formula:
[0241]
[0242] In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, at least one instance of the first linker has the following formula:
[0243]
[0244] In some embodiments, the first 5' cap comprises a nucleotide sequence as shown below:
[0245] / 5 Azide N / rArArArArA-3'; and the second 5' cap includes a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArGrArCrTrGrCrCrArCrCrA*rA*rA*rA*rA*rA* / Azide N / -3' (SEQ ID NO:6); wherein "rA" represents an adenosine ribonucleotide; "rT" represents a thymidine ribonucleotide; "rC" represents a cytidine ribonucleotide; "rG" represents a guanosine ribonucleotide; "dU(c1)" represents a modified uridine deoxyribonucleotide; "5 Azide N" represents a 5' azide portion, "3 Azide N" represents a 3' azide portion, "*" represents a phosphorothioate bond, and "Cap" represents a 5' cap.
[0246] In some embodiments, at least one instance of the second linker is covalently linked to the 3' nucleotide of the first 5' cap. In some embodiments, at least one instance of the second linker is covalently linked to the 3' nucleotide of at least one instance of the second 5' cap.
[0247] Methods for producing modified mRNA
[0248] In some aspects, the present disclosure provides a method for producing modified mRNA, the method comprising connecting an RNA comprising an open reading frame encoding a protein with a tailing nucleic acid comprising two or more poly-A tails and / or a capped nucleic acid comprising two or more 5' caps in the presence of a ligase, whereby the ligase forms a covalent bond between the 3' nucleotide of the RNA and the 5' nucleotide of the tailing nucleic acid, or between the 3' nucleotide of the capped nucleic acid and the 5' nucleic acid of the RNA to produce a modified RNA (e.g., a modified mRNA). In some embodiments, the tailing nucleic acid comprises a poly-A region as described herein, and the capped nucleic acid comprises a 5' cap region as described herein. When the ligase forms a covalent bond between two linear nucleic acids, a new nucleic acid is produced, wherein the nucleic acid produced comprises the nucleic acid sequence of the two nucleic acids. The 3' terminal nucleotide of the first nucleic acid is connected to the 5' terminal nucleotide of the second nucleic acid to produce a third nucleic acid, wherein the third nucleic acid comprises the sequence of the first nucleic acid and the second nucleic acid, and the second nucleic acid sequence is located at 3' (downstream) of the first nucleic acid sequence. The connection performed by RNA ligase occurs in several steps. First, the amino group (-NH2) of the amino acid (e.g., lysine) of the ligase bonds to the phosphate group of adenosine triphosphate (ATP), allowing adenosine monophosphate (AMP) to bind to the RNA ligase. Second, the 5' terminal phosphate of the second nucleic acid replaces the phosphate of AMP to which the RNA ligase binds. Finally, the oxygen of the 3' terminal hydroxyl of the first nucleic acid binds to the phosphorus atom of the 5' terminal phosphate of the second nucleic acid. This last step forms a phosphodiester bond between the terminal nucleotides of the nucleic acid, thereby forming a single nucleic acid with a continuous sugar-phosphate backbone. In some embodiments, the ligase is an RNA ligase. In some embodiments, the RNA ligase is a T4 RNA ligase.
[0249] In some embodiments of the methods for producing modified mRNA provided herein, the RNA to which the tailing nucleic acid and / or the capping nucleic acid are attached is synthesized by in vitro transcription (IVT). IVT is a process in which RNA (such as precursor mRNA / pre-mRNA) or mRNA) is produced by transcribing a DNA template by an RNA polymerase. Typically, the DNA template includes a promoter, such as a bacteriophage promoter, located upstream of the DNA sequence to be transcribed. The RNA polymerase binds to the promoter and begins transcribing the DNA sequence, thereby producing an RNA transcript having the nucleic acid sequence present in the template, except that the thymidine (T) nucleotides in the DNA sequence are replaced by uracil (U) nucleotides in the RNA sequence. The RNA transcript produced by IVT can be modified before the tailing nucleic acid is attached, such as by adding a 5' cap, cutting one or more nucleotides from the RNA, or performing polyadenylation to extend the poly-A region. In some embodiments, the DNA template includes a poly-A region, so that IVT produces an mRNA having a poly-A region. See, e.g., Becker et al., Methods Mol Biol, 2011. 703:29-41.
[0250] In some embodiments of the method for producing modified mRNA provided herein, the 3' nucleotide of RNA includes a 3' terminal hydroxyl group, and the 5' nucleotide of tailing nucleic acid includes a 5' terminal phosphate group. In some embodiments of the method for producing modified mRNA provided herein, the 3' nucleotide of capping nucleic acid includes a 3' terminal hydroxyl group, and the 5' nucleotide of RNA includes a 5' terminal phosphate group. The combination of the 3' terminal hydroxyl group and the 5' terminal phosphate group allows the effective connection of two nucleic acids. In some embodiments, RNA does not include a 5' terminal phosphate group. Due to the addition of a 5' cap or other chemical modifications, RNA may lack a 5' terminal phosphate group. The 5' terminal phosphate can also be removed from RNA by a phosphatase enzyme to produce RNA lacking a 5' terminal phosphate. The lack of a 5' terminal phosphate group on RNA prevents RNA ligase from connecting multiple copies of mRNA together. In some embodiments, tailing nucleic acid does not include a 3' terminal hydroxyl group. If the last nucleotide of the tailing nucleic acid includes a modified nucleotide that does not contain a 3' hydroxyl group, such as dideoxyadenosine, dideoxycytidine, dideoxyguanosine, dideoxythymidine, or reversed deoxythymidine, the RNA may lack a 3' terminal hydroxyl group. The lack of a 3' terminal hydroxyl group on the tailing nucleic acid prevents RNA ligase from joining multiple tailing nucleic acids together. In some embodiments, the 5' nucleotide of the RNA does not include a 5' terminal phosphate group; the 3' nucleotide of the RNA includes a 3' terminal hydroxyl group; the 5' nucleotide of the tailing nucleic acid includes a 5' terminal phosphate group; and the 3' nucleotide of the tailing nucleic acid does not include a 3' terminal hydroxyl group. In some embodiments, the tailing nucleic acid and / or the capping nucleic acid includes at least 3, at least 4, at least 5, or at least 6 thiophosphates. In some embodiments, the tailing nucleic acid includes at least 3, at least 4, at least 5, or at least 6 thiophosphates and does not include a 3' terminal hydroxyl group. In some embodiments, the tailing nucleic acid includes at least 3 thiophosphates and does not include a 3' terminal hydroxyl group. In some embodiments, the tailing nucleic acid includes at least 3 guanine nucleotides and at least 3 thiophosphates and does not include a 3' terminal hydroxyl group. In some embodiments, the tailing nucleic acid includes at least 3 deoxyriboses and does not include a 3' terminal hydroxyl. In some embodiments, the tailing nucleic acid and / or the capping nucleic acid includes at least 20 deoxyriboses. In some embodiments, the tailing nucleic acid includes at least 20 deoxyriboses and does not include a 3' terminal hydroxyl. In some embodiments, the tailing nucleic acid includes at least 3 copies of a G-quadruplex sequence and does not include a 3' terminal hydroxyl. In some embodiments, the tailing nucleic acid includes at least 6 phosphorothioates and does not include a 3' terminal hydroxyl. In some embodiments, the tailing nucleic acid includes at least 6 consecutive phosphorothioates and does not include a 3' terminal hydroxyl. In some embodiments, the tailing nucleic acid includes at least 6 phosphorothioates and 3 guanosine nucleosides and does not include a 3' terminal hydroxyl.In some embodiments, the tailing nucleic acid includes at least 3 copies of the G-quadruplex sequence and at least 6 phosphorothioates, and does not include the 3' terminal hydroxyl. In some embodiments, the tailing nucleic acid includes at least 3 copies of the telomeric repeat sequence and at least 6 phosphorothioates, and does not include the 3' terminal hydroxyl. In some embodiments, the 3' terminal nucleotide that does not include the 3' terminal hydroxyl is a dideoxycytidine or a reverse deoxythymidine. In some embodiments, the ligase used to connect the tailing nucleic acid to the RNA is an RNA ligase. In some embodiments, the RNA ligase is a T4 RNA ligase. In some embodiments, the T4 RNA ligase is a T4 RNA ligase 1. In some embodiments, the T4 RNA ligase is a T4 RNA ligase 2.
[0251] In some embodiments of the methods of producing modified mRNA provided herein, the 5' nucleotide of the RNA does not include a 5' terminal hydroxyl group, the 3' nucleotide of the RNA includes a 3' terminal phosphate group, the 5' nucleotide of the tailing nucleic acid includes a 5' terminal hydroxyl group, the 3' nucleotide of the tailing nucleic acid does not include a 3' terminal phosphate group, and the RNA ligase is RtcB ligase, which ligates a first nucleotide including a 3' terminal phosphate group to a second nucleotide including a 5' terminal hydroxyl group.
[0252] Some embodiments of the method for preparing modified mRNA provided herein further include producing circular mRNA. After linear modified mRNA is produced by connecting RNA and tailing nucleic acid, the cyclization of modified mRNA includes several additional steps. First, the 5' terminal phosphate is introduced into the first nucleotide of modified mRNA, a process called phosphorylation. In some embodiments, the 5' terminal phosphate is introduced by a kinase. "Kinase" refers to an enzyme that introduces a phosphate group into a molecule in a process called "phosphorylation" to form a covalent bond between the phosphate group and the molecule. Second, the modified mRNA is manipulated to produce a modified mRNA with a 3' terminal hydroxyl group. In some embodiments, the modified mRNA is manipulated by cutting one or more nucleotides in the last nucleotide of the modified mRNA to produce a modified mRNA with a 3' terminal hydroxyl group. In some embodiments, the modified mRNA is cut by a restriction enzyme, a ribozyme or an endoribonuclease. In some embodiments, the cutting of one or more nucleotides in the last nucleotide of the modified mRNA occurs before the phosphorylation of the first nucleotide of the modified mRNA. In some embodiments, the cutting occurs after phosphorylation. By connecting two terminal nucleotides, a modified mRNA including a terminal phosphate group at one end and a terminal hydroxyl group at the other end can be cyclized. The RNA ligase that connects the terminal nucleotides of a linear nucleic acid to produce a circular nucleic acid can be referred to as a "circularizing ligase". In some embodiments, the circularizing ligase is an RNA ligase. In certain embodiments, the circularizing ligase is a SplintR ligase. In certain embodiments, the circularizing ligase is a T4 RNA ligase. In certain embodiments, the circularizing ligase is a T4 RNA ligase 1. In certain embodiments, the circularizing ligase is a T4 RNA ligase 2. In certain embodiments, the modified mRNA includes a 5' terminal hydroxyl group and a 3' terminal phosphate group, and the circularizing ligase is an RtcB ligase, which can connect nucleotides to 3' terminal phosphate and 5' terminal hydroxyl groups. In order to connect, the 5' and 3' terminal nucleotides of the modified mRNA must be close enough so that the RNA ligase forms a key between the two nucleotides. Methods for placing two nucleotides of a linear nucleic acid close enough to allow ligation to occur and methods for circularizing RNA are well known in the art (see, e.g., Petkovic et al., Nucleic Acids Research, 2015. 43(4): 2454-2465). In some embodiments, the modified mRNA is incubated with a scaffold nucleic acid capable of hybridizing (hydrogen bonding) with the modified mRNA, such that the modified mRNA forms a circular secondary structure when hybridizing (binding) to the scaffold nucleic acid.
[0253] When the mRNA forms a circular secondary structure, the 5' and 3' terminal nucleotides are physically very close, which is necessary for the RNA ligase to form a covalent bond between them. In some embodiments of the method of cyclizing the mRNA, one or more of the last nucleotides of the mRNA bind to a first hybridization sequence in the scaffold nucleic acid, and one or more of the first nucleotides of the mRNA bind to a second hybridization sequence in the scaffold nucleic acid, the second hybridization sequence being located 3' (downstream) of the first hybridization sequence. In some embodiments, the first hybridization sequence includes 5 or more nucleotides, and the first hybridization sequence is complementary to at least the first five (5) nucleotides of the modified mRNA. In some embodiments, the first hybridization sequence comprises 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, or 50 or more nucleotides, and at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or up to 100% of the nucleotides of the first hybridization sequence are complementary to the last N nucleotides of the modified mRNA, where N is the length of the first hybridization sequence. In some embodiments, the second hybridization sequence comprises 5 or more nucleotides, and the second hybridization sequence is complementary to at least the last five (5) nucleotides of the modified mRNA. In some embodiments, the second hybridization sequence comprises 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, or 50 or more nucleotides, and at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or up to 100% of the nucleotides of the second hybridization sequence are complementary to the last N nucleotides of the modified mRNA, where N is the length of the second hybridization sequence. In some embodiments, at least the first five (5) nucleotides of the modified mRNA hybridize to the first hybridization sequence. In some embodiments, at least the last five (5) nucleotides of the modified mRNA hybridize to the second hybridization sequence. In some embodiments, at least the first five (5) nucleotides of the modified mRNA hybridize to the first hybridization sequence, and at least the last five (5) nucleotides of the modified mRNA hybridize to the second hybridization sequence. In some embodiments, the last nucleotide of the first hybridization sequence and the first nucleotide of the second hybridization sequence are adjacent in the scaffold nucleic acid and are not separated by any other nucleotides.
[0254] In some embodiments of the method for producing circular mRNA provided herein, the scaffold nucleic acid is not used to promote the formation of a circular secondary structure by modified mRNA. On the contrary, modified mRNA includes a first hybridization sequence at the 5' end, and the first hybridization sequence is complementary to the second hybridization sequence at the 3' end. In certain embodiments, each hybridization sequence includes at least five (5) nucleotides. In certain embodiments, each hybridization sequence includes at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45 or at least 50 nucleotides.
[0255] In some embodiments of the method for producing circular mRNA provided herein, the modified mRNA is not cyclized by using a scaffold nucleic acid and a cyclizing ligase, but is cyclized by a ribozyme (a nucleic acid that catalyzes reactions such as the formation of a covalent bond between two nucleotides). In some embodiments, before cyclization, the modified mRNA includes a 3' intron located at the 5' (upstream) of the 5' UTR of the mRNA, and a 5' intron located at the 3' (downstream) of the poly-A region and / or one or more structural sequences of the mRNA. Ribozymes and other enzymes that catalyze the splicing of pre-mRNA to remove introns can catalyze the formation of a covalent bond between the nucleotide located at the 5' intron and the nucleotide located at the 3' intron of the 3' intron, thereby forming a circular mRNA. See, for example, Wesselhoeft et al., Nat Commun. 2018.9: 2629.
[0256] In some embodiments of the methods for producing circular mRNA provided herein, the modified mRNA is not cyclized by using a scaffold core, but is cyclized by using a complementary sequence that promotes the formation of a secondary structure by the mRNA, wherein the 5' and 3' terminal nucleotides of the mRNA are in close proximity. In some embodiments, prior to cyclization, the modified mRNA includes: (i) a first self-hybridizing sequence located at 5' of the open reading frame; (ii) a second self-hybridizing sequence located at 3' of the open reading frame; (iii) a first non-hybridizing sequence located at 5' of the first self-hybridizing sequence; and (iv) a second non-hybridizing sequence located at 3' of the second self-hybridizing sequence. The first self-hybridizing sequence and the second self-hybridizing sequence are capable of hybridizing to each other, while the first self-hybridizing sequence and the second self-hybridizing sequence cannot hybridize to each other. In some embodiments, hybridization of the first self-hybridizing sequence with the second self-hybridizing sequence forms a secondary structure in which the 5' terminal nucleotide and the 3' terminal nucleotide of the modified mRNA are separated by less than In some embodiments, the 5' terminal nucleotide and the 3' terminal nucleotide are separated by less than Less than less than Less than Less than Less than Less than Less than or less than See, for example, Carmona, Ellese Marie. 2019. Circular RNA: Design Criteria for Optimal Therapeutical Utility. PhD dissertation, Harvard University, Graduate School of Arts & Sciences; Petkovic et al. Nucleic Acids Research, 2015. 43(4): 2454-2465; and WO 2020 / 237227.
[0257] In some embodiments of the modified mRNA produced by the methods provided herein, the poly-A region of the modified mRNA includes at least one modified nucleotide. In some embodiments, the tailing nucleic acid includes at least one modified nucleotide. In some embodiments, at least one modified nucleotide includes a modified nucleobase. In some embodiments, at least one modified nucleotide includes a modified sugar. In some embodiments, at least one modified nucleotide includes a modified phosphate. In some embodiments, at least one modified nucleotide includes a modified nucleobase selected from the group consisting of: xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, digoxigenated adenine, digoxigenated cytosine, digoxigenated guanine, digoxigenated uracil, 6-chloropurine nucleoside, N6-methyladenine, methyl pseudouracil, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyluracil, 5,6-dihydrouracil, 5-[(3-indolyl)propionamido-N-allyl]uracil, 5-aminoallylcytosine, 5-aminoallyluracil, 5-bromouracil, 5-bromocytosine, 5-carboxycytosine, 5-carboxymethyl ester uracil, 5-carboxyuracil, 5-fluorouracil, 5-formylcytosine, 5-formyluracil, 5-hydroxycytosine, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5-hydroxyuracil, 5-iodocytosine, 5-iodouracil, 5-methoxycytosine, 5-methoxyuracil, 5-methylcytosine, 5-methyl Uracil, 5-propargylaminocytosine, 5-propargylaminouracil, 5-propynylcytosine, 5-propynyluracil, 6-azacytosine, 6-azauracil, 6-chloropurine, 6-thioguanine, 7-deazaadenine, 7-deazaguanine, 7-guanine-7-propargylaminoadenine, 7-deaza-7-propargylaminoguanine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, arabinoadenine, arabinocytosine, arabinoguanine, arabinouracil, biotin-16-7 -deaza-7-propargylaminoguanine, biotin-16-aminoallylcytosine, biotin-16-aminoallyluracil, cyanine 3-5-propargylaminocytosine, cyanine 3-6-propargylaminouracil, cyanine 3-aminoallylcytosine, cyanine 3-aminoallyluracil, cyanine 5-6-propargylaminocytosine, cyanine 5-6-propargylaminouracil, cyanine 5-aminoallylcytosine, cyanine 5-aminoallyluracil, cyanine 7-aminoallyluracil, dabcyl-5-3-aminoallyluracil, desulfurized bio 16-aminoallyl-uracil, desthiobiotin-6-aminoallyl-cytosine, isoguanine, N1-ethylpseudouracil, N1-methoxymethylpseudouracil, N1-methyladenine, N1-methylpseudouracil, N1-propylpseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthosine, 3-deazaadenine, 2,6-diaminoadenine, 2,6-diaminoguanine, 5-formamide-uracil, 5-ethyluracil, N6-isopentenyladenine (i6A), 2-methyl-thio-N6-isopentenyladenine (ms2i6A), 2-methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine (g6A), N 6-Threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxynorvalylcarbamoyladenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A). In some embodiments, at least one modified nucleotide comprises a modified sugar selected from the group consisting of 2'-thioribose, 2',3'-dideoxyribose, 2'-amino-2'-deoxyribose, 2'deoxyribose, 2'-azido-2'-deoxyribose, 2'-fluoro-2'-deoxyribose, 2'-O-methylribose, 2'-O-methyldeoxyribose, 3'-amino-2',3'-dideoxyribose, 3'-azido-2'-deoxyribose, -2',3'-dideoxyribose, 3'-deoxyribose, 3'-O-(2-nitrobenzyl)-2'-deoxyribose, 3'-O-methylribose, 5'-aminoribose, 5'-thioribose, 5-nitro-1-indolyl-2'-deoxyribose, 5'-biotin-ribose, 2'-O,4'-C-methylene-linked ribose, 2'-O,4'-C-amino-linked ribose, and 2'-O,4'-C-thio-linked ribose. In some embodiments, at least one modified nucleotide comprises a modified phosphate selected from the group consisting of phosphorothioate (PS), thiophosphate, 5'-O-methylphosphonate, 3'-O-methylphosphonate, 5'-hydroxyphosphonate, hydroxyphosphonate, phosphoroselenoate, selenophosphate, phosphoramidate, carbon phosphonate, methylphosphonate, phenylphosphonate, ethylphosphonate, H-phosphonate, guanidine ring, triazole ring, borophosphate (BP), methylphosphonate and guanidinopropylphosphoramidate. ,
[0258] In some embodiments, the poly-A region of the mRNA includes at least 3, at least 4, or at least 5 phosphorothioates, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 phosphorothioates, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 guanine nucleotides and at least 3 phosphorothioates, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 deoxyriboses, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 20 deoxyriboses, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 copies of the G-quadruplex sequence, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 6 phosphorothioates, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 6 consecutive phosphorothioates, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 6 phosphorothioates and 3 guanosine nucleosides, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 copies of the G-quadruplex sequence and at least 6 phosphorothioates, and does not include the 3' terminal hydroxyl group. In some embodiments, the poly-A region of the mRNA includes at least 3 copies of the telomeric repeat sequence and at least 6 phosphorothioates, and does not include the 3' terminal hydroxyl group. In some embodiments, the 3' terminal nucleotide that does not include the 3' terminal hydroxyl group is a dideoxycytidine or an inverted deoxythymidine.
[0259] In some embodiments of the modified mRNA produced by the methods provided herein, the modified mRNA includes more than one type of modified nucleotides. In some embodiments, the modified mRNA includes at least a first modified nucleoside and a second modified nucleoside having a structure different from the first modified nucleoside. In some embodiments, the modified mRNA includes at least a first modified phosphate and a second modified phosphate having a structure different from the first modified phosphate. In some embodiments, the modified mRNA includes modified nucleosides and modified nucleosides.
[0260] In some embodiments of the modified mRNA produced by the methods provided herein, 1% to 90% of the nucleotides in the poly-A region are modified nucleotides. In some embodiments, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% of the nucleotides in the poly-A region are modified nucleotides.
[0261] In some embodiments of the modified mRNA produced by the methods provided herein, 3 or more nucleotides in the last 10-25 nucleotides of the poly-A region are modified nucleotides. In some embodiments, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20 or 25 nucleotides in the last 25 nucleotides of the poly-A region are modified nucleotides.
[0262] In some embodiments of the modified mRNA produced by the methods provided herein, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the nucleotides in the poly-A region are adenosine nucleotides. One or more adenosine nucleotides in the poly-A region can be a canonical adenosine nucleotide or a modified adenosine nucleotide comprising a structure different from the canonical adenosine nucleotide.
[0263] In some embodiments of the modified mRNA produced by the methods provided herein, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the nucleotides of the poly-A region are canonical adenosine nucleotides.
[0264] In some embodiments of the modified mRNA produced by the method provided by this article, the poly-A region includes 10-25 nucleotides. In some embodiments of the modified mRNA produced by the method provided by this article, the poly-A region includes 10-15 nucleotides, 15-20 nucleotides or 20-25 nucleotides. In some embodiments of the modified mRNA produced by the method provided by this article, the poly-A region includes 25-500 nucleotides. In certain embodiments, the poly-A region includes at least 25, at least 30, at least 50, at least 100, at least 150 or at least 200 nucleotides. In some embodiments, the poly-A region includes at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, or at least 300 nucleotides. In some embodiments, the poly-A region includes about 200 to about 300 nucleotides. In some embodiments, the poly-A region includes about 250 nucleotides.
[0265] In some embodiments of the method for producing modified mRNA provided herein, before the connection of tailing nucleic acid, RNA includes an open reading frame and a poly-A district before the connection of tailing nucleic acid. In certain embodiments, before the connection of tailing nucleic acid, the poly-A district of RNA includes 10-25 nucleotides. In certain embodiments, before the connection of tailing nucleic acid, the poly-A district of RNA includes 10-15 nucleotides, 15-20 nucleotides or 20-25 nucleotides. In certain embodiments, before the connection of tailing nucleic acid, the poly-A district of RNA includes 25-500 nucleotides. In certain embodiments, the poly-A district includes at least 25, at least 30, at least 50, at least 100, at least 150 or at least 200 nucleotides. In some embodiments, the poly-A region includes at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, or at least 300 nucleotides. In some embodiments, the poly-A region includes about 200 to about 300 nucleotides. In some embodiments, the poly-A region includes about 250 nucleotides.
[0266] In some embodiments of the method for producing modified mRNA provided herein, before the tailing nucleic acid is connected, the RNA includes a 5'UTR, an open reading frame, a 3'UTR and a poly-A region in a 5' to 3' order. In some embodiments, the open reading frame is located between the 5'UTR and the 3'UTR. In some embodiments, the 3'UTR is located between the open reading frame and the poly-A region.
[0267] In some embodiments of the methods for producing modified mRNA provided herein, the RNA includes a 5' cap before the tailing nucleic acid is attached. In some embodiments, the 5' cap includes 7-methylguanosine. In some embodiments, the 5' cap includes one or more phosphates that connect the 7-methylguanosine to the adjacent nucleotides of the RNA. In some embodiments, the 5' cap is added after the tailing nucleic acid is attached.
[0268] In some aspects of the method for producing modified mRNA including connecting tailing nucleic acid to mRNA provided herein, the tailing nucleic acid includes one or more modified nucleotides. In some embodiments, the tailing nucleic acid includes at least one modified nucleotide, and the at least one modified nucleotide includes a modified nucleoside. In some embodiments, at least one modified nucleotide includes a modified nucleoside, and the modified nucleoside includes a modified nucleobase and / or a modified sugar. In some embodiments, at least one modified nucleotide includes a modified nucleoside, and the modified nucleoside includes a modified nucleobase and a modified sugar. In some embodiments, at least one modified nucleotide includes a modified nucleobase. In some embodiments, at least one modified nucleotide includes a modified sugar. In some embodiments, at least one modified nucleotide includes a modified phosphate. In some embodiments, at least one modified nucleotide comprises a modified nucleobase selected from the group consisting of xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, digoxigenated adenine, digoxigenated cytosine, digoxigenated guanine, digoxigenated uracil, 6-chloropurine nucleoside, N6-methyladenine, methylpseudouracil, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyluracil, 5,6-dihydrouracil, 5-[(3-indolyl)propionamido-N-allyl]uracil, 5-aminoallylcytosine, 5-aminoallyluracil, 5-bromouracil, 5-bromocytosine, 5-carboxycytosine, 5-carboxymethyl ester uracil, 5-carboxyuracil, 5-fluorouracil, 5-formylcytosine, 5-formyluracil, 5-hydroxycytosine, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5-hydroxyuracil, 5-iodocytosine, 5-iodouracil, 5-methoxycytosine, 5-methoxyuracil, 5-methylcytosine, 5-methyl Uracil, 5-propargylaminocytosine, 5-propargylaminouracil, 5-propynylcytosine, 5-propynyluracil, 6-azacytosine, 6-azauracil, 6-chloropurine, 6-thioguanine, 7-deazaadenine, 7-deazaguanine, 7-guanine-7-propargylaminoadenine, 7-deaza-7-propargylaminoguanine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, arabinoadenine, arabinocytosine, arabinoguanine, arabinouracil, biotin-16-7 -deaza-7-propargylaminoguanine, biotin-16-aminoallylcytosine, biotin-16-aminoallyluracil, cyanine 3-5-propargylaminocytosine, cyanine 3-6-propargylaminouracil, cyanine 3-aminoallylcytosine, cyanine 3-aminoallyluracil, cyanine 5-6-propargylaminocytosine, cyanine 5-6-propargylaminouracil, cyanine 5-aminoallylcytosine, cyanine 5-aminoallyluracil, cyanine 7-aminoallyluracil, dabcyl-5-3-aminoallyluracil, desulfurized bio 16-aminoallyl-uracil, desthiobiotin-6-aminoallyl-cytosine, isoguanine, N1-ethylpseudouracil, N1-methoxymethylpseudouracil, N1-methyladenine, N1-methylpseudouracil, N1-propylpseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthosine, 3-deazaadenine, 2,6-diaminoadenine, 2,6-diaminoguanine, 5-formamide-uracil, 5-ethyluracil, N6-isopentenyladenine (i6A), 2-methyl-thio-N6-isopentenyladenine (ms2i6A), 2-methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine (g6A), N 6-Threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxynorvalylcarbamoyladenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A). In some embodiments, at least one modified nucleotide comprises a modified sugar selected from the group consisting of 2'-thioribose, 2',3'-dideoxyribose, 2'-amino-2'-deoxyribose, 2'deoxyribose, 2'-azido-2'-deoxyribose, 2'-fluoro-2'-deoxyribose, 2'-O-methylribose, 2'-O-methyldeoxyribose, 3'-amino-2',3'-dideoxyribose, 3'-azido-2'-deoxyribose, -2',3'-dideoxyribose, 3'-deoxyribose, 3'-O-(2-nitrobenzyl)-2'-deoxyribose, 3'-O-methylribose, 5'-aminoribose, 5'-thioribose, 5-nitro-1-indolyl-2'-deoxyribose, 5'-biotin-ribose, 2'-O,4'-C-methylene-linked ribose, 2'-O,4'-C-amino-linked ribose, and 2'-O,4'-C-thio-linked ribose. In some embodiments, at least one modified nucleotide comprises a modified phosphate selected from the group consisting of phosphorothioate (PS), thiophosphate, 5'-O-methylphosphonate, 3'-O-methylphosphonate, 5'-hydroxyphosphonate, hydroxyphosphonate, phosphoroselenoate, selenophosphate, phosphoramidate, carbon phosphonate, methylphosphonate, phenylphosphonate, ethylphosphonate, H-phosphonate, guanidine ring, triazole ring, borophosphate (BP), methylphosphonate and guanidinopropylphosphoramidate. ,
[0269] In some embodiments of the method for producing modified mRNA provided herein, the tailing nucleic acid includes more than one type of modified nucleotides. In some embodiments, the tailing nucleic acid includes at least a first modified nucleoside and a second modified nucleoside having a structure different from the first modified nucleoside. In some embodiments, the tailing nucleic acid includes at least a first modified phosphate and a second modified phosphate having a structure different from the first modified phosphate. In some embodiments, the tailing nucleic acid includes a modified nucleoside and a modified nucleoside.
[0270] In some embodiments, 1% to 90% of the nucleotides of the tailing nucleic acid are modified nucleotides. In some embodiments, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% of the nucleotides of the tailing nucleic acid are modified nucleotides. In some embodiments, 3 or more nucleotides of the last 10-25 nucleotides of the tailing nucleic acid are modified nucleotides. In some embodiments, at least 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 nucleotides of the last 10-25 nucleotides of the tailing nucleic acid are modified nucleotides.
[0271] In some embodiments, the tailing nucleic acid includes a poly-A region, the poly-A region includes two or more poly-A tails, and at least two instances of the poly-A tail are covalently linked to the first linker. In some embodiments, the tailing nucleic acid includes a poly-A region comprising the following structure: -(first poly-A tail)-[(first linker)-(second poly-A tail) n1]n2; wherein each instance of n1 is independently an integer between 1 and 20 (including the end value); n2 is an integer between 2 and 10 (including the end value); and the first poly-A tail is covalently linked to the 3'UTR of the mRNA.
[0272] In some embodiments, the tailed nucleic acid comprises a poly-A region comprising a brush oligonucleotide comprising two or more poly-A tails.
[0273] In some embodiments, each instance of n1 is 1. In some embodiments, at least one instance of the first linker is covalently linked to an internal nucleotide of the first poly-A tail. In some embodiments, at least one instance of the first linker is covalently linked to the second poly-A tail at the 3' nucleotide of the second poly-A tail. In some embodiments, at least one instance of the first linker comprises at least one portion formed by reacting two orthogonal click chemistry handles. In certain embodiments, the click chemistry handle is as described herein. In some embodiments, each instance of the first linker is independently a substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene or substituted or unsubstituted C 1-200 In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with a substituted or unsubstituted carbocyclylene, a substituted or unsubstituted heterocyclylene, a substituted or unsubstituted arylene, or a substituted or unsubstituted heteroarylene. 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, at least one instance of the first linker has the formula: Where L 1 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 heteroalkylene; and L 2 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 In some embodiments, at least one instance of the first linker has the formula:
[0274] In some embodiments, the first poly-A tail comprises a nucleotide sequence as shown below: 5'-rArArArArArArAdU(a1)rArArArArArArArArArArArAdU(a1)rArArArArArArArArArArAd U(a1)ddC-3'(SEQ ID NO:1); and at least one instance of the second poly-A tail comprises a nucleotide sequence as shown below: 5'-rArArArArArArArArArArArArArArArArArArArArAr A*rA*rA*rA*rA*rA*(b1)-3'(SEQ ID NO:2); wherein each instance of the first linker is independently Wherein "rA" represents an adenosine ribonucleotide; "dU(a1)" represents a modified uridine deoxyribonucleotide; "ddC" represents a cytosine dideoxyribonucleotide; "*" represents a phosphorothioate bond; a1 of each instance of dU(a1) represents a point of attachment on the uridine of said dU(a1); b1 of rA*(b1) represents a point of attachment on the * of said rA*(b1); each instance of a1 is connected to an instance of a2; and each instance of b1 is connected to an instance of b2. In some embodiments, the modified uridine deoxyribonucleotide is 5-octadiynyl deoxyuridine, which is shown in the following structure:
[0275]
[0276] In some embodiments, the tailed nucleic acid comprises a poly-A region comprising a dendrimer comprising two or more poly-A tails.
[0277] In some embodiments, each instance of n1 is independently an integer between 2 and 20 (inclusive). In some embodiments, at least one instance of the first linker comprises a dendrimer. In some embodiments, at least one instance of the dendrimer is a polyamidoamine (PAMAM) dendrimer. In some embodiments, at least one instance of the PAMAM dendrimer has the formula:
[0278]
[0279] wherein each instance of n3 is independently an integer between 1 and 10 (inclusive); each instance of n4 is independently an integer between 0 and 10 (inclusive); R 2 Each instance of is independently hydrogen or The condition is R 2 At least three instances of And R 1 Each instance of is substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene or substituted or unsubstituted C 1-10 In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced by substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and each instance of n5 is independently an integer between 0 and 10 (inclusive). In some embodiments, at least one instance of the PAMAM dendrimer has the following formula:
[0280]
[0281] In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, at least one instance of the first linker has the following formula:
[0282]
[0283] In some embodiments, the first poly-A tail and the second poly-A tail comprise a nucleotide sequence as shown below: 5'-rArArArArArArArArArArArArArArArArArArArArArArA*rA*rA*rA*rA*rA*rA* / Azide N / -3' (SEQ ID NO:3); wherein "rA" represents an adenosine ribonucleotide; "Azide N" represents a 3' azide moiety, and "*" represents a phosphorothioate bond.
[0284] In some embodiments, at least one instance of the first linker is covalently linked to the 3' nucleotide of the first poly-A tail. In some embodiments, at least one instance of the first linker is covalently linked to the 3' nucleotide of at least one instance of the second poly-A tail.
[0285] In some embodiments, the capped nucleic acid includes a 5' cap region, the 5' cap region includes two or more 5' caps, and at least two instances of the 5' cap are covalently linked by a second linker. In some embodiments, the capped nucleic acid includes a 5' cap region comprising the following structure: -(first 5' cap)-[(second linker)-(second 5' cap)m1]m2; wherein each instance of m1 is independently an integer between 1 and 20 (including the end value); m2 is an integer between 2 and 10 (including the end value); the first 5' cap is covalently linked to the 5'UTR; and the second linker is covalently linked to the first 5' cap and the second 5' cap.
[0286] In some embodiments, the capped nucleic acid comprises a 5' cap region comprising a brush oligonucleotide comprising two or more 5' caps.
[0287] In some embodiments, each instance of m1 is 1. In some embodiments, at least one instance of the second linker is covalently linked to an internal nucleotide of the first 5' cap. In some embodiments, at least one instance of the second linker is covalently linked to the second 5' cap at the 3' nucleotide of the second 5' cap. In some embodiments, at least one instance of the second linker comprises at least one portion formed by reacting two orthogonal click chemistry handles. In certain embodiments, click chemistry handles are described herein. In some embodiments, each instance of the second linker is independently substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene or substituted or unsubstituted C 1-200 In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with a substituted or unsubstituted carbocyclylene, a substituted or unsubstituted heterocyclylene, a substituted or unsubstituted arylene, or a substituted or unsubstituted heteroarylene. 1-200Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, at least one instance of the second linker has the formula: Where L 3 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 heteroalkylene; and L 4 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 In some embodiments, at least one instance of the second linker has the formula:
[0288] In some embodiments, the first 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArArAdU(c1)rArArGrArGrArArArGrArArGrArGdU(c1)rArArGrArArGrArArAdU(c1)rA-3'(SEQ ID NO:4); and the second 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArGrArCrTrGrCrCrArCrCrA*rA*rA*rA*rA*rA*(d1)-3'(SEQ ID NO:5); wherein
[0289] Each instance of the second linker is independently Wherein "rA" represents an adenosine ribonucleotide; "rT" represents a thymidine ribonucleotide; "rC" represents a cytidine ribonucleotide; "rG" represents a guanosine ribonucleotide; "dU(c1)" represents a modified uridine deoxyribonucleotide; "*" represents a phosphorothioate bond; "Cap" represents a 5' cap; c1 of each instance of dU(c1) represents a point of attachment on U of said dU(c1); d1 of rA*(d1) represents a point of attachment on * of said rA*(d1); each instance of c1 is connected to an instance of c2; and each instance of d1 is connected to an instance of d2. In some embodiments, the modified uridine deoxynucleotide is 5-octadiynyl deoxyuridine, which is shown in the following structure:
[0290]
[0291] In some embodiments, the capped nucleic acid comprises a 5' cap region comprising a dendrimer comprising two or more 5' caps.
[0292] In some embodiments, each instance of m1 is independently an integer between 2 and 20 (inclusive). In some embodiments, at least one instance of the second linker comprises a dendrimer. In some embodiments, at least one instance of the dendrimer is a polyamidoamine (PAMAM) dendrimer. In some embodiments, at least one instance of the PAMAM dendrimer has the formula:
[0293]
[0294] wherein each instance of m3 is independently an integer between 1 and 10 (inclusive); each instance of m4 is independently an integer between 0 and 10 (inclusive); R 12 Each instance of is independently hydrogen or The condition is R 12 At least three instances of And R 11 Each instance of is substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene or substituted or unsubstituted C 1-10 In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced by substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and each instance of m5 is independently an integer between 0 and 10 (inclusive). In some embodiments, at least one instance of the PAMAM dendrimer comprises the following formula:
[0295]
[0296] In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently In some embodiments, at least one instance of the first linker has the following formula:
[0297]
[0298] In some embodiments, the first 5' cap comprises a nucleotide sequence as shown below: / 5 Azide N / rArArA rArA-3'; and the second 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArGrArCrTrGrCrCrArCrCrA*rA*rA*rA*rA*rA* / 3 Azide N / -3' (SEQ ID NO:6); wherein "rA" represents an adenosine ribonucleotide; "rT" represents a thymidine ribonucleotide; "rC" represents a cytidine ribonucleotide; "rG" represents a guanosine ribonucleotide; "5 Azide N" represents a 5' azide portion, "3 Azide N" represents a 3' azide portion, "*" represents a phosphorothioate bond, and "Cap" represents a 5' cap.
[0299] In some embodiments, at least one instance of the second linker is covalently linked to the 3' nucleotide of the first 5' cap. In some embodiments, at least one instance of the second linker is covalently linked to the 3' nucleotide of at least one instance of the second 5' cap.
[0300] In some embodiments, the modified mRNA described herein is purified by any method known in the art to remove undesirable components (including unincorporated rNTPs, proteases, salts, metal ions, short RNA oligonucleotides, etc.) from IVT or related reactions (e.g., click chemistry reactions). Techniques for isolation of mRNA transcripts are well known in the art. Well-known methods include extraction with alcohol (ethanol, isopropanol) or precipitation with phenol / chloroform in the presence of monovalent cations or lithium chloride. Other non-limiting examples of purification procedures that can be used include size exclusion chromatography (Lukavsky, PJ and Puglisi, JD, 2004, Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides, RNA v. 10, 889-893), silica-based affinity chromatography, and polyacrylamide gel electrophoresis (Bowman, et al. RNA in vitro transcription and RNA purification by denaturing PAGE, Recombinant and invitro RNA synthesizes Methods v. 941 Conn GL (ed.), New York City, NY. Humana Press, 2012). Purification can be performed using a variety of commercially available kits, including but not limited to the SV Total Isolation System (Promega) and the In Vitro Transcription Cleanup and Concentration Kit (Norgen Biotek). Techniques for removing contaminants such as dsDNA have been developed and are known in the art, including but not limited to scalable HPLC purification (see, e.g., Kariko et al., 2011, Nucl Acid Res, v.39e142; Weissman et al., 2012, Synthetic Messenger RNA and Cell Metabolism Modulation v.969 (Rabinovich, PH ed.). In a preferred embodiment, the modified mRNA is purified by HPLC, as it has been reported that the translation level of HPLC-purified mRNA is much higher than that of other purification methods, especially in primary cells and in vivo.
[0301] Compositions comprising modified mRNA and methods of use
[0302] In some aspects, the disclosure provides a composition comprising any of the modified mRNA provided herein. In certain embodiments, the modified mRNA is prepared by any of the methods provided herein, including connecting tailing nucleic acid and / or capping nucleic acid to RNA. Compositions comprising modified mRNA can be used to deliver modified mRNA to cells, so as to vaccinate a subject with a vaccine against an exogenous antigen, or express therapeutic proteins to treat a disease or illness. Compositions comprising modified mRNA can also be used to play a desired role in a subject in the absence of a disease, such as for agricultural purposes. For example, mRNA encoding biopesticides or growth enhancing factors can be used to improve plant tolerance to pests, or to regulate growth in a manner that increases crop yields.
[0303] In some embodiments, the open reading frame (ORF) of mRNA is codon-optimized for expression in the cells of the subject. As used herein, "codon-optimized" refers to the preferential use of codons that are more efficiently translated in cells. Multiple codons can encode the same amino acid, wherein the translation rate and efficiency of each codon are determined by multiple factors (such as the intracellular concentration of aminoacyl-tRNA including complementary anti-codons). Codon optimization of nucleic acid sequences can include replacing one or more codons with codons that encode the same amino acid as the replaced codon but with higher translation efficiency. For example, the amino acid threonine (Thr) can be encoded by ACA, ACC, ACG or ACT (ACU in RNA), but in mammalian host cells, ACC is the most commonly used codon; in other species, different Thr codons can be preferred for codon optimization. Therefore, compared with mRNA with an open reading frame that is not codon-optimized, mRNA with a codon-optimized open reading frame is expected to be more efficiently translated and produce more polypeptides in a given amount of time. In some embodiments, the open reading frame is codon-optimized for expression in human cells.
[0304] In some embodiments of the modified mRNA provided herein, the open reading frame encodes an antigen or therapeutic protein. As used herein, "therapeutic protein" refers to a protein that can prevent, reduce or alleviate one or more signs or symptoms of a disease when expressed in a subject (such as a human subject suffering from a disease or condition or at risk of suffering from a disease or condition). Therapeutic proteins can be, for example, essential enzymes, coagulation factors, transcription factors, growth factors, cytokines, chemokines, antibodies (or their antibody fragments), protein hormones, signal transduction proteins, structural proteins, or cell surface receptors encoded by genes mutated in a subject. Mutations in genes encoding such proteins may cause the protein expression level in one or more cells of a subject to decrease. For example, human IPEX syndrome is caused by mutations in the FOXP3 gene, which hinder the development of FOXP3+ regulatory T cells and lead to increased susceptibility to autoimmune and inflammatory conditions. Therefore, the expression of essential enzymes, coagulation factors, transcription factors, growth factors, cytokines, chemokines, antibodies (or antibody fragments thereof), protein hormones, signaling proteins, structural proteins, or cell surface receptors from mRNA can compensate for mutations in genes encoding such proteins in subjects. In some embodiments, therapeutic proteins are proteins expressed in one or more cells of a subject at a level lower than (e.g., significantly lower than) a reference value (e.g., a typical protein expression level in cells of one or more healthy subjects (i.e., subjects who do not suffer from a disease or condition and do not have a risk of suffering from a disease or condition)). As used herein, "antigen" refers to a molecule (e.g., protein) that triggers the production of antibodies that bind to the antigen when expressed in a subject. In some embodiments, an antigen is a protein derived from a pathogen (e.g., a pathogenic virus, bacteria, protozoa, or fungus). In some embodiments, an antigen is a protein (viral antigen) or a fragment thereof derived from a virus. In some embodiments, an antigen is a protein (bacterial antigen) or a fragment thereof derived from bacteria. In some embodiments, an antigen is a protein (protozoan antigen) or a fragment thereof derived from a protozoa. In some embodiments, an antigen is a protein (fungal antigen) or a fragment thereof derived from a fungus. A fragment of a full-length protein refers to a protein whose amino acid sequence exists in the amino acid sequence of the full-length protein but is shorter than the amino acid sequence.
[0305] In some embodiments, the composition (e.g., pharmaceutical composition) provided herein further includes one or more additional agents. In some embodiments, the additional agent is a nucleotide, nucleic acid, amino acid, peptide, protein, small molecule, aptamer, lipid or carbohydrate. In some embodiments, the additional agent is an agent having a therapeutic effect when administered to a subject. In some embodiments, the additional agent is an agent capable of regulating the expression of a gene and / or protein in a subject, such as a short hairpin RNA (shRNA), a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). In some embodiments, the additional agent is a small molecule inhibitor. In some embodiments, the additional agent is an agent capable of initiating or enhancing an immune response in a subject. In some embodiments, the additional agent is an antigen (e.g., a viral antigen, a bacterial antigen). In some embodiments, the additional agent is an adjuvant, which is defined as an agent that is sufficient to enhance an immune response in a subject when administered in an effective amount but does not induce an immune response in a subject when administered alone. In some embodiments, the additional agent is an enzyme, such as an enzyme capable of catalyzing one or more chemical reactions in a subject or in a subject's cell.
[0306] In some aspects, the disclosure provides a delivery agent comprising any of the modified mRNA provided herein. In some embodiments, any of the modified mRNA provided herein is conjugated with a delivery agent. Any of the modified mRNA provided herein can be conjugated with a delivery agent, and the delivery agent includes, for example, a lipid, a peptide, a protein, an antibody, or a carbohydrate. The lipid for conjugating and delivering the modified mRNA is well known in the art, and includes, for example, cholesterol. The peptide, protein, antibody, and carbohydrate for conjugating and delivering the modified mRNA are well known in the art, and include, for example, any peptide, protein, antibody, or carbohydrate that is specifically bound to a part (e.g., protein) on the surface of a target cell type. The method for conjugating a lipid, a peptide, a protein, an antibody, or a carbohydrate to the modified mRNA includes, for example, a method for conjugating a lipid, a peptide, a protein, an antibody, or a carbohydrate to the modified mRNA at the 5' or 3' end, and is well known in the art.
[0307] In some embodiments, any of the modified mRNA provided herein is conjugated to or encapsulated by a delivery agent, the delivery agent comprising, for example, nanoparticles, microparticles or exosomes.Nanoparticles refer to particles having a diameter of about 10nm to 1000nm.Microparticles are defined as particles having a diameter greater than 1000nm (1 μm), such as particles having a diameter of about 1 μm to 100 μm.In some embodiments, nanoparticles or microparticles are approximately spherical.In some embodiments, nanoparticles or microparticles are hollow, including an internal core.In some embodiments, nanoparticles or microparticles are lipid nanoparticles or lipid microparticles, respectively.Lipid nanoparticles or lipid microparticles refer to compositions comprising one or more lipids forming lipid aggregates or having an enclosed structure with an inner surface and an outer surface.In some embodiments, lipid nanoparticles or lipid microparticles include a lipid bilayer enclosing an aqueous core.Lipids used to formulate lipid nanoparticles and lipid microparticles for delivering mRNA are well known in the art, and include, but are not limited to, ionizable amino lipids, non-cationic lipids, sterols and polyethylene glycol-modified lipids. See, for example, Buschmann et al. Vaccines. 2021.9(1):65. In some embodiments, the modified mRNA is surrounded by lipids of a lipid nanoparticle or lipid microparticle and is present inside the lipid nanoparticle or lipid microparticle. In some embodiments, the mRNA is dispersed in the lipids of the lipid nanoparticle or lipid microparticle. In some embodiments, the lipid nanoparticle or lipid microparticle comprises an ionizable amino lipid, a non-cationic lipid, a sterol and / or a polyethylene glycol (PEG)-modified lipid. Lipid nanoparticles and lipid microparticles comprising modified mRNA can be prepared by any method well known in the art, such as detergent dialysis, emulsion, centrifugation, evaporation, thin film hydration or ethanol dilution. See, for example, Barba et al. Pharmaceutics. 2019.11(8):360. Exosomes refer to a type of lipid nanoparticle produced by eukaryotic cells due to inward budding of vesicles in multivesicular bodies, and are typically 30 nm to 150 nm in diameter. Exosomes include a heterogeneous mixture of endogenous lipids, such as phospholipids, membrane-anchored proteins, and carbohydrates present in eukaryotic cells, and enclose an aqueous core. Exosomes may have beneficial features that are difficult to achieve with synthetically produced lipid nanoparticles, for example, the ability to cross the blood-brain barrier and deliver modified mRNA to tissues in the brain. Exosomes including modified mRNA can be produced by any means well known in the art, for example, by sonicating or electroporating isolated exosomes in the presence of modified mRNA, or by mixing exosomes with lipid-conjugated modified mRNA (e.g., modified mRNA conjugated to cholesterol).See, for example, Roberts et al., Nat Rev Drug Discov. 2020.19(10):673-694.
[0308] In some embodiments, the nanoparticles or microparticles are polymer nanoparticles or polymer microparticles, respectively. Polymer nanoparticles or polymer microparticles refer to nanoparticles or microparticle compositions comprising one or more polymers forming polymer aggregates or having an inner surface and an outer surface. In some embodiments, polymer nanoparticles or polymer microparticles include a polymer layer of a closed aqueous core. The polymers used to formulate polymer nanoparticles and polymer microparticles for delivering mRNA are well known in the art and include cationic polymers such as, but not limited to, polyethyleneimine (PEI), poly-amido-amine (PAA), poly-β amino-ester (PBAE), polylysine (PLL), spermine, chitosan, polyurethane and its derivatives (e.g., PEI stearic acid (PSA) copolymer). See, for example, Liu et al. Frontiers of Bioengineering and Biotechnology (Front Bioeng Biotechnol). 2021.9: 718753. In some embodiments, the modified mRNA is surrounded by the polymer of the polymer nanoparticle or polymer microparticle and is present inside the polymer nanoparticle or polymer microparticle. In some embodiments, the mRNA is dispersed in the polymer of the polymer nanoparticle or polymer microparticle.
[0309] In some embodiments, the nanoparticles or microparticles are protein nanoparticles or protein microparticles, respectively. Protein nanoparticles or protein microparticles refer to nanoparticles or microparticle compositions comprising one or more proteins forming protein aggregates or having an inner surface and an outer surface. In some embodiments, protein nanoparticles or protein microparticles include a protein layer of a closed aqueous core. Proteins used to prepare protein nanoparticles and protein microparticles for delivering mRNA are well known in the art and include, but are not limited to, viral coat proteins and ferritin. See, for example, Wang et al. "Nature Nanotechnology (Nat Nanotechnol)". 2020.15 (5): 406-416. In some embodiments, the modified mRNA is surrounded by proteins of protein nanoparticles or protein microparticles and is present inside the protein nanoparticles or protein microparticles. In some embodiments, the modified mRNA is located outside the protein of the protein nanoparticles or protein microparticles and is connected to the outer surface of the protein nanoparticles or protein microparticles. In some embodiments, the modified mRNA is conjugated to a protein of a protein nanoparticle or protein microparticle via a covalent bond, such as formed by a click chemistry reaction or by fusing the modified mRNA and protein to a protein or peptide of a protein / peptide pair known to react to form a covalent bond (e.g., a SpyCatcher / SpyTag protein / peptide pair).
[0310] In some embodiments, the nanoparticles or microparticles are solid nanoparticles or solid microparticles. Solid nanoparticles or solid microparticles refer to nanoparticles or microparticle compositions comprising one or more materials forming a solid structure having an outer surface and may or may not include an inner surface. Solid nanoparticles or solid microparticles may include any suitable material well known in the art, such as gold, silver or silicon dioxide / silica. In some embodiments, the modified mRNA is conjugated to the outer surface of the solid nanoparticle or solid microparticle. Solid nanoparticles and solid microparticles comprising modified mRNA can be produced by any means well known in the art, for example, by connecting the modified mRNA to the surface of the solid nanoparticle or solid microparticle through a thiol bond (e.g., modifying DNA to include a cyclic disulfide anchoring group), or by modifying the outer surface of the solid nanoparticle or solid microparticle with one or more cationic materials (e.g., PEI) in which the modified mRNA is present. See, for example, Roberts et al., Nature Reviews Drug Discovery. 2020. 19(10): 673-694; Lee et al., Nano Lett. 2007, 7(7): 2112-2115; and Paris and Vallet-Regi. Pharmaceutics. 2020, 12(6): 526.
[0311] In some aspects, the disclosure provides a cell comprising any of the modified mRNA provided herein. In certain embodiments, the cell is a human cell comprising any of the modified mRNA provided herein. "Cell" is the basic structural and functional unit of all known independent organisms. It is the smallest life unit classified as an organism. Some organisms, such as most bacteria, are unicellular (composed of a single cell). Other organisms such as plants, fungi and animals (including cattle, horses, chickens, turkeys, sheep, pigs, dogs, cats and humans) are multicellular. In certain embodiments, the half-life of the modified mRNA in the cell is 15-900 minutes. In certain embodiments, the half-life of the modified mRNA in the cell is 30-600 minutes. In certain embodiments, the half-life of the modified mRNA in the cell is 60-300 minutes. In certain embodiments, the half-life of the modified mRNA is at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60 minutes. In some embodiments, the half-life of the modified mRNA in the cell is at least 30, at least 60, at least 90, at least 120, at least 150, at least 180, at least 210, at least 240, at least 270, at least 300, at least 330, at least 360, at least 390, at least 420, at least 450, at least 480, at least 510, at least 540, at least 570, at least 600, at least 630, at least 660, at least 690, at least 720, at least 750, at least 780, at least 810, at least 840, or at least 870 minutes.
[0312] In some aspects, the present disclosure provides a composition including any one of the modified mRNA, delivery agent or cell provided herein. In some embodiments, the composition further includes one or more additional agents, such as nucleotides, nucleic acids, amino acids, peptides, proteins, small molecules, aptamers, lipids or carbohydrates. In some embodiments, additional agents have a therapeutic effect when applied to a subject. In some embodiments, additional agents are agents for regulating the expression and / or activity of one or more gene products (e.g., proteins) of a subject. In some embodiments, additional agents are nucleic acids for reducing the expression and / or activity of one or more gene products (e.g., proteins), such as short hairpin RNA (shRNA), small interfering RNA (siRNA) or antisense oligonucleotides (ASO). In some embodiments, additional agents are inhibitors for reducing the activity of one or more gene products (e.g., proteins). In some embodiments, agents are small molecule inhibitors. In some embodiments, additional agents are agents for enhancing immune responses in a subject. In some embodiments, additional agents are antigens, such as nucleic acid antigens, protein antigens or phospholipid antigens. In some embodiments, the additional agent is an adjuvant, such as aluminum hydroxide or potassium aluminum sulfate (alum), monophosphoryl lipid A (MPL), an oil-in-water emulsion (e.g., squalene emulsion), cytosine phosphate guanine (CpG) oligodeoxynucleotides, or another adjuvant known in the art. See, for example, DiPasquale, A et al. Vaccine. 2015.3(2):320-343. In some embodiments, the composition is a pharmaceutical composition comprising any of the modified mRNA, delivery agent, or cell provided herein and a pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients, carriers, buffers, stabilizers, isotonic agents, preservatives, or antioxidants, or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The exact nature of the carrier or other material may depend on the route of administration, for example, parenteral, intramuscular, intradermal, sublingual, buccal, ocular, intranasal, subcutaneous, intrathecal, intratumoral, oral, vaginal, or rectal.
[0313] In some aspects, the present disclosure provides a method of applying any one of the modified mRNA, delivery agent, cell, composition or pharmaceutical composition provided herein to a subject. In some embodiments, the subject is a human. In some embodiments, administration is parenteral, intramuscular, intradermal, sublingual, buccal, ocular, intranasal, subcutaneous, intrathecal, intratumoral, oral, vaginal or rectal. In some embodiments, the composition should be stored below 50°C, below 40°C, below 30°C, below 20°C, below 10°C, below 0°C, below -10°C, below -20°C, below -30°C, below -40°C, below -50°C, below -60°C, below -70°C or below -80°C, so that the nucleic acid is relatively stable over time. In some embodiments, the modified mRNA is introduced into the cells of the subject by in vivo electroporation. In vivo electroporation is the process of introducing nucleic acid or other molecules into the cells of the subject using electric pulses, which promotes nucleic acid or other molecules to pass through cell membranes and / or cell walls. See, for example, Somiari et al., Molecular Therapy., 2000.2(3):178-187. The modified mRNA to be delivered is administered to the subject by injection, and an electric pulse is applied to the injection site, thereby electrically promoting the nucleic acid to enter the cell at the administration site. In some embodiments, the modified mRNA is delivered to the subject's cells (e.g., cells local to the administration site or throughout the subject's body) by a delivery agent conjugated to the modified mRNA and absorbed by it. In some embodiments, the modified mRNA is administered together with other elements (such as buffers and / or excipients) that improve the efficiency of electroporation.
[0314] In some aspects, the present disclosure provides a kit comprising any one of the RNAs provided herein and any one of the tailing nucleic acids and / or capping nucleic acids. RNA and tailing nucleic acids and / or capping nucleic acids can be combined in the presence of RNA ligase to produce a modified mRNA, such as one of the modified mRNAs provided herein. In some embodiments, the kit comprises a ligase. In some embodiments, the kit comprises an RNA ligase. In some embodiments, the kit comprises a T4 RNA ligase. In some embodiments, the kit comprises a T4 RNA ligase 1. In some embodiments, the kit comprises a T4 RNA ligase 2. In some embodiments, the kit comprises an RtcB RNA ligase. In some embodiments, the kit further comprises a buffer for ligation. In some embodiments, the kit further comprises a nucleotide triphosphate, such as ATP, for providing the energy required for the ligase. In some embodiments, the kit should be stored at 50°C or less, 40°C or less, 30°C or less, 20°C or less, 10°C or less, 0°C or less, -10°C or less, -20°C or less, -30°C or less, -40°C or less, -50°C or less, -60°C or less, -70°C or less, or -80°C or less, so that the nucleic acid is relatively stable over time.
[0315] In some aspects, the present disclosure provides a kind of kit including any one of the pharmaceutical compositions provided herein and a delivery device.Delivery device refers to a machine or device suitable for administering the composition to a subject, such as a syringe or a needle.In certain embodiments, the kit should be stored at below 50°C, below 40°C, below 30°C, below 20°C, below 10°C, below 0°C, below -10°C, below -20°C, below -30°C, below -40°C, below -50°C, below -60°C, below -70°C or below -80°C, so that the nucleic acid of the pharmaceutical composition is relatively stable over time.In certain embodiments, the kit further includes instructions for administering any one of the pharmaceutical compositions provided herein to a subject.
[0316] Examples
[0317] In order to more fully understand the present disclosure, the following examples are described. These examples are provided to illustrate the modified mRNA, pharmaceutical compositions, kits and methods provided herein, and should not be interpreted in any way as limiting the scope thereof.
[0318] Materials and methods
[0319] Plasmid cloning, characterization, and purification
[0320] The DNA coding sequence (CDS) of the protein of interest was inserted into an optimized backbone containing (in order) an SP6 or T7 promoter sequence, 5' human α-globin UTR, CDS, 3' human α-globin UTR, 100×A template-encoded poly(A) tail, and an Esp3I linearization site. Plasmids / gene blocks containing the CDS were PCR amplified, gel purified, and assembled into the optimized backbone using NEBuilder HiFi DNA Assembly Master Mix (NEB, E2621S), transformed into stable cells, and sequence verified using Sanger sequencing.
[0321] Firefly luciferase construct is obtained by pmirGLO dual luciferase miRNA target expression vector (Plomag, E1330). Destabilized firefly luciferase construct (i.e., firefly-PEST) is obtained by inserting a gene block (GeneBlock) encoding a degrader derived from mouse ornithine decarboxylase (IDT, human codon optimized). The construct encoding Cas9 is obtained by Addgene (plasmid number 52962) preserved by Feng Zhang Laboratory. Gene-synthesized nano-luciferase constructs are obtained from Genewiz. Renilla luciferase construct is obtained by pmirGLO, without being cloned into an optimized vector.
[0322] Linear mRNA synthesis and characterization
[0323] DNA plasmid is linearized by Esp3I (NEB, R0734S). With DNA cleaning and concentrator-25 kit (D4033) from Zymo Research, linearized plasmid is purified and characterized by agarose gel electrophoresis. Except replacing UTP with pseudouridine-5'-triphosphate N1-methyl ester (Trilink, N-1081-1) 100% and adding 1:50 SUPERase-In RNase inhibitor [Thermo Fisher Scientific, AM2694], according to the manufacturer's scheme, mMESSAGE mMACHINE SP6 transcription kit [Thermo Fisher Scientific, AM1340] (for SP6 promoter construct) or HiScribe T7 high yield RNA synthesis kit [NEB, E2040S] (for T7 promoter construct) is used to synthesize mRNA construct by in vitro transcription (IVT). For SP6 promoter constructs, all linear mRNA constructs were co-transcriptionally capped by replacing GTP with a final concentration of 2 mM GTP and 8 mM 3'-O-Me-m7G (5') ppp (5') G RNA anti-retrograde cap analog (ARCA) [NEB, S1411S]. T7 constructs were co-transcriptionally capped with CleanCap reagent AG [Tri-link, N-7113]. After the IVT reaction, the DNA template was digested by TURBO DNA enzyme and purified using the MEGAclear transcription cleanup kit [Thermo Fisher Scientific, AM1908]. Immediately before use, the mRNA concentration was quantified using the Qubit RNA HS assay [Thermo Fisher Scientific, Q32852]. Unless otherwise stated, the mRNA product was suspended in RNase-free water (hereinafter referred to as RNase-free water) containing 1:50 (v / v) RNase inhibitor and stored at -80°C.
[0324] Chemical conjugation of modified synthetic poly(A) oligonucleotides
[0325] Chemically modified poly(A) oligonucleotides were obtained from IDT and suspended in RNase-free water to a final concentration of 100 μM.
[0326] For thiol-ene / yne conjugation, disulfide-protected thiol-oligonucleotides were deprotected with 100 moles of TCEP (tris(2-carboxyethyl)phosphine) and immediately mixed with an equimolar amount of alkene / alkyne-modified oligonucleotide and incubated for 30 minutes to 1 hour at 37° C. In case free radical conditions were used, a substoichiometric amount of 2,2-dimethoxy-2-phenylacetophenone was added and incubated at room temperature under 370 nm irradiation [Kessil, KSPR160L370].
[0327] For amine-phosphate conjugation, the oligonucleotides were mixed in excess imidazole with 1 to 2 equivalents of EDC as an additive. The reaction mixture was incubated at 37°C for 30 minutes to 1 hour.
[0328] For IEDDA (inverse demand Diels-Alder reaction) conjugation, methyltetrazine (Me-Tz) and trans-cyclooctene (TCO) labeled oligonucleotides were obtained from the corresponding amine-modified oligonucleotides after labeling with tetrazine-PEG5-NHS ester (Tetrazine-PEG5-NHS Ester) (Click Chemistry Tools, 1143) or TCO-PEG4-TFP ester (TCO-PEG4-TFP Ester) [Click Chemistry Tools, 1198] at a molar ratio of 500:1 (small molecule:oligonucleotide) in 100 mM NaHCO3 at 4°C overnight. The NHS labeled products were purified using ethanol precipitation. The Me-Tz / TCO labeled oligonucleotides were suspended in RNase-free water and incubated at 55°C for 30 minutes.
[0329] For CuAAC (copper-catalyzed azide-alkyne conjugation) conjugation, oligonucleotides containing azide / alkyne are mixed at a specified molar ratio (single branched oligonucleotide is 1: 1, dibranched oligonucleotide is 2: 1, and tribranched oligonucleotide is 3: 1). The oligonucleotide mixture is diluted in a modified 1.5-fold click chemistry buffer (Lumiprobe, 61150, containing 5% SUPERase inhibitor, 5% DMSO and 5% 10mM dNTP mixture [Thermo Fisher Scientific, 18427089]), and the buffer is briefly degassed for 20 minutes by argon purging before the reaction. For a typical 100 μL reaction, 33 μL of oligonucleotide solution is mixed with 66 μL of click chemistry buffer, and 2 μL of 100mM L-ascorbic acid solution [Sigma-Aldrich, A5960] is added immediately before the reaction. The mixture was incubated at 37°C for 1 hour and the reaction was stopped by adding 1 μL of 500 mM EDTA (pH 8.0). The reaction was first purified using the Monarch RNA Cleanup Kit [NEB, T2040] and the crude product was repurified using RNase-free HPLC on an Agilent 1260 Infinity II HPLC using acetonitrile [Sigma Aldrich, 34851] and 100 mM hexylamine / acetic acid (pH 7.0, containing 10% urea w / v) as mobile phase. The HPLC fractions were analyzed by Novex TBE urea gel, stained by 1x SYBR Gold [Thermo Fisher Scientific, S11494], and visualized using the BioRad ChemiDoc MP imaging system [12003154]. The desired fractions were then combined, desalted, and concentrated using the Monarch RNA Cleanup Kit (for small-scale preparations) or ethanol precipitation (for large-scale preparations).
[0330] Enzymatic ligation of modified oligonucleotides to mRNA
[0331] The synthetic oligonucleotide and mRNA were mixed at a molar ratio of 100: 1 and diluted in 2.5 times 50% PEG-8000, 10 times T4 RNA ligase buffer, 8 times T4 RNA ligase [Promega, M1051] and RNase-free water. The reaction was incubated at 37 ° C for 45 minutes and inactivated by adding 50 times 500mM EDTA (pH 8.0). In addition to using 1 volume of beads, the product was purified by RNA Clean XP [Beckman Coulter] according to the manufacturer's protocol. For large-scale reactions, the connection product was purified by HPLC and the residual modified oligonucleotide was recovered. As described previously, the connection product was characterized by RNase H determination. In the case of residual oligonucleotides detected, a second purification was performed. The eluted mRNA was quantified with Qubit, suspended in RNase-free water, and stored at -80 ° C. For each batch of mRNA ligation, a “mock ligation” condition was included, in which all reaction settings were identical except for the addition of synthetic oligonucleotides, and the recovered product was used as a linear mRNA control.
[0332] Screening of mRNA modifications using a time-course dual-luciferase assay
[0333] HeLa cells (CCL-2, ATCC) were maintained in DMEM medium (Thermo Fisher Scientific, 119951) containing 10% FBS and 1% penicillin-streptomycin (Thermo Fisher Scientific, 15070063) in a 37°C incubator with 5% CO2, and passaged every 3 days at a ratio of 1:10. The day before mRNA transfection, HeLa cells were seeded in each well on three white transparent bottom 96-well plates [Corning, 3610] at 75% confluence. The next day, 30 ng of Renilla luciferase (internal control) mRNA and 30 ng of modified firefly luciferase mRNA were transfected using Lipofectamine MessengerMAX transfection reagent [Thermo Fisher Scientific, LMRNA003] according to the manufacturer's protocol. Additional controls containing only Renilla luciferase mRNA or only lipid transfection reagent were included. For each condition, three separate transfections were performed. At 24 / 48 / 72 hours after transfection, the cell culture medium was removed and the cells were rinsed with 1 times of DPBS. The cells were lysed and the luciferase activity was measured using the Promega Dual Glo Luciferase Assay System [Promega, E2920]. In short, 50 μL of PBS and 50 μL of firefly luciferase working solution (prepared according to the manufacturer's protocol) were added to each well using a multichannel pipette and mixed by pipetting. After gently shaking and incubating in the dark for 10 minutes at room temperature, the firefly luciferase luminescence was measured using a microplate reader. Add 50 μL of freshly prepared Renilla luciferase to stop and luminescent working solution (prepared according to the manufacturer's protocol). After incubation for 10 minutes, the Renilla luciferase luminescence was similarly measured. For both firefly luminescence and Renilla luminescence, the background was subtracted by measuring the cells treated with only lipofectamine reagent. The firefly luminescence / Renilla luminescence of each well was used as mRNA activity readings.
[0334] Firefly luciferase degradon assay
[0335] The day before mRNA transfection, HeLa cells were confluent and seeded in each well on 24-well plates with 75%. On the second day, according to the manufacturer's scheme, Lipofectamine MessengerMAX was used to transfect 200ng of unmodified Renilla luciferase (internal control) mRNA and 200ng of the modified firefly-degrader mRNA carrying design into each well. After incubation for 6 hours, the cell culture medium containing the transfection mixture was removed, and cells were rinsed and trypsinized with 1 times of DPBS, and re-seeded into four white transparent bottom 96-well plates with a ratio of 8:6:4:3 respectively, so that luciferase was quantitatively carried out at 8,24,48,72 hours. Luciferase was quantitatively carried out at each time point using the aforementioned scheme. For each time point, firefly luciferase activity was normalized by cell number (reseeding ratio) and then normalized by luminescence activity using Firefly Luminescence / Renilla Luminescence*Average Renilla Luminescence; calculated firefly luciferase luminescence was normalized to the 8 hour reading.
[0336] mRNA quantification in transfected cell cultures using STARmap / RIBOmap
[0337] The day before mRNA transfection, HeLa cells were inoculated in each well on 24-well plates with 75% convergence. On the second day, according to the manufacturer's scheme, 500ng of unmodified Renilla luciferase (internal control) mRNA and 500ng of the firefly-degrader mRNA carrying the modification of design were transfected into each well using Lipofectamine MessengerMAX. After incubation for 6 hours, the transfection mixture was removed, and cells were rinsed and trypsinized with 1 times of DPBS, and six (two at each time point) glass-bottom 96-well plates (MatTek company (MatTek), PBK96G-1.5-5-F, coated with poly-D-lysine [Sigma Aldrich, A-003-M]) were re-seeded with a ratio of 6:4:3 respectively, so that in situ sequencing was carried out quantitatively at 24,48 and 72 hours after transfection. For each time point, each well of transfected cells was replated equally onto two 96-well plates, one of which was measured by STARmap (firefly) + STARmap (Renilla) and the other by RIBOmap (firefly) + STARmap (Renilla).
[0338] For quantification of mRNA quantities, the STARmap / RIBOmap procedures as published for cell culture were followed (Wang et al. "Three-dimensional intact-tissue sequencing of single-cell transcriptional states" (2018) Science 361(6400), eaat5691; Hu et al. "Spatially Resolved Single-cell Translatomics at Molecular Resolution" (2022) bioRxiv). Briefly, at 24 / 48 / 72 hours after transfection, the culture medium was removed and the cells were washed with 150 μL PBS solution. The cells were then fixed with 1.6% paraformaldehyde (Electron Microscope Sciences, 15710-S) / 1x PBS (Gibco, 10010-023) at room temperature for 15 minutes, and then further fixed and permeabilized with pre-cooled methanol for one hour at -20°C. Subsequently, the methanol was removed and the cells were rehydrated with PBSTR / glycine / YtRNA (PBS containing 0.1% Tween-20 [TEKNOVA INC, 100216-360], 0.5% SUPERaseIn [Invitrogen, AM2696], 100 mM glycine, 1% yeast tRNA) at room temperature for 5 minutes, followed by one PBSTR wash. The samples were then hybridized overnight in a humidified oven at 40°C with SNAIL probes targeting firefly and Renilla luciferase mRNA sequences in hybridization buffer (2x SSC [Sigma-Aldrich, S6639], 10% formamide [Calbiochem, 655206], 1% Tween-20, 20 mM RVC [vanadyl ribonucleoside complex, New England Biolabs, S1402S], 0.5% SUPERaseIn, and 1% yeast tRNA, 100 nM for each probe) while shaking and parafilm-embedded (see Supplementary Table 2 for probe sequences). For RIBOmap quantification, the SNAIL probe targeting firefly luciferase was replaced by the RIBOmap primer / padlock probe and splint probe targeting 18S rRNA, and the rest of the protocol remained unchanged.After hybridization, the cells were washed twice with PBSTR at 37° C. (20 min each wash) and once with high salt wash buffer (PBSTR with 4× SSC) at 37° C., followed by a rinse with PBSTR at room temperature. The ligation reaction was performed at room temperature for 2 hours to circularize the padlock probe adjacent to the primer in ligation buffer (1× T4 DNA ligase buffer, T4 DNA ligase, 0.1 Weiss U / μL [Thermo Fisher Scientific, EL0012], 0.5 mg / mL ultrapure BSA [Thermo Fisher Scientific, AM2618], 0.5% SUPERaseIn). The cells were washed twice with PBSTR and subjected to rolling circle amplification (RCA) at 30°C in RCA buffer (1× Phi29 buffer, 0.2 Weiss U / μL Phi29 DNA polymerase [Thermo Fisher Scientific, EP0094], 250uM dNTP mixture [Thermo Fisher Scientific, 18427089], 0.5mg / mL BSA, 0.5% SUPERaseIn) for 2 hours, followed by washing twice with PBST. The samples were then stained with fluorescent detection oligonucleotides for 1 hour at room temperature in washing and imaging buffer (2× SSC, 10% formamide, 100nM / detection probe, 1× DAPI [Molecular Probes, D1306]) (see Supplementary Table 2 for the sequence of fluorescent detection probes). Confocal imaging stacks were taken with a Leica Stellaris 8 with a pixel size of 283×283nm using a 60× oil objective. 14-μm stacks were imaged with 2 μm / step × 7 steps. For each condition, three independent transfections were performed, with at least four representative FOVs taken. The same imaging settings were used for all samples to be compared. Excitation / detection wavelengths were as follows: DAPI, diode 405 nm / ~[420-489] nm; Alexa546, WLL 557 nm / ~[569-612] nm; Alexa647, WLL 653 nm / ~[668-738] nm.
[0339] MATLAB 2021a and CellProfiler 4.0.7 were used for fluorescence image analysis based on amplicon counting. First, the centroid of the amplicon in each fluorescent channel (firefly, Renilla) was identified by finding the extended maximum value on the image. Then a 3*3*3 voxel volume centered on the centroid of each fluorescent spot was defined. Within each voxel volume, the integrated intensity in the firefly and Renilla channels was calculated, and the ratio between the firefly intensity and the Renilla intensity was used for amplicon classification. For STARmap quantification, all measurements were merged together and the distribution of log(firefly / Reniella) values was plotted. The corresponding ratio value at the lowest point (local minimum) on the distribution plot was determined as the cutoff value. The first cutoff value less than 0 was recorded as cutoff 1, and the first cutoff value greater than 0 was recorded as cutoff 2. For RIBOmap quantification, cutoff 1 was assigned to -0.3 and cutoff 2 was assigned to 0.3. Any amplicon with a log(firefly / Reniella) value less than cutoff 1 was determined to be a Renilla amplicon. Any amplicon with a log(firefly / renilla) value greater than cutoff 2 is determined to be a firefly amplicon. Any amplicon with a log(firefly / renilla) value between cutoff 1 and cutoff 2 is determined to be a particle. Amplicon classification information and the position of each amplicon are saved in the file. In each figure, the ratio between the number of firefly amplicons and the number of renilla amplicons is calculated and used to reflect the amount of firefly luciferase mRNA. In single-cell STARmap quantification, cell segmentation is performed using the same method as cell segmentation in single-cell protein quantification (see GFP ablation using Cas9 mRNA), and the segmentation mask is saved as a uint16 image. Then, the amplicon is assigned to the cell according to its position on the mask. The ratio between the number of firefly amplicons and the number of renilla amplicons in each cell is calculated and used to reflect the amount of firefly luciferase mRNA in a single cell. Cells without firefly amplicons or without renilla amplicons are considered to have failed transfection and are therefore excluded from the analysis.
[0340] EMSA (Electrophoretic Mobility Shift Assay / Gel Shift Assay)
[0341] The codon-optimized DNA sequence encoding the full-length human PABPC1 (residues 1-636) (GST-tagged) was cloned into the pBluescript II KS(-) vector by GenScript. The transformed Escherichia coli cells [BL21 competent E. coli, New England Biolabs] were grown in 1 L Luria Bertani medium at 37°C in the presence of 50 mg ampicillin to an absorbance of 0.6-0.8 at 600 nm. The expression of glutathione S-transferase (GST)-fusion protein was induced by adding 0.5 or 1 mM isopropyl β-D-1-thiogalactopyranoside, and the cells were grown overnight at 18°C. Cells were harvested by centrifugation and disrupted by ultrasound in 30 mL of lysis buffer (10 mM Na2HPO4 (pH 7.4), 1.8 mM KH2PO4, 637 mM NaCl, 2.7 mM KCl, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, 0.15 μM aprotinin, 1 μM E-64 and 1 μM leupeptin) containing 0.15% polyethyleneimine to remove nucleic acids from the lysate. Cell debris was removed by centrifugation. The supernatant was applied to a glutathione sepharose 4B column [GE Healthcare] equilibrated with PBS at 4°C and washed with PBS at 4°C. The GST fusion protein was eluted with elution buffer (100 mM Tris-HCl (pH 7.8), 300 mM NaCl and 20 mM glutathione 3 (reduced form)). The eluted solution of the separated PABPC1-GST was concentrated using a spin filter and the concentration of the protein was quantified using the Qubit Protein Broad Range (BR) Assay Kit [Invitrogen, Q33211]. Branched / linear poly(A) oligonucleotides labeled at the 5' end with AlexaFluor 546 were synthesized as described in the previous section. The poly(A) oligonucleotides were incubated in binding buffer (10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, 5 mM MgSO4, 1 mM DTT, Novex High Density TBE Sample Buffer [Invitrogen, LC6678]) with different PABPC1-GST concentrations prepared by serial dilution from stock solutions. For competitive binding assays, the concentrations of Alexa 546-labeled branched oligonucleotides and PABPC1-GST were kept constant while adding different concentrations of unlabeled linear poly(A) oligonucleotides.Oligonucleotides and PABP were incubated at 4°C for 30 min and characterized by EMSA using Novex TBE gels (4-20% [Invitrogen, EC6225BOX]) at 4°C. Alexa546-labeled oligonucleotides were imaged using the BioRad ChemiDocMP imaging system [12003154] and band intensities were quantified using ImageJ. For Kd calculations, the percentage of poly(A) oligonucleotides bound to x-mers of PABP was calculated as the total percentage of oligonucleotides bound to >x-mers of PABP, and Kd was calculated by plotting the percentage of poly(A) oligonucleotides bound to PABP versus PABP concentration using GraphPad Prism (specific binding with Hill slope).
[0342] GFP ablation using Cas9 mRNA
[0343] Linear / branched Cas9 mRNA was synthesized using the aforementioned protocol. sgRNA was designed and synthesized using the IDT sgRNA design tool [IDT, Alt-RCRISPR-Cas9 sgRNA]. One day before mRNA transfection, HEK293 cells expressing GFP [Gene Target Inc, SC058] were seeded in individual wells on a 12-well plate at 50% confluence. The next day, cells were co-transfected with 100ng sgRNA and varying amounts of linear / branched Cas9 mRNA using Lipofectamine MessengerMAX. After 48 hours of incubation, the cell culture medium was removed, and the cells were rinsed with 1x DPBS, trypsinized, and re-seeded onto a glass-bottom 12-well plate [MatTek, P12G-1.5-14-F, coated with poly-D-lysine]. 72 hours after transfection, the medium was removed and the cells were rinsed once with 1x DPBS and then incubated for 10 min at 37°C in nuclear staining medium (FluoroBrite DMEM [ThermoFisher, A1896701] and Hoechst 33342 [ThermoFisher, 62249] diluted 1:2000). Confocal images of nuclei (Hoechst) and GFP were taken with a Leica Stellaris 8 at a pixel size of 1135 × 1135 nm using a 10x air objective. 14-μm stacks were imaged with 2 μm / step × 7 steps. For each condition tested, at least six representative FOVs were taken and the same imaging settings were used for all samples to be compared. Excitation / detection wavelengths were as follows: Hoechst, diode 405 nm / ~[430-480] nm; GFP, WLL 489 nm / ~[500-576] nm.
[0344] Maximum projection images of the original image stack were analyzed. CellProfiler 4.0.7 was used for single-cell protein quantification. For single-cell analysis, first, the Hoechst-stained nucleus was identified as the primary target. Then, the Hoechst channel and the GFP channel were merged and subsequently converted to a gray scale image. In this gray scale image, cells were identified as secondary targets. After cell segmentation, the GFP intensity in each cell was measured.
[0345] Circular RNA synthesis
[0346] A circular RNA sequence encoding a secreted NanoLuc with a translationally enhanced UTR (iHRVB3+PABPv3) from a previous study was used (Chen et al., “Engineering circular RNA for enhanced protein production” Nature biotechnology (2022) 1-11). A DNA template was synthesized from GENEWISE, PCR amplified, and gel purified for use as an IVT template. CircRNA was synthesized using the HiScribe T7 High Yield RNA Synthesis Kit [New England Biolabs, E2040S]. After IVT, the DNA template was digested with Turbo DNA enzyme [Thermo Fisher Scientific, AM2238]. The reaction mixture was heated to 70°C for 5 minutes and then immediately placed on ice for 3 minutes, after which GTP was added to a final concentration of 2 mM and the reaction mixture was incubated at 55°C for 15 minutes. CircRNAs were enriched by treatment with RNase R [Lucigen Corporation, RNR07250] for 1.5 h and the products were column purified. The circRNA products were characterized by gel electrophoresis and, in the case of residual linear RNA precursors, another round of RNase R digestion was performed. The precursor and product patterns were consistent with previous reports.
[0347] In vitro secreted NanoLuc assay
[0348] On the day before mRNA transfection, HeLa cells were seeded in each well on a 96-well plate at 75% confluence. In order to minimize the effect of phenol red on the assay, FluoroBrite DMEM supplemented with 10% fetal bovine serum and 4mM L-glutamine was used for culture. On the second day, equimolar linear / branched / circular RNA (corresponding to 50ng, 59ng and 90ng of mRNA, respectively) was transfected into the cells using lipofectamine. 6 hours after transfection, the culture medium was replaced with 150 μL of the aforementioned FluoroBrite culture medium. Every day, the old culture medium of each well was replaced with 150 μL of a new aliquot of FluoroBrite culture medium, and 50 μL of the old culture medium was used for bioluminescence measurement using the Nano-Glo luciferase assay system [Promega, N1110]. For each condition tested, at least three independent transfections were performed, and background luminescence was subtracted from each well. This assay was performed for a total of 14 days.
[0349] Mouse
[0350] All animal procedures followed the animal care guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of the Broad Institute of MIT and Harvard under animal protocol number 0255-08-19. Animal experiments were performed in accordance with IACUC policies and NIH guidelines.
[0351] In vivo delivery of mRNA
[0352] BALB / c (male and female, 6-8 weeks old) mice used for in vivo NanoLuc assays in this study were purchased from The Jackson Laboratory (JAX). Branched and linear mRNA encoding NanoLuc were formulated into LNPs using the NanoAssemblr Spark Kit-Hepato9 mRNA [Precision Nanosystems, NWS0016] on a NanoAssemblr Spark instrument [Precision Nanosystems] according to the manufacturer's protocol. After formulation, the mRNA-LNPs were diluted in 10 mL of 1x PBS solution and buffer exchanged by concentration with a 30 kDa spin filter [MilliporeSigma, UFC901008] to remove residual ethanol. The concentration of mRNA was determined using the Quant-it RiboGreen RNA Assay Kit [Thermo Fisher, R11490], and the encapsulation efficiency was greater than 95%. Each mouse was immediately injected with 390 pg / nucleotide of linear / circular mRNA-LNPs (corresponding to 350 ng of linear mRNA) by retro-orbital injection in an injection volume of 100 μL. Three male and three female mice were used per condition.
[0353] In vivo imaging of NanoLuc
[0354] NanoLuc in vivo activity in mice was measured using a Competent IVIS-Perkin Elmer IVIS Spectrum CT system [Perkin Elmer]. At each time point, mice were anesthetized with isoflurane. Fluorofurazine substrate [Promega] was freshly reconstituted in 1.05 ml PBS / vial and injected into mice at a dose of 44 nmol / gram body weight. Mice were imaged using default settings 5 minutes after injection. Luminescent activity was quantified using Aura 4.0 imaging software. Background was determined by including mice injected with polyC-LNP negative controls and subtracted from each measurement.
[0355] In vivo toxicity assay
[0356] To evaluate in vivo toxicity and immune responses, blood was collected from mice and serum was prepared on day 15 after mRNA-LNP administration. AST, ALT, and TNF-α were measured using ELISA kits for AST [G-Biosciences, IT5530], ALT [G-Biosciences, IT5508], and TNF-α [R&D Systems, MTA00B] according to the manufacturer's protocol.
[0357] Example 1. Generation of multi-tailed and multi-capped mRNAs.
[0358] Both the 3' poly-A tail and the 5' cap are required for efficient translation of eukaryotic mRNA molecules ( Figure 1A However, both the poly-A tail and the 5' cap are easily degraded by exonucleases that remove nucleotides from mRNA molecules ( Figure 1B ). Once the exonuclease degrades the coding portion of the mRNA (e.g., protein coding sequence), the mRNA cannot be effectively translated. Strategies to enhance the stability of mRNA include methods of modifying mRNA molecules to produce resistance to exonuclease activity. Exonuclease resistance can be conferred to mRNA molecules by modifying the mRNA to include additional poly-A tails and / or 5' caps. Additional poly-A tails and 5' caps can be introduced into mRNA molecules by any number of techniques.
[0359] For example, in one technique, an additional poly-A tail can be introduced into an mRNA molecule (e.g., an mRNA isolated from a cell or organism, or an mRNA molecule produced by in vitro transcription (IVT)) by attaching the 3' end of the mRNA to a "brush" poly-A tail oligonucleotide that includes an internal covalent linkage to the 3' end or 5' end of one or more second nucleic acid sequences ( Figure 1C Brush-like poly-A tail oligonucleotides can be generated by starting with poly-A oligonucleotides modified with several internal nucleotides capable of click chemistry (e.g., 5-octadiynyl dU) and attaching additional poly-A oligonucleotides including 3' azide moieties to these nucleotides ( Figure 1DFor additional exonuclease resistance, any of the oligonucleotides can be modified with one or more modified nucleotides or internucleotide bonds, such as phosphorothioate bonds. For example, a first poly-A oligonucleotide can include a sequence of / 5Phos / rArArArArArA / i5OctdU / rArA rArArA rArArA rArArA rArArA / i5OctdU / rA rArArA rArArA rArArA rArA / i5OctdU / / 3ddC / (SEQ ID NO:7) to which is linked an oligonucleotide comprising a sequence of / 5Phos / rArArA rArArA rArArA rArArA rArArA rArArA rArArA rArArA rA*rA*rA*rA*rA*rA* / 3AzideN / (SEQ ID NO:8), wherein "*" indicates a phosphorothioate bond. After assembly via a click chemistry reaction (e.g., Cu(I)-catalyzed azide-alkyne cycloaddition), the 5' end of the brush poly-A oligonucleotide can then be ligated using an RNA ligase (e.g., T4 RNA ligase) to the 3' end of an mRNA molecule, which may or may not already include a poly-A tail.
[0360] Alternatively, an additional poly-A tail can be introduced into the mRNA molecule by ligating the 3' end of the mRNA to a dendrimer modified with a poly-A tail ( Figure 1E Dendrimers including poly-A tails can be generated by first functionalizing a dendrimer (e.g., PAMAM dendrimer; CAS No.: 1174157-65-3) with an alkyne group. This functionalization can be achieved by nucleophilic substitution between propargyl-N-hydroxysuccinimide ester (CAS No.: 1174157-65-3) and an amino group on the dendrimer, which is effective under mild conditions. The functionalized dendrimer can then be linked to a poly-A tail oligonucleotide including a 3' azide moiety via a click chemistry reaction ( Figure 1F). For additional exonuclease resistance, any of the oligonucleotides can be modified with one or more modified nucleotides or internucleotide bonds, such as phosphorothioate bonds. For example, a poly-A oligonucleotide can include a sequence of / 5Phos / rArArArArArArArA rArArArA rArArArA rArArA rArArA rArArA rArArA rA*rA*rA*rA*rA*rA* / 3AzideN / (SEQ ID NO:8), where "*" indicates a phosphorothioate bond. The 5' end of one of the poly-A oligonucleotides, which is linked to the dendrimer by a click chemistry reaction (e.g., Cu(I)-catalyzed azide-alkyne cycloaddition), can then be ligated to the 3' end of an mRNA molecule, which may or may not already include a poly-A tail, using an RNA ligase (e.g., T4 RNA ligase).
[0361] Orthologous pathways can also be used to generate multi-capped mRNAs. For example, multi-capped mRNAs can be generated by ligating the 5' end of an mRNA to a "brush" 5' capping oligonucleotide ( Figure 1G ). Similar to the way brush-like poly-A tail oligonucleotides are generated, by starting with a multi-capped oligonucleotide modified with several internal nucleotides capable of click chemistry (e.g., 5-octanediynyl dU) and attaching additional multi-capped oligonucleotides including 3' azide moieties to these nucleotides ( Figure 1H), a brush-shaped multi-cap oligonucleotide can be produced. For additional exonuclease resistance, any of the oligonucleotides can be modified with one or more modified nucleotides or internucleotide bonds (such as phosphorothioate bonds). The 5' cap can be a 7-methylguanosine (m7G) cap, or a modified cap, for example, a cap including a modified nucleotide or internucleotide bond. For example, the first polycap oligonucleotide can include a sequence of 5'- / Cap / rGrGrG rArArA / i5OctdU / rArA rGrArG rArGrA rArArArGrArA rGrArG / i5OctdU / rArA rGrArA rGrArA rA / i5OctdU / rA (SEQ ID NO:9), to which an oligonucleotide is linked, the oligonucleotide including a sequence of 5'- / Cap / rGrGrG rArGrA rCrTrG rCrCrArCrCrA*rA*rA*rA*rA*rA* / Azide N / -3' (SEQ ID NO:6), wherein "*" indicates a phosphorothioate bond. After assembly via a click chemistry reaction (eg, Cu(I)-catalyzed azide-alkyne cycloaddition), the 3' end of the brush poly-A oligonucleotide can then be ligated to the uncapped 5' end of the mRNA molecule using an RNA ligase (eg, T4 RNA ligase).
[0362] Alternatively, an additional 5' cap can be introduced into the mRNA molecule by ligating the 5' end of the mRNA to a dendrimer modified with a 5' cap ( Fig. 1I ). Similar to the manner in which dendrimers modified with poly-A tails are produced, dendrimers including 5' caps can be produced by first functionalizing a dendrimer (e.g., PAMAM dendrimer; CAS No.: 1174157-65-3) with an alkyne group. This functionalization can be achieved by nucleophilic substitution between propargyl-N-hydroxysuccinimide ester (CAS No.: 1174157-65-3) and an amino group on the dendrimer, which is effective under mild conditions. The functionalized dendrimer can then be linked to a 5' capped oligonucleotide including a 3' azide moiety via a click chemistry reaction ( Figure 1J). An uncapped oligonucleotide comprising a 5' azide is also attached to the functionalized dendrimer. The rate of attachment of a capped oligonucleotide comprising a 3' azide moiety and an uncapped oligonucleotide comprising a 5' azide moiety to the dendrimer can be controlled by adjusting the stoichiometry between the oligonucleotides. For additional exonuclease resistance, any of the oligonucleotides can be modified with one or more modified nucleotides or internucleotide bonds, such as phosphorothioate bonds. The 5' cap can be a 7-methylguanosine (m7G) cap, or a modified cap, for example, a cap comprising a modified nucleotide or internucleotide bond. For example, a 5' capped oligonucleotide may include a sequence of 5'- / Cap / rGrGrGrArGrA rCrTrGrCrCrA rCrCrA*rA*rA*rA*rA*rA* / AzideN / -3' (SEQ ID NO: 6), while an uncapped oligonucleotide may include a sequence of / 5AzideN / rArArA rArA, where "*" indicates a phosphorothioate bond. The 3' end of the uncapped oligonucleotide, which is attached to the dendrimer by a click chemistry reaction (e.g., Cu(I)-catalyzed azide-alkyne cycloaddition), can then be ligated to the 5' end of the uncapped mRNA molecule using an RNA ligase (e.g., T4 RNA ligase).
[0363] Modified mRNA molecules that include additional poly-A tails can also be modified to include additional 5' caps, and vice versa. In addition to having enhanced resistance to exonucleases, mRNA molecules modified with additional poly-A tails and / or 5' caps can also have enhanced translation efficiency relative to unmodified mRNA molecules. For example, adding one or more additional poly-A tails or 5' caps to an mRNA molecule can enhance the binding between the mRNA molecule and one or more components of the eukaryotic translation machinery, such as poly-A binding protein (PABP) and the eukaryotic initiation factor 4E (eIF4E) cap binding protein of the eukaryotic initiation factor 4 complex (eIF4F) ( Figure 1C , E, G and I).
[0364] Example 2. Effect of multiple poly(A) tails on in vitro mRNA translation.
[0365] In order to preliminarily test the translation efficiency of mRNA molecules modified with other ploy (A) tails, as described in Example 1, the mRNA encoding fluorescent protein or luminescent protein is modified with brush-shaped poly-A tail oligonucleotides. In short, the constitutive fluorescent variants of green fluorescent protein (hMGFP) or the mRNA molecules of firefly luciferase are connected to brush-shaped poly-A oligonucleotide precursors, brush-shaped poly-A oligonucleotide precursors connected to poly-A oligonucleotides with 5' azide or brush-shaped poly-A oligonucleotide precursors connected to poly-A oligonucleotides with 3' azide (Table 1). Also tested the analog connection with mRNA and no oligonucleotide and untreated mRNA. Each mRNA is transfected into human HeLa cell culture together with a constant amount of control mRNA. The transfection carried out with the mRNA encoding hMGFP is co-transfected with the mRNA encoding mCherry. The transfection carried out with the mRNA encoding firefly luciferase is co-transfected with Renilla luciferase. The ratio of hMGFP / mCherry fluorescence to firefly luciferase / renilla luciferase was measured 24 h, 48 h, and 72 h after transfection and used to assess the translation efficiency of the transfected mRNA.
[0366] Similar ratios of fluorescence and luminescence were measured in cells transfected with untreated mRNA or mock-linked mRNA, which generally did not change over the 72-hour time course ( Figure 1K , L). Cells transfected with mRNA linked only to brush oligonucleotide precursors showed an increase in fluorescence / luminescence after 48 and 72 hours, indicating that linking to the brush poly-A tail precursor enhanced mRNA stability and translation efficiency. This effect was further enhanced by adding a poly(A) oligonucleotide comprising a 5' azide moiety to the brush poly(A) tail precursor, indicating that the number of poly-A tails linked to the mRNA was positively correlated with the stability and translation efficiency of the mRNA. However, linking a poly-A oligonucleotide comprising a 3' azide moiety to the brush poly-A tail precursor reduced the observed fluorescence / luminescence. This result is not surprising, as linking the poly-A oligonucleotide to the brush poly-A tail precursor via a 3' azide results in the brush oligonucleotide having an uncapped 5' phosphate at its end, rather than a set of continuous phosphorothioate-modified adenosine ribonucleotides positioned at the 3' end. Therefore, directing azide-modified poly-A oligonucleotides in this manner is expected to result in the poly-A oligonucleotide being susceptible to exonucleases.
[0367] It should also be noted that 72 hours after transfection, the ratio of hMGFP to mCherry fluorescence was observed to be stable, while 72 hours later, the ratio of firefly luciferase to Renilla luciferase luminescence was still observed to increase ( Figure 1K , L). These results indicate that translation of mRNA modified with an additional poly-A tail is sustained and can therefore be used for in vivo applications (e.g., prophylactic and therapeutic uses).
[0368] Table 1: Oligonucleotides used to synthesize brush-shaped poly-A tail oligonucleotides
[0369]
[0370] Wherein " / 5Phos / " refers to the 5' phosphate group, "rA" refers to an adenosine ribonucleotide, " / i5OctdU / " refers to an internal 5-octadiynyl uracil deoxyribonucleotide, "3ddC" refers to a 3' cytosine dideoxyribonucleotide, " / 5AzideN / " refers to the 5' azide moiety, " / 3AzideN / " refers to the 3' azide moiety, and "*" refers to a phosphorothioate internucleotide bond. Internucleotide bonds not explicitly indicated are phosphodiester internucleotide bonds.
[0371] Example 3. Development of topologically novel capped branched mRNA oligonucleotides that are chemically modified and carry multivalent ploy (A) tails.
[0372] In the most widely accepted model of cap-dependent translation, the rate-limiting step is the assembly of the m7G cap-centered translation initiation complex (TIC) by eukaryotic translation initiation factors (eIFs) including eIF4E and eIF4G ( Figure 1A , left). TIC is further stabilized by the interaction of eIF4G with the cytoplasmic ploy(A) binding protein (PABPC), which recognizes the 3' ploy(A) tail, thereby forming a closed loop structure ( Figure 1A, right). PABPC thus has a dual role, initiating translation by engaging eIF and prolonging mRNA stability by protecting mRNA from deadenylation. It has been shown that site-specific introduction of exonuclease-resistant modifications at the terminus of the poly(A) tail effectively increases mRNA stability and protein production in cells, likely by stabilizing the nascent poly(A) tail and maintaining the poly(A)-PABPC interaction. Additionally, structural studies revealed that PABPC functions as a multimeric protein complex in which individual PABPC1 proteins bound to the poly(A) tail form a stable complex. This structural insight facilitated the study of the enhanced multivalent interaction of mRNA transcripts with PABPC1 achieved through multimerization of the poly(A) tail via a branched topology, in which each individual poly(A) tail carries a wide range of nuclease-resistant modifications ( Figure 2A ).
[0373] Branched mocRNAs were developed based on the ligation of chemically synthesized oligonucleotides with dense modifications to the 3' end of in vitro transcribed (IVT) mRNA using T4 RNA ligase. Various synthetic strategies for the generation of branched ploy(A) oligonucleotides were tested. Branched RNA topologies can occur naturally in the form of lariat intronic RNAs, which are byproducts of pre-mRNA splicing, with "branched" bonds between the 2'-hydroxyl of an internal nucleotide and the 5' end of the spliced intron that can be rapidly cleared by debranching enzymes. Therefore, the focus of the screening was on non-natural branched bonds that could not be hydrolyzed intracellularly and had high kinetics at micromolar concentrations to facilitate large-scale synthesis. Several oligonucleotide cross-linking chemistries were tested, including thiol-ene and thiol-yne reactions, phosphate-amine-based reactions, and click chemistry methods such as tetrazine-trans-cyclooctene (Tz-TCO) and copper-catalyzed azide-alkyne cycloaddition (CuAAC) ( Figure 2B ). When using free radical initiators, thiol-ene and thiol-yne reactions had low conversions under non-radical conditions and resulted in oligomerization, while phosphate-amine reactions produced trace amounts of products even under EDC / imidazole catalysis. Both Tz-TCO(IEDDA) and CuAAC reactions proceeded well with high conversions, indicating that CuAAC is a preferred choice due to its ability to introduce an alkyne handle on 5-octadiynyl deoxyU(EU) during solid phase synthesis, whereas Tz-TCO(IEDDA) requires an additional functionalization step ( Figure 2C -D).
[0374] To further endow the ploy(A) oligonucleotide with multiple branches, a 30-nucleotide (nt) "stem" oligonucleotide was designed containing a 5'-phosphate for subsequent enzymatic ligation and multiple internal EU-modified branching sites for PABPC1 binding separated by 12 A's, paired with a 30nt "branch" ploy(A) oligonucleotide containing a 5' azide handle. Both the stem and branch ploy(A) contain chain-terminating dideoxycytidine (ddC) at the ends to prevent self-ligation, and phosphorothioate (PS) modifications on the last 6nt to block deadenylation. As shown in gel electrophoresis, CuAAC conjugation produced a mixture of 7 products with 1 to 3 different topological branches ( Figure 2D ). Preliminary testing was performed by ligating the crude branched product to a firefly luciferase reporter gene, showing a 4.6-5.3-fold increase in bioluminescence in the CuAAC-treated construct compared to the unligated control (p<0.0001, ANOVA). However, reversing the direction of the branched ploy (A) completely abolished the increase in luminescence, indicating that normal 5' to 3' directionality is still required on the branched tail ( Figure 2E ).
[0375] Example 4. Establishment of a pipeline for branched mocRNA synthesis and purification.
[0376] By incorporating HPLC purification, a branched mocRNA synthesis and purification pipeline was established to allow for the systematic screening of various chemically modified moieties ( Figure 3A In this pipeline, eight synthetic ploy(A) oligonucleotides (e.g., Figure 3F The ligation yield was controlled by RNase H assay ( Figure 3E ), the ligation products were transfected into HeLa cells, and Renilla luciferase mRNA was used as an internal transfection control, where the effect of the modified branched poly(A) tail on protein production was quantified by the ratio of firefly / Renilla bioluminescence. In all constructs, Figure 3F Construct 8, shown to have three branches and coordinated incorporation of 2'-O-methoxyethyl (2MOE) and PS on both the stem and branch ploy (A) oligonucleotides, had the highest enhancement, generating luminescence signals 4, 11, and 19 times that of the linear mRNA at 24, 48, and 72 hours post-transfection, respectively (p<0.0001, ANOVA, Figure 3F ).
[0377] Table 2: Branched ploy(A) tail variants
[0378]
[0379]
[0380] The "backbone" portion of the sequence is the unbranched segment of the poly-A tail (see, e.g., Figure 2A , horizontally highlighted region (poly-A tail).
[0381] Example 5. Mechanistic characterization of mRNA stabilization by polymerizing the poly(A) tail.
[0382] To gain mechanistic insight into how branched poly(A) tails stabilize mRNA transcripts, the overall impact on protein translation capacity was separated into two layers, mRNA stability and translation efficiency. To minimize the error introduced by protein half-life in luciferase assays, branched mRNA transcripts encoding degrader-tagged firefly luciferase (firefly-PEST) were synthesized, which have been shown to effectively shorten the luciferase half-life in HeLa cells from 20.4 hours to approximately 0.92 hours. Luminescence decay kinetics revealed that branched mRNA increased the luminescence half-life from an estimated 7.2 hours to 17.1 hours, confirming the increase in mRNA stoichiometry at each time point ( Figure 4A -B). Such enhancement is not due to differences in transfection efficiency, as the decay kinetics of the internal Renilla control appear similar under all conditions ( Figure 4C ).
[0383] To dissect the translation efficiency of mRNA stability at the molecular level, in situ analyses were performed to quantify RNA copy number at subcellular resolution, where STARmap detects all transcripts of the target sequence and RIBOmap detects only the ribosome-bound fraction of mRNA copies ( Figure 4D , see Materials and Methods above). Six hours after lipofection, cells treated under the same conditions were re-seeded into two replicates at three time points, one of which was analyzed by STARmap and the other by RIBOmap for the modified firefly luciferase construct. In both replicates, unmodified Renilla luciferase was analyzed by STARmap to normalize the transfection efficiency. In the STARmap / RIBOmap images, magenta and yellow dots correspond to amplicons generated from cytoplasmic firefly and Renilla mRNAs. The bright RNA particles in STARmap correspond to lipid vesicles formed by the lipofectamine reagent, in which a large amount of non-translated mRNA is located ( Figure 4ENo such particles were observed in RIBOmap, further confirming that these combined in situ sequencing approaches successfully capture ribosome loading on individual transcripts and that their spatial resolution allows filtering of non-translating aggregates, thereby achieving more accurate results than traditional bulk ribosome profiling and RT-qPCR approaches. Both STARmap and RIBOmap recapitulated the trends observed with the luciferase assay, as cells transfected with branched firefly luciferase mRNA produced significantly higher numbers of cytoplasmic amplicons throughout the cell population than their linear counterparts at all time points ( Figure 4F -G). To roughly estimate translation efficiency (TE), single-cell mRNA stoichiometry was measured by log10 (Firefly STARmap / Renilla STARmap) and ribosome load was measured by log10 (Firefly RIBOmap / Renilla STARmap). TE was calculated by taking the ratio of the two values from cells re-plated under the same biological conditions. ( Figure 4H ) Interestingly, at 24 hours, the TE difference between branched and linear constructs was not significant, indicating that the poly(A) tail neither hindered nor enhanced translation efficiency at this time point. However, at 48 and 72 hours, branched mRNAs exhibited higher TE than linear mRNAs, indicating that branched constructs retained more functional poly(A) tails at later time points to maintain cap-dependent translation initiation.
[0384] To test whether the stabilizing effect of the branched poly(A) tail was due to its enhanced binding to PABP, the dissociation constant (Kd) of linear versus branched poly(A) oligonucleotides with full-length recombinant PABPC1 protein was quantified using EMSA (electrophoretic mobility shift assay). Linear / branched modified poly(A) oligonucleotides were labeled with Alexa Fluor 546 at the 5' end and incubated with different concentrations of PABPC1-GST protein ( Fig. 4I Linear and branched ploy (A) bound to the first PABPC1 protein with Kd of 10.7 and 6.4 nM, respectively, which is consistent with previously reported nanomolar range Kd for PABPC1 (32, 45) and suggests that PABPC1 has a higher affinity for branched oligonucleotides ( Figure 4J ). Additionally, branched ploy (A) binding to multiple molecules of PABPC1 was clearly resolved in EMSA with apparent Kd values of 6.4 / 10.9 / 15.3 / 35 nM relative to the first / second / third / fourth equivalents of PABPC1 ( Figure 4G , top). In contrast, the linear ploy (A) molecule was only able to bind to two equivalents of PABP in the same concentration range tested ( Figure 4G, middle). In a competitive binding assay, the branched ploy (A) again showed superior binding to PABP, with a substantial fraction being bound when 250-fold more of its linear counterpart was added ( Figure 4G , bottom). These results indicate that branching of the ploy (A) region promotes cooperative PABP multimerization.
[0385] Example 6. Comparison of branched mRNA and circular RNA technologies.
[0386] Many efforts have been made to broaden and improve the pharmacokinetic window of mRNA drugs. The use of circular RNAs (circRNAs) that are resistant to exonuclease cleavage, the major degradation pathway of their linear counterparts, has been considered a promising approach to avoid mRNA degradation. However, circRNA technology as a universal mRNA drug is limited: translation initiation in circRNAs depends on the internal ribosome entry site (IRES), which is significantly less efficient than the 7-methylguanylate (m7G) cap-dependent translation initiation mechanism; additionally, circRNAs are incompatible with most chemical modifications, including N1-methylpseudouridine (m1ψ), because they block RNA splicing required for circRNA synthesis and abolish IRES-based translation initiation. Therefore, alternative strategies are needed to protect mRNA transcripts from exonuclease-dependent rapid decay, especially deadenylation of the 3'ploy (A) tail, while retaining an efficient cap-dependent translation initiation mechanism.
[0387] To compare branched mRNA with state-of-the-art circular RNA (circRNA) technology, linear / branched / circular mRNA vectors encoding secreted nanoluciferase (NLuc) were synthesized, which allow for repeated collection of culture medium and measurement of protein expression kinetics over a longer time course. The circular mRNA vector will contain an engineered iHRV IRES carrying an eIF4G binding motif 5' upstream of the CDS and a ploy(A) binding motif 3' downstream, which have been reported to strongly enhance the translation of circular RNAs. circRNAs were synthesized using IVT, circularized by backsplicing, and enriched by RNase R treatment ( Figure 5A Even at higher doses of circRNA, linear and branched capped mRNAs carrying the translation-enhancing human α-globin UTR outperformed the circRNA constructs by more than three orders of magnitude ( Figure 5B Although linear and branched mRNA produced similar amounts within the first 24 h, branched mRNA maintained high levels of luciferase protein secretion for 5 days after mRNA lipid transfection, whereas protein secretion from linear mRNA-treated cells declined rapidly after day 1 ( Figure 5C ).
[0388] Example 7. Branched mRNA as a platform for therapeutic applications.
[0389] Compared to DNA vectors such as adeno-associated virus (AAV), mRNA-LNP delivery of CRISPR-based therapeutic constructs has been shown to have better performance and lower safety risks. However, high doses of mRNA-LNPs are still generally required to observe significant genome editing efficiency. To test whether branched mocRNA can further enhance the efficacy of mRNA-based CRISPR-Cas9, a reporter HEK cell line expressing destabilized green fluorescent protein (uGFP) was treated with branched / linear Cas9 mRNA co-transfected with a guide RNA (sgRNA) targeting a GFP coding sequence. Fig. 6A ). Both linear and branched Cas9 mRNAs produced observable levels of GFP ablation at 72 hours post-transfection, with the branched RNA knocking out the GFP gene more efficiently ( Figure 6B ); the average level of GFP intensity in cells treated with branched RNA was 7.1% of that in untreated cells, whereas the same dose of linear mRNA achieved 56.5% of the original average GFP intensity ( Figure 6C ). Such differences in ablation efficacy could not be overturned by simple dose escalation. Increasing the dose of linear mRNA by 2-fold or 4-fold reduced GFP intensity to 27.2% and 25.1%, respectively, which were still not comparable to branched mRNA ( Fig.6D -E).
[0390] Then, to test the in vivo translation efficiency and immunotoxicity of mocRNA, branched and linear mRNA encoding NanoLuc were studied in mice. The synthesized mRNA was encapsulated in LNPs and administered by intravenous (iv) injection ( Fig. 6F At a single minimal dose of ng, branched mRNAs exhibited enhanced and prolonged protein expression in vivo ( Figure 6G -H). Observable levels of luminescence were still observed in male mice treated with mRNA 6 to 10 days after LNP administration, when expression of the linear mRNA had fallen to background levels. The mRNA turnover kinetics in female mice was slightly different, but a similar trend was observed ( Fig.6IImmunogenicity was assessed by plasma levels of tumor necrosis factor alpha (TNF-α), and toxicity was measured by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) because iv delivery is prone to targeting the liver. Levels of all biomarkers were indistinguishable in male and female mice treated with linear and branched mRNA and in male mice treated with a poly(C) negative control, all of which were significantly lower than levels in male mice treated with a known RNA immunosensitizer, poly(I:C), which recognizes and induces interferon (IFN)-β through toll-like receptor 3 (TLR3). Fig.6I ). Therefore, the branched ploy(A) topology and non-native triazole chemical bonds do not increase immunotoxicity in vivo, making it suitable for therapeutic RNA.
[0391] Example 8. Production of polycapped mRNA.
[0392] As mentioned above, the rate-limiting step in translation initiation is the assembly of a TIC centered around a 7-methylguanosine (m7G) cap by eIFs. Fig. 7A The chemical structure of the m7G cap represented by the chemical shapes in the example below is depicted. Figure 7B Schematic diagram showing the closed loop structure of a TIC-bound mRNA, leading to the recruitment of ribosomes for translation. Thus, in addition to regulating TE via an altered poly(A) tail, increasing the affinity of the 5' cap for eIFs may also lead to higher TE of mRNA transcripts. Alternatively, mRNAs carrying multiple 5' caps may increase TE by forming multiple translation initiation complexes or increasing local eIF concentrations, thereby recruiting more ribosomes ( Figure 7C ). Such multi-capped mRNAs are summarized into two types of structures (type 1 and type 2). Type 1 multi-capped mRNAs are characterized by a continuous phosphodiester backbone throughout the transcript, with chemical conjugation handles in the 5' untranslated region (UTR) connected by modified nucleotides. These handles are cross-linked to the multi-capped oligonucleotides by click chemistry, such as copper-catalyzed azide-alkyne cycloaddition (CuAAC) or tetrazine-trans-cyclooctene reverse demand Diels-Alder reaction (IEDDA) ( Fig.7D Alternatively, multiple capped oligonucleotides are first conjugated to a small molecule handle carrying multiple click chemistry sites. This multi-capped oligonucleotide is then ligated to the 5' end of the mRNA to generate type 2 multi-capped mRNA ( Fig. 7E ).
[0393] Example 9.1 Synthesis workflow of poly-capped mRNA.
[0394] For mRNAs with relatively short coding sequences (CDS), mRNA transcripts are completely chemically synthesized, such that a terminal phosphate is introduced on the 5' end using a click chemistry handle in the 5'UTR. This modified mRNA is chemically capped and conjugated to a capping oligonucleotide ( Fig. 8A Alternatively, the order of capping and conjugation is reversed ( Figure 8B For longer mRNA constructs, multi-capped branched oligonucleotides were synthesized similarly by capping and conjugation. Subsequently, this multi-capped oligonucleotide was ligated to a 5'-monophosphorylated mRNA synthesized by in vitro transcription (IVT) and triphosphate hydrolysis to produce a multi-capped mRNA oligonucleotide conjugate (mocRNA) ( Figure 8C -D). Such approaches can be generalized across multiple transgenics.
[0395] Example 10. Multi-capped mRNA achieves improved translation efficiency.
[0396] A proof-of-concept experiment was performed by synthesizing a double-capped mRNA encoding HiBit, a split luciferase tag that can be monitored by a bioluminescent assay. HiBit mRNA was chemically synthesized to contain a 5'-phosphate and an internal 5-octadiynyl deoxyU (EU) modification in the 5'-UTR. Another short oligonucleotide containing a 5'-phosphate and a terminal azide handle on the 3' end was similarly designed and synthesized. Fig.9A Both oligonucleotides were generated by solid phase phosphoramidite chemistry using ammonia as the counterion. Both oligonucleotides and HiBit mRNA were prepared by treating with m7G-imidazole ( Fig. 9B ), chemical capping catalyzed by 1-methylimidazole. The oligonucleotides were subsequently purified using reverse phase HPLC to separate uncapped and capped transcripts to ensure 100% capping ( Fig. 9C The capped oligonucleotides were conjugated by CuAAC using copper (II) sulfate and ascorbic acid at room temperature for 1 hour and then column purified ( Fig.9D Synthetic HiBit encoding constructs (0-4) were transfected into HeLa cells and bioluminescence was assessed 12 hours after transfection ( Fig.9E ). Branching in the 5'UTR without incorporating an additional cap resulted in minimal reduction in protein expression (Construct 1 vs. Construct 2). However, capping of branched oligonucleotides resulted in additional increases in protein expression, with the 15-nt capped oligonucleotide resulting in an approximately 2-fold increase in protein expression (Construct 1 vs. Construct 3). Thus, multiple m7G caps resulted in an increase in TE.
[0397] Table 3: Branched 5' cap variants
[0398]
Claims
1. A modified mRNA comprising: (i) an open reading frame (ORF), which encodes a protein; (ii) poly-A region; as well as (iii) 5' cap region; wherein the poly-A region is located 3' to the ORF and comprises 10 or more nucleotides, and the 5' cap region is located 5' to the ORF; and The poly-A region comprises two or more poly-A tails, and / or the 5' cap region comprises two or more 5' caps.
2. The modified mRNA according to claim 1, wherein the modified mRNA comprises a poly-A region and a 5' cap region, wherein the poly-A region comprises two or more poly-A tails, and the 5' cap region comprises a 5' cap.
3. The modified mRNA according to claim 1, wherein the modified mRNA comprises a poly-A region and a 5' cap region, the poly-A region comprises a poly-A tail, and the 5' cap region comprises two or more 5' caps. 4 . The modified mRNA according to claim 1 , wherein the modified mRNA comprises a poly-A region and a 5′ cap region, the poly-A region comprising two or more poly-A tails, and the 5′ cap region comprising two or more 5′ caps.
5. The modified mRNA according to any one of claims 1 to 4, wherein the modified mRNA comprises a 5' untranslated region (5'UTR) and a 3' untranslated region (3'UTR), wherein the ORF is located between the 5'UTR and the 3'UTR, wherein the 3'UTR is located between the ORF and the poly-A region, and wherein the 5'UTR is located between the 5' cap region and the ORF.
6. The modified mRNA according to any one of claims 1 to 5, wherein the modified mRNA is a linear mRNA, wherein the 5' cap region is located at the 5' end of the modified mRNA, and the poly-A region is located at the 3' end of the modified mRNA.
7. The modified mRNA according to claim 5 or 6, wherein the modified mRNA is a circular mRNA, wherein the poly-A region is located between the 3'UTR and the 5' cap region.
8. The modified mRNA of any one of claims 1 to 7, wherein the poly-A region comprises two or more poly-A tails, and at least two instances of the poly-A tail are covalently linked via a first linker.
9. The modified mRNA according to claim 8, wherein: The poly-A region includes -(first poly-A tail)-[(first linker)-(second poly-A tail) n1 ] n2 ; Each instance of n1 is independently an integer between 1 and 20, inclusive; n2 is an integer between 2 and 10, inclusive; The first poly-A tail is covalently linked to the 3'UTR; and The first linker is covalently linked to the first poly-A tail and the second poly-A tail.
10. The modified mRNA of claim 9, wherein each instance of n1 is 1.
11. The modified mRNA of claim 10, wherein at least one instance of the first linker is covalently linked to an internal nucleotide of the first poly-A tail.
12. The modified mRNA of claim 10 or 11, wherein at least one instance of the first linker is covalently linked to the second poly-A tail at the 3' nucleotide of the second poly-A tail.
13. The modified mRNA of any one of claims 10 to 12, wherein at least one instance of the first linker comprises at least one portion formed by reacting two orthogonal click chemistry handles.
14. The modified mRNA of claim 13, wherein at least one portion formed by reacting two orthogonal click chemistry handles has the formula:
15. The modified mRNA according to any one of claims 10 to 14, wherein: Each instance of the first linker is independently substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene, substituted or unsubstituted C 1-200 heteroalkynylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and Optionally, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with a substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
16. The modified mRNA according to any one of claims 10 to 15, wherein the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently replace.
17. The modified mRNA according to any one of claims 10 to 16, wherein: At least one instance of the first linker has the formula: L 1 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 heteroalkylene; and L 2 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 Heteroalkylene.
18. The modified mRNA of any one of claims 10 to 17, wherein at least one instance of the first linker has the formula:
19. The modified mRNA of claim 9, wherein each instance of n1 is independently an integer between 2 and 20, inclusive.
20. The modified mRNA of claim 19, wherein at least one instance of the first linker comprises a dendrimer.
21. The modified mRNA of claim 20, wherein at least one instance of the dendrimer is a polyamidoamine (PAMAM) dendrimer.
22. The modified mRNA of claim 21, wherein at least one instance of the PAMAM dendrimer has the formula: in Each instance of n3 is independently an integer between 1 and 10, inclusive; Each instance of n4 is independently an integer between 0 and 10, inclusive; R 2 Each instance of is independently hydrogen or The condition is R 2 At least three instances of R 1 Each instance of is substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene or substituted or unsubstituted C 1-10 heteroalkynylene; Optionally, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 one or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and Each instance of n5 is independently an integer between 0 and 10, inclusive.
23. The modified mRNA of claim 22, wherein at least one instance of the PAMAM dendrimer comprises:
24. The modified mRNA according to claim 21, wherein the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently replace.
25. The modified mRNA of claim 24, wherein at least one instance of the first linker has the formula:
26. The modified mRNA of any one of claims 8 to 25, wherein at least one instance of the first linker is covalently linked to the 3' nucleotide of the first poly-A tail.
27. The modified mRNA of any one of claims 8 to 26, wherein at least one instance of the first linker is covalently linked to the 3' nucleotide of the second poly-A tail.
28. The modified mRNA according to any one of claims 1 to 27, wherein the poly-A region of the modified mRNA comprises one or more modified nucleotides.
29. The modified mRNA of claim 28, wherein 3 or more nucleotides of the last 10 nucleotides of at least one of the two or more poly-A tails are modified nucleotides and / or non-adenosine nucleotides.
30. The modified mRNA of claim 28 or 29, wherein the one or more modified nucleotides of the poly-A region are modified adenosine nucleotides.
31. The modified mRNA of any one of claims 28 to 30, wherein the one or more modified nucleotides of the poly-A region are modified non-adenosine nucleotides.
32. The modified mRNA of any one of claims 28 to 31, wherein the one or more modified nucleotides in the poly-A region comprise a modified nucleobase.
33. The modified mRNA of claim 32, wherein the modified nucleobase is selected from the group consisting of xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, digoxigenated adenine, digoxigenated cytosine, digoxigenated guanine, digoxigenated uracil, 6-chloropurine nucleoside, N6-methyladenine, methylpseudouracil, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyl ...6-dihydrouracil, 5-[(3-indolyl)propionamido-N-allyl]uracil, 5-aminoallylcytosine, 5-aminoallyluracil, 5-bromouracil, 5-bromocytosine, 5-carboxycytosine, 5-carboxymethyl ester uracil, 5-carboxyuracil, 5-fluorouracil, 5-formylcytosine, 5-formyluracil, 5-hydroxycytosine, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5-hydroxyuracil, 5-iodocytosine, 5-iodouracil, 5-methoxycytosine, 5-methoxyuracil, 5-methylcytosine, 5-methyluracil, 5-propargylaminocytosine pyrimidine, 5-propargylaminouracil, 5-propynylcytosine, 5-propynyluracil, 6-azacytosine, 6-azauracil, 6-chloropurine, 6-thioguanine, 7-deazaadenine, 7-deazaguanine, 7-guanine-7-propargylaminoadenine, 7-deaza-7-propargylaminoguanine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, araadenine, aracytosine, araguanine, araadenine, aracine uracil, biotin-16-7-deaza-7-propargylaminoguanine, biotin-16-aminoallylcytosine, biotin-16-aminoallyluracil, cyanine 3-5-propargylaminocytosine, cyanine 3-6-propargylaminouracil, cyanine 3-aminoallylcytosine, cyanine 3-aminoallyluracil, cyanine 5-6-propargylaminocytosine, cyanine 5-6-propargylaminouracil, cyanine 5-aminoallylcytosine, cyanine 5-aminoallyluracil, cyanine 7-aminoallyluracil, dabcyl-5-3-amino 1-aminoallyl uracil, desthiobiotin-16-aminoallyl-uracil, desthiobiotin-6-aminoallyl cytosine, isoguanine, N1-ethyl pseudouracil, N1-methoxymethyl pseudouracil, N1-methyladenine, N1-methyl pseudouracil, N1-propyl pseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthosine, 3-deazaadenine, 2,6-diaminoadenine, 2,6-diaminoguanine, 5-formamide-uracil, 5-ethyluracil, N6-isopentenyladenine (i6A), 2-methyl-thio-N6-isopentenyladenine (ms2i6A), 2-methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine (g6A), N 6-Threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxynorvalylcarbamoyladenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A).
34. The modified mRNA of any one of claims 28 to 33, wherein one or more modified nucleotides comprise a modified sugar.
35. The modified mRNA of claim 34, wherein the modified sugar is selected from the group consisting of 2'-thioribose, 2',3'-dideoxyribose, 2'-amino-2'-deoxyribose, 2'-deoxyribose, 2'-azido-2'-deoxyribose, 2'-fluoro-2'-deoxyribose, 2'-O-methylribose, 2'-O-methyldeoxyribose, 3'-amino-2',3'-dideoxyribose, 3'-azido-2'-deoxyribose, Nitro-2',3'-dideoxyribose, 3'-deoxyribose, 3'-O-(2-nitrobenzyl)-2'-deoxyribose, 3'-O-methylribose, 5'-aminoribose, 5'-thioribose, 5-nitro-1-indolyl-2'-deoxyribose, 5'-biotin-ribose, 2'-O,4'-C-methylene-linked ribose, 2'-O,4'-C-amino-linked ribose, and 2'-O,4'-C-thio-linked ribose.
36. The modified mRNA of any one of claims 28 to 35, wherein one or more modified nucleotides comprise a modified phosphate.
37. The modified mRNA of claim 36, wherein the modified phosphate is selected from the group consisting of phosphorothioate (PS), thiophosphate, 5'-O-methylphosphonate, 3'-O-methylphosphonate, 5'-hydroxyphosphonate, hydroxyphosphonate, phosphoroselenoate, selenophosphate, phosphoramidate, carbophosphonate, methylphosphonate, phenylphosphonate, ethylphosphonate, H-phosphonate, guanidine ring, triazole ring, boranophosphate (BP), methylphosphonate, and guanidinopropylphosphoramidate.
38. The modified mRNA of claim 36 or 37, wherein the poly-A region comprises 1 to 3, 3 to 5, 5 to 10, 10 to 15, 15 to 30, 30 to 50, 50 to 100, or 100 to 200 phosphorothioates.
39. The modified mRNA of claim 38, wherein the poly-A region comprises 5 to 30 phosphorothioates.
40. The modified mRNA of any one of claims 28 to 39, wherein the poly-A region comprises 3 to 5, 5 to 10, 10 to 15, 15 to 30, 30 to 50, 50 to 100, or 100 to 200 deoxyribose sugars.
41. The modified mRNA of claim 40, wherein the poly-A region comprises 5 to 30 deoxyribose sugars.
42. The modified mRNA of any one of claims 28 to 41, wherein the mRNA comprises a 3' terminal nucleotide, wherein the 3' terminal nucleotide is dideoxyadenosine, dideoxycytidine, dideoxyguanosine, dideoxythymidine, dideoxyuridine or inverted deoxythymidine.
43. The modified mRNA of any one of claims 1 to 42, wherein the poly-A region comprises 25 to 500 nucleotides.
44. The modified mRNA of claim 43, wherein the poly-A region comprises 50 to 100, 100 to 150, 150 to 200, 200 to 300, 300 to 400, or 400 to 500 nucleotides.
45. The modified mRNA of any one of claims 1 to 44, wherein the poly-A region comprises 10 or more adenosine nucleotides.
46. The modified mRNA of any one of claims 1 to 45, wherein 25-100%, 30-100%, 40-100%, 50-100%, 60-100%, 70-100%, 80-100%, 90-100%, 95-100%, 96-100%, 97-100%, 98-100% or 99-100% of the nucleotides in the poly-A region are adenosine nucleotides.
47. according to the modified mRNA described in any one in claim 8 to 46, wherein said first poly-A tail comprises 10 to 50 adenosine ribonucleotides, 1 to 10 modified uridine deoxyribonucleotides comprising a point of attachment and 3' terminal dideoxyribonucleotides or reverse deoxyribonucleotides; and said second poly-A tail comprises 10 to 50 adenosine ribonucleotides.
48. The modified mRNA of claim 47, wherein: The first poly-A tail comprises a nucleotide sequence as shown below: 5′-rArArArArArAdU(a1)rArArArArArArArArArArArAdU(a1)rArArArArArArArArArArAd U(a1)ddC-3′ (SEQ ID NO: 1); At least one example of the second poly-A tail includes a nucleotide sequence as shown below: 5′-rArArArArArArArArArArArArArArArArArArArArArArA*rA*rA*rA*rA*rA*(b1)-3′ (SEQ ID NO: 2); Each instance of the first linker is independently "rA" indicates adenosine ribonucleotide; "dU(a1)" indicates a modified uridine deoxyribonucleotide; "ddC" indicates cytosine dideoxyribonucleotide; "*" indicates a phosphorothioate bond; a1 of each instance of dU(a1) represents the attachment point on the uridine of said dU(a1); b1 of rA*(b1) represents the connection point on * of rA*(b1); Every instance of a1 is connected to an instance of a2; and Each instance of b1 is connected with an instance of b2.
49. The modified mRNA of claim 47 or 48, wherein the modified uridine deoxynucleotide is 5-octadiynyl deoxyuridine.
50. The modified mRNA of any one of claims 8 to 46, wherein the first poly-A tail and the second poly-A tail comprise 10 to 50 adenosine ribonucleotides and a 3' terminal azide moiety.
51. The modified mRNA of claim 50, wherein the first poly-A tail and the second poly-A tail comprise a nucleotide sequence as shown below: 5'-rArArArArArArArArArArArArArArArArArArArA*rA*rA*rA*rA*rA* / azide N / -3' (SEQ ID NO: 3); wherein "rA" represents an adenosine ribonucleotide; "Azide N" represents a 3' azide moiety, and "*" represents a phosphorothioate bond.
52. The modified mRNA of any one of claims 8 to 46, wherein the first poly-A tail and the second poly-A tail comprise 10 to 50 adenosine ribonucleotides and a 5' terminal azide moiety.
53. The modified mRNA of claim 52, wherein the first poly-A tail and the second poly-A tail comprise a nucleotide sequence as shown below: 5'- / azide N / rArArArArArArArArArArArArArArArArArArArAr A*rA*rA*rA*rA*rA-3' (SEQ ID NO: 27); wherein "rA" represents an adenosine ribonucleotide; "Azide N" represents a 3' azide moiety, and "*" represents a phosphorothioate bond.
54. The modified mRNA of any one of claims 1 to 53, wherein the 5' cap region comprises two or more 5' caps, and at least two instances of the 5' cap are covalently linked via a second linker.
55. The modified mRNA of claim 54, wherein: The 5' cap region comprises -(first 5' cap)-[(second linker)-(second 5' cap) m1 ] m2 ; Each instance of m1 is independently an integer between 1 and 20, inclusive; m2 is an integer between 2 and 10, inclusive; The first 5' cap is covalently linked to the 5'UTR; and The second linker is covalently linked to the first 5' cap and the second 5' cap.
56. The modified mRNA of claim 55, wherein each instance of ml is 1.
57. The modified mRNA of claim 56, wherein at least one instance of the second linker is covalently linked to an internal nucleotide of the first 5' cap.
58. The modified mRNA of claim 56 or 57, wherein at least one instance of the second linker is covalently linked to the second 5' cap at the 3' nucleotide of the second 5' cap.
59. The modified mRNA of any one of claims 56 to 58, wherein at least one instance of the second linker comprises at least one portion formed by reacting two orthogonal click chemistry handles.
60. The modified mRNA of claim 59, wherein at least one portion formed by reacting two orthogonal click chemistry handles has the formula:
61. The modified mRNA according to any one of claims 56 to 60, wherein: Each instance of the second linker is independently substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene, substituted or unsubstituted C 1-200 heteroalkynylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and Optionally, the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 One or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with a substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
62. The modified mRNA of any one of claims 49 to 54, wherein the substituted or unsubstituted C 1-200 Alkylene, substituted or unsubstituted C 1-200 Alkenylene, substituted or unsubstituted C 1-200 Alkyne, substituted or unsubstituted C 1-200 Heteroalkylene, substituted or unsubstituted C 1-200 heteroalkenylene and substituted or unsubstituted C 1-200 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently replace.
63. The modified mRNA according to any one of claims 56 to 62, wherein: At least one instance of the second linker has the formula: L 3 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 heteroalkylene; and L 4 Each instance of is independently substituted or unsubstituted C 1-199 Alkylene or substituted or unsubstituted C 1-199 Heteroalkylene.
64. The modified mRNA of any one of claims 56 to 62, wherein at least one instance of the second linker has the formula:
65. The modified mRNA of claim 56, wherein each instance of ml is independently an integer between 2 and 20, inclusive.
66. The modified mRNA of claim 65, wherein at least one instance of the second linker comprises a dendrimer.
67. The modified mRNA of claim 66, wherein at least one instance of the dendrimer is a polyamidoamine (PAMAM) dendrimer.
68. The modified mRNA of claim 67, wherein at least one instance of the PAMAM dendrimer has the formula: in Each instance of m3 is independently an integer between 1 and 10, inclusive; Each instance of m4 is independently an integer between 0 and 10, inclusive; R 12 Each instance of is independently hydrogen or The condition is R 12 At least three instances of R 11 Each instance of is substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene or substituted or unsubstituted C 1-10 heteroalkynylene; Optionally, the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 one or more carbon atoms in the parent chain of each instance of heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and Each instance of m5 is independently an integer between 0 and 10, inclusive.
69. The modified mRNA of claim 67 or 68, wherein at least one instance of the PAMAM dendrimer comprises:
70. The modified mRNA of claim 68, wherein the substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 1-10 Heteroalkylene, substituted or unsubstituted C 1-10 heteroalkenylene and substituted or unsubstituted C 1-10 The carbon atom or atoms in the parent chain of each instance of heteroalkynylene are independently replace.
71. The modified mRNA of claim 68, wherein at least one instance of the first linker has the formula:
72. The modified mRNA of any one of claims 50 to 71, wherein at least one instance of the second linker is covalently linked to the 5' or 3' nucleotide of the first 5' cap.
73. The modified mRNA of any one of claims 50 to 72, wherein at least one instance of the second linker is covalently linked to the 5' or 3' nucleotide of at least one instance of the second 5' cap.
74. The modified mRNA of any one of claims 50 to 73, wherein the 5' cap region of the modified mRNA comprises one or more modified nucleotides.
75. The modified mRNA of claim 74, wherein the one or more modified nucleotides comprise a modified nucleobase.
76. The modified mRNA of claim 75, wherein the modified nucleobase is selected from the group consisting of xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, digoxigenated adenine, digoxigenated cytosine, digoxigenated guanine, digoxigenated uracil, 6-chloropurine nucleoside, N6-methyladenine, methylpseudouracil, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyluracil, 5,6-dihydrouracil, 5-[(3-indolyl)propionamide-N-allyl]uracil, 5-aminoallylcytosine, 5-aminoallyluracil, 5-bromouracil, 5 -bromocytosine, 5-carboxycytosine, 5-carboxymethyl ester uracil, 5-carboxyuracil, 5-fluorouracil, 5-formylcytosine, 5-formyluracil, 5-hydroxycytosine, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5-hydroxyuracil, 5-iodocytosine, 5-iodouracil, 5-methoxycytosine, 5-methoxyuracil, 5-methylcytosine, 5-methyluracil, 5-propargylaminocytosine, 5-propargylaminouracil, 5-propynylcytosine, 5-propynyluracil, 6-azacytosine, 6-azauracil, 6-chloropurine, 6-thioguanine, 7-deazaadenine, 7-deazaguanine, 7-guanine-7-propargylaminoadenine , 7-deaza-7-propargylaminoguanine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, arabinoadenine, arabinocytosine, arabinoguanine, arabinouracil, biotin-16-7-deaza-7-propargylaminoguanine, biotin-16-aminoallylcytosine, biotin-16-aminoallyluracil, cyanine-3-5-propargylaminocytosine, cyanine-3-6-propargylaminouracil, cyanine-3-aminoallylcytosine, cyanine-3-aminoallyluracil, cyanine-5-6-propargylaminocytosine, cyanine-5-6-propargylaminouracil, cyanine-5-aminoallylcytosine, cyanine-5-amino cyanine 7-aminoallyl uracil, dabcyl-5-3-aminoallyl uracil, desthiobiotin-16-aminoallyl-uracil, desthiobiotin-6-aminoallyl cytosine, isoguanine, N1-ethyl pseudouracil, N1-methoxymethyl pseudouracil, N1-methyladenine, N1-methyl pseudouracil, N1-propyl pseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthosine, 3-deazaadenine, 2,6-diaminoadenine, 2,6-diaminoguanine, 5-formamide-uracil, 5-ethyluracil, N6-isopentenyladenine (i6A), 2-methyl-thio-N6-isopentenyladenine (ms2i6A), 2-methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine (g6A), N 6-Threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxynorvalylcarbamoyladenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A).
77. The modified mRNA of any one of claims 74 to 76, wherein one or more modified nucleotides comprise a modified sugar.
78. The modified mRNA of claim 77, wherein the modified sugar is selected from the group consisting of 2'-thioribose, 2',3'-dideoxyribose, 2'-amino-2'-deoxyribose, 2'-deoxyribose, 2'-azido-2'-deoxyribose, 2'-fluoro-2'-deoxyribose, 2'-O-methylribose, 2'-O-methyldeoxyribose, 3'-amino-2',3'-dideoxyribose, 3'-azido-2'-deoxyribose, Nitro-2',3'-dideoxyribose, 3'-deoxyribose, 3'-O-(2-nitrobenzyl)-2'-deoxyribose, 3'-O-methylribose, 5'-aminoribose, 5'-thioribose, 5-nitro-1-indolyl-2'-deoxyribose, 5'-biotin-ribose, 2'-O,4'-C-methylene-linked ribose, 2'-O,4'-C-amino-linked ribose, and 2'-O,4'-C-thio-linked ribose.
79. according to the modified mRNA described in any one of claim 74 to 78, wherein one or more modified nucleotides comprise modified phosphate.
80. The modified mRNA of claim 79, wherein the modified phosphate is selected from the group consisting of phosphorothioate (PS), thiophosphate, 5'-O-methylphosphonate, 3'-O-methylphosphonate, 5'-hydroxyphosphonate, hydroxyphosphonate, phosphoroselenoate, selenophosphate, phosphoramidate, carbonylphosphonate, methylphosphonate, phenylphosphonate, ethylphosphonate, H-phosphonate, guanidine ring, triazole ring, borophosphate (BP), methylphosphonate, and guanidinopropylphosphoramidate.
81. The modified mRNA of claim 79 or 80, wherein the 5' cap region comprises 1 to 3, 3 to 5, 5 to 10, 10 to 15, 15 to 30, 30 to 50, 50 to 100, or 100 to 200 phosphorothioates.
82. The modified mRNA of claim 81, wherein the 5' cap region comprises 5 to 30 phosphorothioates.
83. The modified mRNA of any one of claims 74 to 82, wherein the 5' cap region comprises 3 to 5, 5 to 10, 10 to 15, 15 to 30, 30 to 50, 50 to 100 or 100 to 200 deoxyribose sugars.
84. The modified mRNA of claim 83, wherein the 5' cap region comprises 5 to 30 deoxyribose sugars.
85. The modified mRNA of any one of claims 74 to 84, wherein the mRNA comprises a 3' terminal nucleotide, wherein the 3' terminal nucleotide is dideoxyadenosine, dideoxycytidine, dideoxyguanosine, dideoxythymidine, dideoxyuridine or inverted deoxythymidine.
86. The modified mRNA of any one of claims 50 to 85, wherein the 5' cap region comprises 25 to 500 nucleotides.
87. The modified mRNA of claim 86, wherein the 5' cap region comprises 50 to 100, 100 to 150, 150 to 200, 200 to 300, 300 to 400, or 400 to 500 nucleotides.
88. The modified mRNA of any one of claims 50 to 87, wherein the 5' cap region comprises 1 to 3, 3 to 5, 5 to 7 or 7 to 10 5' caps.
89. The modified mRNA of any one of claims 50 to 88, wherein the 5' cap region comprises one or more 7-methylguanylate caps comprising a 5'-5' triphosphate bond.
90. The modified mRNA of any one of claims 50 to 89, wherein the 5' cap region comprises one or more 2,2,7-trimethylguanosine caps comprising a 5'-5' triphosphate bond.
91. The modified mRNA of any one of claims 50 to 90, wherein the 5' cap region comprises one or more modified 5' caps.
92. The modified mRNA of claim 91, wherein the one or more modified 5' caps are locked nucleic acid (LNA) modified caps, 5' caps comprising a 5'-5' triphosphate bond modified by a 5'-phosphorothioate, or 5' caps comprising a 5'-5' tetraphosphate bond.
93. The modified mRNA of claim 91 or 92, wherein the 5' cap region comprises one or more 5' caps comprising one or more modified nucleotides.
94. The modified mRNA of claim 93, wherein one or more modified nucleotides are 2'-O-methylated nucleotides.
95. The modified mRNA of any one of claims 50 to 94, wherein the first 5' cap comprises 10 to 50 ribonucleotides, 1 to 10 modified uridine deoxyribonucleotides including a point of attachment, and a 5' cap; and the second 5' cap comprises 10 to 50 ribonucleotides and a 5' cap.
96. The modified mRNA of claim 95, wherein: The first 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArArAdU(c1)rArGrArGrArGrArArArArGrArArGrArGdU(c1)rArArGrArAr GrArArAdU(c1)rA-3' (SEQ ID NO: 4); The second 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArGrArCrTrGrCrCrArCrCrA*rA*rA*rA*rA*rA*(d1)-3' (SEQ ID NO: 5); Each instance of the second linker is independently "rA" indicates adenosine ribonucleotide; "rT" indicates thymidine ribonucleotide; "rC" indicates cytidine ribonucleotide; "rG" indicates guanosine ribonucleotide; "dU(c1)" indicates a modified uridine deoxyribonucleotide; "*" indicates a phosphorothioate bond; "Cap" indicates 5' cap; The c1 of each instance of dU(c1) represents the attachment point on the uridine of said dU(c1); d1 of rA*(d1) represents the connection point on * of said rA*(d1); Every instance of c1 is connected to an instance of c2; and Each instance of d1 is connected to an instance of d2.
97. The modified mRNA of claim 95 or 96, wherein the modified uridine deoxynucleotide is 5-octadiynyl deoxyuridine.
98. The modified mRNA of any one of claims 50 to 94, wherein the first 5' cap comprises 5 to 10 ribonucleotides and a 5' azide moiety; and the second 5' cap comprises 10 to 50 ribonucleotides, a 3' azide moiety, and a 5' cap.
99. The modified mRNA of claim 98, wherein the first 5' cap comprises a nucleotide sequence as shown below: 5'- / / 5azideN / rArArA rArA-3'; And the second 5' cap comprises a nucleotide sequence as shown below: 5'- / Cap / rGrGrGrArGrArCrTrGrCrCrArCrCrA*rA*rA*rA*rA*rA* / 3 azide N / -3' (SEQ ID NO: 6); wherein "rA" represents an adenosine ribonucleotide; "rT" represents a thymidine ribonucleotide; "rC" represents a cytidine ribonucleotide; "rG" represents a guanosine ribonucleotide; "5AzideN" represents a 5'azide moiety, "3AzideN" represents a 3'azide moiety, "*" represents a phosphorothioate bond, and "Cap" represents a 5' cap.
100. A method for producing a modified mRNA according to any one of claims 1 to 99, the method comprising ligating a first RNA comprising an open reading frame (ORF) encoding a protein to a tailing nucleic acid comprising two or more poly-A tails and / or a capping nucleic acid comprising two or more 5' caps in the presence of an RNA ligase, whereby the RNA ligase forms a covalent bond between the 3' nucleotides of the first RNA and the 5' nucleotides of the tailing nucleic acid, and / or forms a covalent bond between the 5' nucleotides of the first RNA and the 3' nucleotides of the capping nucleic acid to produce the modified mRNA.
101. The method of claim 100, wherein the modified mRNA comprises a 5' untranslated region (5'UTR) and a 3' untranslated region (3'UTR), wherein the ORF is located between the 5'UTR and the 3'UTR, wherein the 3'UTR is located between the ORF and the linked tailing nucleic acid, and wherein the 5'UTR is located between the ORF and the linked capping nucleic acid.
102. The method of claim 100 or 101, wherein the tailed nucleic acid comprises a first poly-A tail and one or more second poly-A tails, wherein the first poly-A tail is covalently linked to the 3'UTR.
103. A modified mRNA produced by the method according to any one of claims 98 to 100.
104. A delivery agent comprising the modified mRNA of any one of claims 1 to 99, wherein the delivery agent comprises a lipid, a peptide, a protein, an antibody, a carbohydrate, a nanoparticle, or a microparticle.
105. The delivery agent of claim 104, wherein the nanoparticle or microparticle is a lipid nanoparticle or lipid microparticle, a polymer nanoparticle or polymer microparticle, a protein nanoparticle or protein microparticle, or a solid nanoparticle or solid microparticle.
106. A cell comprising the modified mRNA of any one of claims 1 to 99.
107. The cell of claim 106, wherein the cell is a mammalian cell.
108. A composition comprising the modified mRNA of any one of claims 1 to 99, the delivery agent of claim 104 or 105, or the cell of claim 106 or 107.
109. The composition of claim 108, wherein the composition further comprises an additional agent.
110. The composition of claim 109, wherein the additional agent is an agent that has a therapeutic effect when administered to a subject.
111. The composition of claim 109 or 110, wherein the additional agent is a nucleotide, a nucleic acid, an amino acid, a peptide, a protein, a small molecule, an aptamer, a lipid, or a carbohydrate.
112. The composition of claim 111, wherein the additional agent is shRNA, siRNA or ASO.
113. The composition of any one of claims 109 to 111, wherein the additional agent is an antigen or an adjuvant.
114. The composition of any one of claims 108 to 113, wherein the composition is a pharmaceutical composition, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
115. A method comprising introducing into a cell the modified mRNA of any one of claims 1 to 99 or the delivery agent of claim 104 or 105.
116. A method comprising introducing into a subject a modified mRNA according to any one of claims 1 to 99, a delivery agent according to claim 104 or 105, a cell according to claim 106 or 107, or a composition according to any one of claims 108 to 114.
117. A method for preventing a disease in a subject in need thereof, the method comprising introducing into the subject an effective amount of a modified mRNA according to any one of claims 1 to 99, a delivery agent according to claim 104 or 105, a cell according to claim 105 or 107, or a composition according to any one of claims 108 to 114, wherein the open reading frame of the modified mRNA encodes a protein.
118. A method of treating a disease in a subject in need thereof, the method comprising introducing an effective amount of a modified mRNA according to any one of claims 1 to 99, a delivery agent according to claim 104 or 105, a cell according to claim 106 or 107, or a composition according to any one of claims 108 to 114 into the subject, wherein the open reading frame of the modified mRNA encodes a protein.
119. The method of claim 117 or claim 118, wherein the protein is a protein antigen or fragment thereof from a cell or virus causing the disease.
120. The method of claim 117 or claim 118, wherein the protein is a protein that is expressed in the subject at a level lower than a reference value.
121. A method of replacing an enzyme in a subject, the method comprising introducing into the subject a modified mRNA according to any one of claims 1 to 99, a delivery agent according to claim 104 or 105, a cell according to claim 106 or 107, or a composition according to any one of claims 108 to 114, wherein the open reading frame of the modified mRNA encodes an enzyme.
122. The method of any one of claims 116 to 117, wherein the subject is a human.
123. A modified mRNA according to any one of claims 1 to 99, a delivery agent according to claim 104 or 105, a cell according to claim 106 or 107, or a composition according to any one of claims 108 to 114 for use in preventing a disease in a subject in need thereof.
124. A modified mRNA according to any one of claims 1 to 99, a delivery agent according to claim 104 or 105, a cell according to claim 106 or 107, or a composition according to any one of claims 108 to 114 for use in treating a disease in a subject in need thereof.
125. A kit comprising the first RNA, the tailing nucleic acid and / or the capping nucleic acid of any one of claims 100 to 102.
126. The kit of claim 125, further comprising an RNA ligase.
127. A kit comprising the pharmaceutical composition of claim 114, a device for administering the pharmaceutical composition to a subject, and instructions for administering the pharmaceutical composition to a subject.
Citation Information
Patent Citations
Circular RNA compositions and methods
WO2020237227A1
